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Abstract 
Over  fifty, structurally diverse, novel fluorinated heteroarenes, have been successfully synthesised 
by SNAr reaction of a range of fluorinated arenes including pentafluoropyridine, hexafluorobenzene, 
and methyl pentafluorobenzoate by introduction of a range of groups such as imidazole, triazole, 
benzimidazole, benzotriazole, and carbazole. Different water solubilising side chains were 
introduced to some of the successfully synthesised fluorinated heteroarenes to improve water 
solubility and potential biological activity. X-ray crystal structures of over 10 compounds were 
obtained including those of two macrocyclic compounds containing 21- and 24-membered rings. The 
synthesised compounds have been characterized by elemental analysis, IR, 
1
H and 
19
F spectroscopy 
and high resolution mass spectrometry. These compounds have been screened for their biological 
activities and possible interaction with DNA by methods including UV-visible spectroscopy, 
fluorescence spectroscopy, co-crystallization for X-ray diffraction analysis, and antimicrobial 
activity. A number of the fluoroaryl benzimidazole derivatives have been tested against K-562 and 
MCF-7 cell lines and G361 and HOS cell lines. From the all tested compounds three tethered 
fluoroaryl benzimidazole derivatives demonstrated micromolar inhibition against K-562 and MCF-7 
cell lines. These compounds, in addition to 1-tetrafluoropyrid-4-yl-2-tetrafluoropyrid-4-ylsulfanyl-
1H-benzimidazole, also demonstrated micromolar inhibition against G361 and HOS cell lines. Two 
of the compounds were found to activate caspases leading to apoptosis.  
 
 
 
 
 
 
 
 
 
 
vi 
 
Abbreviations 
 ACTD              Actinomycin D  
 A                                        Adenine 
 AFM                                  Atomic-force microscopy 
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1. Introduction 
Heterocyclic compounds are the largest of the traditional divisions of organic chemistry and are of 
huge importance biologically and industrially. For more than one century heterocyclic chemistry has 
been the largest area for research in organic chemistry. Heterocycles have been used in the 
development of biologically active compounds, and also in the understanding of living processes, 
and in improving the quality of life. Large numbers of drugs such as morphine, atropine, procaine, 
codeine, and reserpine are heterocycles.
1,2
 Also many synthetic drugs such as diazepam, 
chlorpromazine, isoniazid, metronidazole, azidothymidine are heterocycles due to their useful 
solubility profile and their rigid structures which can bind to a broad range of receptors for valuable 
biological activity.
3,4
 Therefore heterocyclic chemistry is very important in the pharmaceutical 
industry for the synthesis of new drugs including antibacterial, antifungal, antimycobacterial, anti-
inflammatory and especially anti-cancer agents because cancer is a leading cause of premature 
deaths in the world. In cancer, abnormal cells divide rapidly without control and are able to invade 
and destroy healthy tissues.
1,5 
These uncontrolled, unregulated cells which divide rapidly and grow 
abnormally produce malignant tumours which affect and invade nearby parts of the body leading to 
human death. It has been estimated that in the United States over 1 million cases of cancer are 
reported per year and it is expected that by the year 2017 cancer-related deaths will reach 12 million 
world-wide.
1
 Therefore in recent years, a wide range of research has been carried out in the field of 
anti-cancer drug development.
1 
On the other, hand fluorine use in medicinal chemistry has exploded 
over recent decades and significant improvement in pharmaceutical and biological activity of drugs 
containing fluorine has been shown. Therefore fluorination of a heterocyclic compound or 
combination of heterocycles with fluorinated arenes is a major concern in drug design and discovery, 
and is the main focus of this thesis. 
  
1.1. Fluorine in medicinal chemistry 
Fluorinated compounds have shown important improvement of biological activity of pharmaceutical 
compounds and drugs in medicinal chemistry. The fundamental properties of fluorine impart 
significant improvement on the biological activity of the fluorinated molecules. Therefore many 
fluorinated analogues of natural compounds have been synthesised and investigated due to the 
increase in understanding of the impact of fluorination on the biological properties of a molecule. 
This has supported the design and synthesis of more active and selective pharmaceutical agents 
2 
 
during the last 15 years, and development of synthetic methodologies in organic fluorine chemistry. 
There are more than 150 fluorinated compounds among those marketed pharmaceutical drugs in the 
world which is a huge number compared with other halogen-containing pharmaceuticals. Organo-
chlorine and -bromine compounds are far more abundant as natural compounds.
 6
 
As a good example of the effect of a fluorine atom modifying the activity of the parent compound is 
introduction of fluorine into quinolone derivatives which led to the first fluoroquinolone, 
(norfloxacin) that is a broad-spectrum antibiotic. Replacing a CH bond by a CF bond improves 
metabolic stability. Also replacement of hydrogen with fluorine in uracil 1 gives 5-fluorouracil 2 
which shows potent antitumor activity (Scheme 1).
6,7 
The fluorinated version of the molecule binds 
irreversibly to the active site of thymidylate synthetase preventing thymine biosynthesis in tumour 
cells. 
 
 
Scheme 1: Commercial synthesis of 5-fluorouracil. 
 
1.1.1. Physical characteristics of fluorine 
Among all elements fluorine has the highest electronegativity value (EN) of 4 (on the Pauling scale) 
with very low polarizability and very low bond dissociation energy (155 kJ/mol).
8 
The low polarizability effect of fluorine and the three non-bonding electron pairs are important 
physical characteristics of biological activity of fluorinated compounds.
6, 9, 10
 
The high elecronegativity of fluorine causes it to attract electrons more powerfully than any other 
element and it is never found as the free element in the natural environment. Moreover, the bonding 
between the ligand and the target in the active centre of a protein molecule possessing fluorophobic 
and fluorophilic areas can be improved due to the electronegativity of the fluorine atom which causes 
particular dipole-type interactions. It is necessary to mention that in organic compounds, the fluorine 
3 
 
atoms can accept hydrogen bonds only in the absence of better acceptors, such as oxygen or nitrogen, 
as fluorine is more electronegative and not able to compete with stronger hydrogen-bond acceptors.
11
 
The fluorine atom has the second smallest van der Waals radius, (1.47 Å) which is sited between 
hydrogen (1.20 Å)12 and oxygen (1.52 Å)
112
 and allows fluorine to behave like a hydroxyl group and 
contribute in hydrogen bonding interactions.
10
 Also the C-F bond has greater strength than  C-H 
bond which results in high chemical stability of fluorinated compounds.
10,13
 
Furthermore, fluorine containing substituents (especially perfluorinated groups, like CF3, C6F5,  
OCF3) can provide significant steric volume distressing the arrangement of the parent molecule and 
its isomers, conformations or transition states. Therefore it affects chemical properties such as 
solubility, acidity, basicity and metabolic stability of molecules. In addition the incorporation of 
fluorine into organic molecules often leads to increasing lipophilicity thereby enhancing their affinity 
for natural receptors.
11 
In nuclear magnetic resonance spectroscopy, 
19
F deserves special attention due to its desirable 
characteristics (nuclear spin ½, relatively narrow lines, high sensitivity, short longitudinal relaxation 
time, and 100% abundance). Therefore, 
19
F NMR spectroscopy is ideally suited to following the fate 
of fluorinated drug molecules. The selective detection of molecules containing fluorine reduces the 
background and interfering signals. In addition, this method is very sensitive to changes in the 
environment due to larger chemical shifts than 
1
H NMR. 
19
F NMR can be used in laboratory 
research; for example in studying the mechanism of interaction with receptors in tumour and normal 
tissue localization of anti-cancer drugs. Moreover, 
19
F NMR spectroscopy can be useful as a tool for 
therapeutic monitoring of fluoropyrimidine analogues and their prodrugs. 
19
F NMR spectroscopy 
studies of the metabolism of the successful fluoropyrimidine anti-cancer drugs, such as fluorouracil, 
and prodrug capecitabine, as well as antifungal agents have been carried out.
 9, 11 
1.1.2. Improving Metabolic Stability with Fluorine  
One of the problems in many drug discovery projects is low metabolic stability because lipophilic 
compounds are likely to be oxidized by liver enzymes, especially cytochrome P450. There are 
different approaches to minimise this problem such as increasing the polarity of the molecule. 
Another strategy is to introduce a fluorine substituent to block the metabolically labile site and 
optimally the fluorine atom will not harm the bonding to the target protein. Certainly, this method is 
commonly employed and results in many successful compounds. The discovery of the cholesterol-
absorption inhibitor Ezetimibe 4 (Scheme 2) is counted as one of the nicest examples of this 
strategy.
14,15,16
 
4 
 
 
Scheme 2. Development of Ezetimibe 4 by optimization of the lead. 
As seen in (Scheme 2), the target compound SCH58235 (Ezetimibe) was afforded by introducing 
two fluorine substituents to starting compound SCH48461, which is a very effective compound that 
was recently approved by the FDA. By substitution of hydrogen by fluorine the phenyl ring does not 
oxidize to a phenol, and dealkylation of the methoxy group is prevented by replacement of OMe by F 
on the N-phenyl substituent. 
Another significant example indicating the strong effect of fluorine on metabolic stability is the 
development of cyclo-oxygenase 2 (COX-2), inhibitor 4 (Scheme 3). In this case, fluorine was 
replaced by a metabolically labile methyl group to reduce the very long biological half-life to a more 
acceptable level by really decreasing the metabolic stability of the lead compound. Interestingly, 
there are also a few cases known for which the introduction of a fluorine substituent does not prevent 
oxidation at that site. This phenomenon is observed in particular for phenyl rings with a nitrogen 
substituent in the para position to the fluorine substituent.
17,18
  
 
Scheme 3. Discovery of the COX 2 inhibitor Celecoxib 6 by replacing the a fluorine group with 
methyl group which is reduces the very long half-life to an acceptable level.
14,17,18
 
  
5 
 
1.1.3. The effect of fluorine on the pKa and bioavailability  
Fluorine has a very strong effect on the basicity or acidity (pKa) of neighbouring functional groups. 
pKa shift changing will be depend to the position of the fluorine substituent relative to the acidic or 
basic group in the molecule. For example, the pKa
’s of ethylamine and its β-fluorinated analogues 
decrease in almost linear fashion by introduction of fluorine, CH3CH2NH2 = 10.7, CH2FCH2NH2 = 
8.97, CHF2CH2NH2 = 7.52, and CF3CH2NH2 = 5.7. Similarly, the acidities or pKa’s of acetic acid 
and its α-fluorinated analogues increase with CH3COOH = 4.76, CH2FCOOH = 2.59, CHF2COOH = 
1.24 and CF3COOH = 0.23 
14,19
 
Also, the pKa value of the piperidine ring decreases about 2 log units by substitution of fluorine at 
the position 3 and 4. A change in the pKa has a result on both the pharmacokinetic properties of the 
molecule and its binding affinity. For example, for binding within a certain leads series a strongly 
basic group is essential, however simultaneously this basic group may cause low bioavailability of 
compounds as a result of the partial ability of a strong basic group to pass through membranes. 
Therefore a drug discovery project team should be trying to finding an optimum between these 
conflicting effects. This challenge is well emphasised by the work of van Niel et al.
20
 on the 
development of novel fluorinated indole derivatives as selective 5HT1D receptor ligands.  
As seen in figure 1, the pKa values of the compounds significantly decrease by amalgamation of 
fluorine.  This reduction of basicity was shown potent effect on oral absorption or bioavailability but 
associated weakening of the affinity to the receptor.
20,21,22
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Figure 1. Effect of pKa value on the receptor binding and bioavailability for a set of 5HT1D 
agonists.
20
 
The nonfluorinated parent compound 7 has very low bioavailability but it is a very strong receptor 
binding ligand. The monofluorinated compound 8 has a lower pKa which is still well-matched with 
the requirements for receptor binding, but significantly increased bioavailability of compound. The 
difluoro compound 9 is basic enough to achieve high binding affinity for the 5HT1D receptor due to 
low pKa value of 6.7. 
1.1.4. The effect of fluorine on molecular lipophilicity  
One of the important molecular parameters in medicinal chemistry is lipophilicity. Naturally the 
ligand needs appropriate lipophilicity for good binding affinity to the target protein but too high 
lipophilicity will reduce solubility and causes other undesirable properties for a compound.
14
 Thus, 
the equilibrium between required lipophilicity and a certain minimal overall polarity of the molecule 
is another regular challenge for medicinal chemists. To improve the effect of fluorine on the 
lipophilicity of compound the hydrogen atom was replaced by fluorine atom in 293 pairs of 
molecules and log D values (logarithmic coefficient of the distribution of the compound between 
octanol and water at a given pH) was measured. The result indicated lipophilicity slightly increased 
7 
 
by substitution of hydrogen with fluorine.
23
 Interestingly, in the compounds which are characterized 
by the presence of an oxygen atom close to the fluorine substitution show decreased lipophilicity. 
Possibility the fluorine polarizes the neighbouring oxygen atom causing stronger hydrogen bonds 
between the oxygen and neighbouring water molecules. Therefore the idea of H/F exchange should 
be used with care because it does not always increase lipophilicity, however in general an additional 
fluorine substituent will improve the binding affinity due to an increase in the lipophilicity of the 
molecule.
14,23
 
1.1.5. Fluorinated heterocyclic compounds based on natural products 
In many therapeutic classes the presence of fluorinated drugs and drug candidates based on natural 
compounds, such as fluorocorticoid and fluorouracil derivatives are still used as major drugs for 
many clinical therapeutic classes, and recent research focuses on fluorinated nucleosides, alkaloids, 
macrolides, steroids, amino acids and prostaglandins. Most of the applications are found in anti-
cancer, anti-viral and anti-infectious fields.
6,24 
1.1.5.1. Nucleosides 
Fluorinated analogues of nucleosides, such as trifluridine 15, have been developed as anti-cancer and 
anti-infection drugs, due to their interaction either with DNA and RNA, or their effect on an 
enzymatic reaction. The main targeted enzymes by fluoronucleosides and fluoronucleobases are 
thymidylate synthesis, ribonucleotide diphosphate reductase (RDPR), DNA polymerases and viral 
reverse transcriptases. 
For example thymidylate synthesis (TS) is one of the main enzymes for DNA synthesis effecting 
transformation of 2-deoxyuridine monophosphate into thymidine monophosphate, which trifluridine 
as anti-viral drug can inactivate by blocking release of the substrate and co-factor from the active 
site.
6,24
 Trifluridine 15 can be formed in two ways; it can be formed by trifluoromethylation of the 
protected iodonucleosides 13 or by radical trifluoromethylation of uracil followed by enzymatic or 
chemical coupling with the protected deoxyribose 12 as seen in Scheme 4.
6
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Scheme 4. Syntheses of trifluridine. 
 
1.1.5.2. Alkaloids 
Vinblastine and its analogue vinorelbine are anticancer drugs based Vinca indole dimer alkaloids 
which work by binding to tubulin and inhibiting polymerisation into microtubules. It is important to 
mention that second-generation vinca dimer alkaloids, (e.g. vinflumine) show a better therapeutic 
effect in cancer therapy and are more active than vinorelbine.
25,6
 
Vinflunine 17 is formed by fluorination of vinorelbine 16 in presence of super-acid media (HF-SbF5) 
and trichloromethane (CHCl3) which generated a super-electrophilic agent such as 
difluoromethylation to abstract hydrogen from protonated alkaloid. Difluorination extraordinarily 
takes place selectively at C-4 of the clavamine part (Scheme 5).
6
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Scheme 5. Synthesis of vinflunine.
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1.1.5.3. Steroids 
Pharmaceutical research in the fluorocorticoid field is now essentially devoted to the search for new 
formulation of registered drugs. Nevertheless, there has been recently a renewal of interest for 
steroids in medicinal chemistry. It mainly concerns selective ligands for steroid hormone receptors 
for the treatment of several hormonal disorders. 
One of the most important drugs acting on steroid hormone receptors is Fulvestrant 21, which works 
by binding to the oestrogen receptor in a competitive way with estradiol with similar affinity. 
Therefore fulvestrant can be used as a treatment for hormone-dependent breast cancer.
6,26
 
Fulvestrant 21 has been synthesised as shown in (Scheme 6), and contains a long-chain substituent 
with the terminal two carbons fluorinated. 
 
Scheme 6. Synthesis of fulvestrant.
6 
10 
 
  
Dutasteride is another fluorinated steroid drug which is a 4-azasteroid. It works by inhibition of type 
1 and 2, 5α-reductases, enzymes which convert testosterone to dihydrotestosterone in the prostate. 
Therefore Dutasteride 25 can be used to treat the Benign Prostatic Hyperplasia (BPH). In the 
synthesis of Dutasteride 25 the fluorine containing starting compound 2,4-bis(trifluoromethyl)aniline 
24 can be formed by trifluoromethylation of the corresponding di-iodobenzene 22, followed by 
nitration and reduction (Scheme 7).
6
 
 
Scheme 7. Synthesis of dustasteride.
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1.2. Heterocyclic chemistry  
The cyclic compounds in which the ring contains carbon plus one or more atoms of other elements 
are called heterocyclic compounds, and the non-carbon atoms are named as hetero atoms. The most 
common hetero atoms are nitrogen, oxygen and sulphur. Among heterocyclic compounds, those 
containing five to six atoms in the ring are generally the most important. Heterocyclic compounds 
are widely distributed in nature and they are mostly important due to extensive variety of 
physiological activity attributed to them. 
Some of the significant compounds containing heterocyclic rings are antibiotics, amino acids, dyes, 
drugs, enzymes, the genetic material DNA, and so on. A few of the fundamental ring systems of the 
heterocyclic compounds which were used in this study are listed below (Figure 2).
27
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Figure 2. Fundamental heterocyclic rings. 
 
1.2.1. Imidazole in medicinal chemistry 
Imidazole is one of the heterocyclic compounds which is common and is very important in 
mechanical chemistry. Imidazole is a 5-membered planar ring containing two nitrogen atoms which 
is highly polar and therefore soluble in water and other polar solvents, due to its two nitrogen atoms 
easily leading to the formation of hydrogen bonds. It exists as two tautomers since the hydrogen can 
move and locate on either nitrogen atom. The imidazole contains a sextet of π-electrons, two 
electrons from the protonated nitrogen, and four from the remaining atoms in the ring therefore it is 
classified as an aromatic compound. Imidazole is amphoteric so it can act as an acid or a base.
5,28,29
 
Also, because of these special structural features of imidazole ring, its derivatives can freely bind 
with a range of enzymes and receptors in biological systems through hydrogen bonds, ion–dipole, π–
π stacking, and van der Waals forces, thus showing broad bioactivity.5,30 
In fact, the imidazole ring is part of many natural compounds such as purine, histamine, histidine and 
nucleic acid.
31,32
 Mainly, imidazole-based compounds are very important in medicinal chemistry and 
encouraged medicinal chemists to synthesize novel imidazole containing chemotherapeutic agents 
such as anticancer (dacarbazine), antifungal (clotrimazole), antiparasitic (metronidazole), 
antihistaminic (cimetidine) and antihypertensive (losartan) drugs which have been widely used to 
treat various types of diseases with high therapeutic potency.
33,34
 
In terms of anti-cancer activity imidazole derivatives could delay DNA synthesis through weak 
interactions such as hydrogen bond or π-π stacking which stop cell growth or division. 
12 
 
Temporarily, imidazole could bind to protein molecules much easily compared with other 
heterocyclic rings. More importantly, incessant work has been done leading to synthesis 
newimidazole-based anticancer agents targeting various enzymes or receptors such as 
topoisomerases, microtubule, cytochrome P450 enzymes, rapidly accelerated fibrosarcoma (RAF) 
kinases and so on.
5
 
So far, many imidazole derivatives as anticancer and antitumour drugs such as dacarbazine 33, 
zoledronic acid 34 and azathioprine 35 have been widely used in the clinic (Figure 3).
5,35,36,37
 
 
 
.  
Figure 3. Some clinical imidazole-based anticancer drugs.
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1.2.2. Benzimidazole in medicinal chemistry 
Benzimidazole is a heterocyclic aromatic organic compound which results from the formal fusion of 
benzene and imidazole. It is an essential pharmacophore and an advantaged or priviledged structure 
in medicinal chemistry.
38,39
 
Benzimidazole is typically soluble in polar solvents and less soluble in non-polar ones due to the 
imide nitrogen. The solubility in non-polar solvents increases by introducing other non-polar 
substituents in various positions of the benzimidazole ring. On the other hand, by introducing a polar 
group into the molecule the solubility in polar solvents will be improved. Benzimidazoles are 
sufficiently acidic to be usually soluble in aqueous alkali. Also they are weakly basic. Benzimidazole 
is slightly less basic than imidazole and is usually soluble in dilute acids. Benzimidazole with 
unsubstituted NH groups, show fast prototropic tautomerism which leads to equilibrium mixtures of 
asymmetrically substituted compounds. benzimidazole ring is very stable and unaffected by strong 
acid such as concentrated sulfuric acid or hot hydrochloric acid in addition to alkalis.  Is it fairly 
resistant to oxidation and reduction. A further characteristic of benzimidazoles is that they have the 
ability to form salts.
39-41
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Benzimidazoles 31 are generally synthesised from the reaction of 1, 2-diaminobenzenes 36 with 
carbonyl-containing compounds (carboxylic acids) under tough dehydrating reaction conditions, 
using strong acids such as polyphosphoric acid (PPA), hydrochloric acid, or boric acid (Scheme 8).
27
 
 
 
Scheme 8. Synthesis of benzimidazole from ortho-phenylene diamine.
 27
 
The benzimidazole nucleus is a vital core in many compounds acting at different targets to cause a 
range of pharmacological effects. However all seven positions in the benzimidazle nucleus can be 
substituted with different chemical units, but in the most of the biologically benzimidazole based 
compounds functional groups are located at the 1, 2, 5 or 6 positions. Therefore, the compounds 
might be mono-, di- or tri-substituted derivatives of the nucleus. Suitably substituted benzimidazole 
derivatives have established different therapeutic applications such as in antimicrobial 
39
 antiviral, 
antifungal, anticancer, antiulcer, antihypertensive and antihistaminics1.
29,42,43
 
The optimization of benzimidazole-based structures led to several drugs which are presently on the 
market.(Figure 4).
28
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Figure 4. Benzimidazole-based structures drugs.
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1.2.3. Triazole in medicinal chemistry 
Triazole is one of the organic heterocyclic compounds consisting of a five-membered ring structure. 
It contains three nitrogen atoms and two carbon atoms. Triazole is pale yellow crystalline solid 
which is soluble in water and alcohol. It exists as a pair of isomeric compounds, 1,2,3-triazole 28 and 
1,2,4-triazole 41 (Figure 5) depending on whether the carbon atoms are adjacent or not.
43,44,45
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Figure 5. Pair of triazole isomers. 
This unique structure of triazole allows its derivatives to freely bind with a range of receptors and 
enzymes in biological systems and to show an extensive spectrum of biological activitiy.
46-48
 
Moreover, the triazole ring can be combined with different pharmacophore groups to create novel 
drug molecules as an attractive linker. Therefore it provides a useful and effective pathway to 
develop different bioactive molecules.
49-51
 
Triazole based compounds with pharmacological activity indicated some advantages such as low 
toxicity, high bioavailability, less multi-drug resistance, broad spectrum activity, better therapeutic 
effect, and fewer adverse effects. Therefore they have been regularly applied in the treatment of 
different types of disease including cancer.
52-54
 In general, triazole derivatives have various 
pharmacological activities such as antifungal, antihistaminic, antimicrobial, anti-inflammatory, and 
antineoplastic. in addition to anticancer activities which is a major target for medicinal chemists 
(Figure 6).
43,55
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Figure 6. Examples of antitumor triazole-base compounds in vitro.
43
 
 
1.2.4. Benzotriazole in medicinal chemistry 
Benzotriazole 45 is another of the important scaffolds found in many biologically active compounds 
and drugs. It is an inexpensive, non-toxic, highly stable, aromatic nitrogen heterocycle consisting of 
a benzene ring fused to a triazole. Benzotriazole can be produced by diazotization of one the amine 
groups in benzene-1,2-diamine 36 with sodium nitrite and an acid (often a carboxylic acid) (Scheme 
9). The reaction is usually best conducted at lower temperature (5-10 ᵒC) to avoid loss of nitrous acid 
or decomposition of the unstable diazonium intermediate.
56-59
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Scheme 9. Synthesis of benzotriazole.
59
 
Benzotriazole, because of its fused, more highly conjugated structure, can form stronger π-π stacking 
interactions compared to triazole. In addition, the three nitrogen atoms allow it to form coordination 
and hydrogen bonds easily. Therefore the benzotriazole-based compounds can bind to enzymes and 
receptors in biological systems more easily through different non-covalent binding modes which 
results in an extensive spectrum of biological activity. Moreover, benzotriazole can form BTA-
containing metal complexes by binding the benzotriazole nucleus to different metal ions which could 
exert a double action mechanism to overcome drug resistance, due to both benzotriazole derivatives 
themselves and their supramolecular agent activity.
60
 For the above reasons, the benzotriazole moiety 
has been regularly employed to design novel drug molecules.
61-63
 
Recently, medicinal chemists working on benzotriazole derivatives have reached great improvement. 
They have discovered a number of BTA-base compounds with effective pharmacological properties, 
low toxicity, few side effects, little multi-drug resistance, good water solubility, promising 
bioavailability, diversity of drug administration, as well as a broad bioactivity spectrum.
62-64
 
Generally, bioactive BTA-based compounds are being extremely investigated all over the world to 
treat different types of disease including cancers. 
Some anticancer benzotriazole derivatives such as Vorozole and TBB have been in clinical use 
(Figure 7). The successful examination of these drug encourages continuation of work to make the 
new BTA-based anticancer compounds targeting different kinases or receptors.
65-68
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Figure 7. Examples of clinical antitumor BTA-based compounds. 
 
1.2.5. Reactions of Perfluorinated Arenes and Heteroarenes 
Examining fluorinated arene and heteroarene systems for the chemical synthesis of a wide range of 
polyfunctional carbo- and hetero-cyclic derivatives, has been one of the early research programs that 
has been pursued in organofluorine chemistry since the 1960s. For synthesis of a wide range of 
highly functionalised heteroaromatic and ring fused polycyclic systems, perfluoroarenes such as 
pentafluoropyridine, and hexafluorobenzene can be used as core scaffolds.
69
 
Reaction of a perfluoroaromatic as an acceptor moiety with various nucleophiles as the donor moiety 
involves nucleophilic aromatic substitution (SNAr) and occurs readily under usually mild conditions. 
The reaction can involve displacement of fluorine from highly fluorinated aromatic systems by 
carbon, nitrogen, oxygen and sulphur centred nucleophiles, due to the strong electron withdrawing 
effect of the fluorine substituents, rendering the compounds extremely sensitive towards nucleophilic 
attack.  
The majority of reactions of perfluoroaromatic systems proceed by the two-step addition-elimination 
nucleophilic aromatic substitution (SNAr) mechanism. The first step of the reaction involves the 
flouting of the aromaticity of the fluoroaromatic ring and creation of a tetrahedral intermediate (the 
19 
 
so-called Meisenheimer intermediate). The Meisenheimer intermediate usually breaks down quickly 
through the ejection of a fluoride ipso to the site of initial nucleophilic attack therefore aromaticity is 
recouped (Scheme 10). 
70
 
 
 
Scheme 10. Mechanism of nucleophilic substitution reaction.
71
 
Highly fluorinated systems are more receptive towards SNAr reaction compared to chlorinated or 
brominated complements, because the rate of reaction depends on the electrophilicity of the aromatic 
ring and the electronic stabilisation of the Meisenheimer intermediate. 
SNAr reactions of hexafluorobenzene 48 are well documented and interesting. Relevant examples 
have been selected for more detailed discussion.
70
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Scheme 11. Examples of SNAr reactions of hexafluorobenzene. 
 
As the examples shown in Scheme 11 these SNAr reactions show how an extensive variety of 
substituted pentafluorobenzene derivatives may be formed in a single synthetic step.
70
 
There is no selectivity matter regarding the first nucleophilic substitution due to the symmetrical 
structure of hexafluorobenzene 48. Occasionally, some di-substituted product is isolated as well as 
the mono-substituted compound in SNAr reactions of hexafluorobenzene 48 especially when the 
21 
 
added functional group is more activating than fluorine itself. For example, the reaction of sodium 
methanethiolate with an excess of hexafluorobenzene 48 which resulted in formation of mono- and 
di-substituted compounds 56 and 57 in approximately equal amounts from a single pot reaction 
(Scheme 12).72 
 
 
Scheme 12. Reaction of hexafluorobenzene 48 with methanethiolate.
72
 
 
Also, the reaction of hexafluorobenzene 48 with 2-bromophenol 58 is another example of mono and 
di-substituted formation in single step of SNAr reactions (Scheme 13).
73
 
 
Scheme 13. Reaction of hexafluorobenzene 48 with 2-bromophenol 58.
73
 
As seen in scheme 14, addition of a further nucleophile to mono-substituted perfluorobenzene is 
possible. The same, or a different, nucleophile substituent can add to pentafluorobenzene 49 
derivatives.
74
 
 
Scheme 14. Addition of second nucleophilic substituent to petafluorobenzene derivative.
74
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In the vast majority of cases, the 1,4-disubstituted product is obtained and nucleophilic substitution 
occurs preferentially at para position due to the destabilizing effect of a para-fluorine (Scheme 15). 
The lone pair on the fluorine atom is believed to repel the build up of charge at the centre of the 
pentadienyl anion system of the incipient Meisenheimer complex. 
 
Scheme 15. Examples where asecond nucleophilic substituent attaches to 1,2,3,4,5-pentafluoro-
6-(trifluoromethyl)benzene.
70
 
However, significant variation from total selectivity of para substituent is observed in several cases. 
(Table 1).  Initially, SNAr reactions of pentafluoroaniline 65 with ammonia, primary and secondary 
amines and alkoxide nucleophiles indicated nucleophilic substitution to occur mainly at the meta 
position. Corresponding reactions of pentafluoro-N-methylaniline 66 give about equal amounts of 
meta and para– substituted products, however practically exclusive para substitution is observed for 
reactions of pentafluoro-N,N-dimethylaniline 67. The observed results indicate the amino group 
powerfully deactivated the ortho and para positions due to the resonance donation of electron 
density into the aromatic ring by the amino group lone pair. However as the dimethylamino group is 
much larger, and twists out of the plane, the lone pair can no longer conjugate with the -system, and 
therefore cannot successfully deactivate the ortho and para sites.
71
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Table 1. Typical SNAr reactions of pentafluoroaniline, pentafluoro-N-methylaniline and 
pentafluoro-N,N-dimethyl aniline.
71
 
 
Substrate Nucleophile Isomer substitution % 
Ortho Meta Para 
 
           
 
NH3 
MeNH2 
Me2NH 
NaOMe 
 
 
0 
0 
0 
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87 
88 
90 
79 
 
 
13 
12 
10 
16 
 
 
 
 
 
NH3 
MeNH2 
Me2NH 
NaOMe 
 
0 
0 
0 
5 
 
40 
60 
52 
43 
 
60 
40 
48 
52 
 
 
 
 
NH3 
MeNH2 
Me2NH 
NaOMe 
 
 
0 
0 
3 
1 
 
 
7 
6 
5 
2 
 
 
93 
94 
92 
97 
 
Similarly, reaction of pentafluorobenzaldehyde 68 with dimethylamine (Me2NH) results in the 
formation of ortho and para substituted products in one step SNAr reaction in diethyl ether as solvent 
(Scheme 16).
75 
Hydrogen bonding of the amine to the carbonyl oxygen may be involved in directing 
24 
 
attack at the ortho position which would involve addition para to a fluorine with the associated 
repulsion effect of the fluorine lone pair. 
 
 
Scheme 16. SNAr reaction of pentafluorobenzaldehyde 68 with dimethyl amine.
75
 
Another recent reaction of a perfluoroaromatic as acceptor moiety with various difunctional 
nucleophiles with nitrogen as the donor atom involved nucleophilic aromatic substitution (SNAr) of 
ortho-dipyrrol-3-ylbenzene 71 with hexafluorobenzene 48 in the presence of NaH as base in DMF 
and THF to form the macrocyclic stacked fluoroarenes 72 and 73, which can used in the field of 
molecular electronics as conductors and field effect transistors (FET) due to the π-stacked structure 
(Scheme 17). 
 
Scheme 17. Reaction of ortho-dipyrrol-3-ylbenzene and hexafluorobenzene 
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1.2.5.1. Perfluorinated pyridine 
The perfluoroheteroaromatic systems such as pentafluoropyridine 74 are exceptional core scaffolds 
for the synthesis of different functionalized heteroaromatic and ring fused polycyclic compounds. 
Pentafluoropyridine, because of presence of five highly electronegative fluorine atoms and the ring 
nitrogen atom, is very reactive toward nucleophilic attack and all the five fluorine atoms can be 
replaced by nucleophiles in SNAr reactions.
76
 
 
 
Scheme 18. General reaction of pentafluoropyridine75 with difunctional nucleophiles.
77-79 
As seen in the above (Scheme 18), the first nucleophile adds at para position (4-position) of 
pentafluoropyridine 74 which is most active site, to the stabilizing nitrogen, and avoiding the 
repulsion of a para-fluorine atom. Following nucleophiles then attack at C-2 and C-6 of compound 
75 which are adjacent to the ring nitrogen. The final nucleophiles tend to add to C-3 and C-5 of 
compound 76 to give final compound 77.  
Scheme 19 shows some examples of the one-step nucleophilic substitution of pentafluoropyridine in 
which all the nucleophilic substituents added at the para position as most active site.
80-82
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Scheme 19. SNAr reactions of pentafluoropyridine. 
Di- and tri-substitution is possible as shown by the examples in Scheme 20.
78, 83
 The sodium salt of 
benzenesulfinic acid 82 reacted with pentafluoropyridine 74 to form compound 83 which was in turn 
treated with a second nucleophile (diethylamine) which added to the ortho position to form di-
substituted compound 84 in moderate yield, On the other hand reaction of compound 83 with 
ethylenediamine led to the tri-substitution product. In this case addition is most likely to have 
occurred firstly at ortho (C-2) position and the other amino group then attacking the less reactive, but 
geometrically accessible, meta position (C-3) to form the piperazine ring. This reaction shows the 
possibility of forming an additional fused ring.
78,84
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Scheme 20. Di-and tri-substitution reactions of pentafluoropyridine.
78
 
An additional example of ring formation involved the reaction of pentafluoropyridine 74 with 2-
iminopiperidine 86 to form the tricyclic compound 87 after heating with NaHCO3 at 180 °C for 30 
minutes under microwave irradiation. Initial attack at the para position is most likely to have 
occurred, followed by a second SNAr reaction at the meta position to close the imidazole ring 
(Scheme 21).
78
 
 
 
 
Scheme 21. Reaction of pentafluoropyridine with 2-iminopiperidine.
78
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However, in some case the cyclization failed and a ring did not form (Scheme 22). As seen in the 
reaction of pentafluoropyridine 74 with acetamidine 88 in the presence of NaHCO3 under reflux in 
acetonitrile for 17 h which gave the uncyclised amidine derivative 89.
78
 
 
Scheme 22. Reaction of pentafluoropyridine with acetamidine. 
Ring formation of fluorinated aryl ethers is another aim of the Weaver research group. As seen in 
Scheme 23, lithium-bromine exchange in ether was predicted to generate an aryllithium which would 
lead to intramolecular substitution of the fluorine at C-3 of the pyridine ring to close the furan ring 
forming 92a. But treatment of the compound 34 with n-BuLi in THF at −78 °C followed by 
warming to room temperature gave a compound 91 which was not the expected tricyclic furan 92a. 
The compound (2-(tetrafluoropyrid-4-yl)phenol) 91 was isolated indicating that the reaction had 
proceeded by a Smiles-type rearrangement. It seems that the aryllithium formed prefers to attack at 
C-4 rather than at C-3 to avoid the destabilizing effect of a para-fluorine. Treatment of the 
unexpected compound 91 with sodium hydride in DMF did then give the fused benzofuran 92b 
quantitatively with the phenoxide oxygen effecting nucleophilic substitution of the fluorine atom at 
3-position of the pyridine ring.
73
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Scheme 23. Smiles-type reaction in lithiation of 4-(2-bromophenoxy)tetrafluoropyridine.
73
 
On the other hand, when the corresponding thioether 93 was treated with n-BuLi, direct cyclization 
occurred by SNAr reaction at C-3 and no rearrangement was observed. The anion stabilizing effect of 
the sulfur is thought to lower the activation energy for attack at C-3 overcoming the repulsive effect 
of the para-fluorine (Scheme 24).
73
 
 
 
Scheme 24. Cyclization of thioether 93 with n-BuLi 
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1.3. Fluorinated heterocyclic compounds as potential DNA binding ligands 
1.3.1. DNA double helix structure 
Deoxyribonucleic acid (DNA) is a double-stranded molecule where each strand is composed of a 
mixture of four different types of bases which are named as adenine (A), thymine (T), cytosine (C) 
and guanine (G). In the strand these bases are connected to deoxyribose sugars to form nucleosides 
which are joined by phosphodiester links at both the 3’-hydroxyl and 5’-hydroxyl groups (Figure 8). 
The two strands are held together by Watson Crick hydrogen bonds where A form two hydrogen 
bonds with T and C forms three hydrogen bonds with G.
85-86
 
DNA plays a significant role in the life process as it carries genetic information which instructs the 
biological synthesis of enzymes and proteins through the process of transciption and translation of 
genetic information in living cells. It is a major target for drug interaction as it is the starting point of 
significant cellular processes of replication, transcription and translation which are vital for cell 
growth and division. Small ligand molecules bind to DNA and unnaturally change and/or inhibit 
DNA function. These small ligand molecules are used as drugs when inhibition of DNA function 
which is essential to treat or control a disease.
86
 
The interaction mechanisms of drugs with DNA have an important role in biological studies in drug 
discovery, and pharmaceutical development procedures, which can be used for the determination of 
new drugs targeting DNA.
87 
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Figure 8. DNA double Helix structure.
88
 
 
 
Figure 8a. DNA base pair structure which bind together by hydrogen binding. 
1.3.2. Type of drug-DNA interactions 
Drugs can interact with DNA in three different ways. i) by interaction of the drug with proteins that 
bind to the DNA, which control transcription factors and polymerases. ii) through the RNA binding 
to double helical DNA to form a triple helix structure, to open DNA single strand regions forming 
DNA-RNA hybrids that may affect transcriptional action and iii) by interaction of small aromatic 
drugs with DNA double strand structures. Interaction of drugs with DNA can involve binding of a 
planar aromatic ring compound between the base pairs of DNA which is called intercalation (for 
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example actinomycin D and daunomycin), or electrostatic interaction and DNA groove binding 
interactions of flexible chains which can wrap themselves around either the minor or major grooves.
 
86,89
 
1.3.3. Modes of drug-DNA binding 
There are two modes of drug–DNA binding, covalent and noncovalent. 
1.3.3.1. Covalent mode of binding 
Some anticancer drugs bind to DNA through covalent interaction such as via alkylation or inter- and 
intra-strand cross linking.
90
 In covalent interactions the binding is irreversible and invariably 
proceeds to complete inhibition of DNA and as a result cell death (apoptosis) will take place. The 
covalent binders have very high binding strength. In addition, they can cause DNA backbone 
distortion, which in turn can affect both transcription and replication. The covalent binders are 
usually alkylating agents, and as a result of adduct formation, they are used in cancer treatment to 
cross link DNA.
9
 DNA alkylating drugs are the oldest class of anticancer drug, but are still 
commonly used today. They show significant anti-cancer activity by damaging DNA and can cause 
cancer cells to undergo apoptosis.
6 
Alkylation usually occurs on the N-7 of guanine in DNA, 
although alkylation of other positions and other types of cross-links can occur. 
Another well-known covalent binder used as an anticancer drug is cis-platin, cis-
diamminedichloroplatinum(II) which makes intra- and inter-strand cross-links through replacement 
of chloride ligands by the nitrogens on the purine bases(Figure 9).
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Figure 9. (A) Cisplatin covalently bonded to DNA. B. (a) Modes of binding of cisplatin to 
guanine (G) and adenine (A); (b) 1,2-intrastrand GpG (structure a), 1,2-intrastrand. 
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1.3.3.2. Non-covalent mode of binding 
Non-covalent binding agents are normally considered less cytotoxic than DNA covalent binding 
agents. The non-covalent binding mode is reversible and is preferred over a covalent interaction 
which leads to irreversible DNA damage and severe toxic side effects. 
Non-covalent binders cause DNA conformation change, interrupt protein–DNA interactions and 
potentially initiate DNA strand breaks which substantial effects on gene expression.
90
 
The non-covalent mode of drug–DNA binding can be classified into intercalation and groove 
binding.
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1.3.3.3. Groove binding drug-DNA interaction 
Minor groove binding drugs typically have several aromatic rings, such as pyrrole, furan or benzene 
connected by bonds possessing torsional freedom. Groove binder drugs can bind with DNA by van 
der Waals interaction and hydrogen bonding. In addition, these drugs can form hydrogen bonds to 
bases, typically to N-3 of adenine and O-2 of thymine. 
Nucleotide asymmetry generates two grooves with different geometrical characteristics. The major 
groove is wide and relatively small and shallow, and approximately 22 Å in width. However the 
minor groove is deeper and narrower, and only about 12 Å in width (Figure 10).
87,92
 
 
 
 
Figure 10. B-DNA conformation, with the main structural dimensions.
87 
 
Furthermore, studies of the functional groups on the base pairs shows that in the major groove the 
donor-acceptor pattern is more variable. Actually, in the minor groove A/T and T/A are degenerate 
while in the major groove all four possible base pairs can be distinguished by particular donor–
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acceptor combinations.
87
 In nature, proteins can bind to the major groove, some to the minor groove, 
and some require binding to both. Most DNA interactive proteins do bind in the major groove which 
is richer in the number and specificity of the hydrogen bond donor and acceptor sites compared to 
the minor groove. However, most small molecules of less than 1000 Da bind in the minor groove.
92
 
 
 
Figure 11. A) Minor groove filled with two drug molecules of diimidazole lexitropsin. B) major 
groove binding of DMAADD molecule.
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The minor groove binders are usually curved in shape, which matches well with the topology of 
double-stranded DNA, and increasingly are of interest as potential anti-cancer drugs 
87,90 
which can 
bind either non-covalently and covalently to DNA.
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It is important to recognise that due to the sterically obstructive amine groups, G-C base pairs are not 
good binding sites in most minor groove DNA sections. However the anti-microbial agents that bind 
to A/T base pairs in the minor groove frequently have anti-tumour activity and are more selective 
than other typical DNA-reactive anti-tumour drugs which regularly cause wide damage to areas that 
are also vital for the operating of non-replicative cells. Moreover, such agents can cause damage to 
normal tissues by producing mutagenic lesions.
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Non-covalent minor groove binding drugs as potential anticancer compounds are interesting to work 
on. The polypyrrole, Bis (benzimidazole) and the bis-quaternary ammonium heterocycles are some 
examples of A/T minor groove binding drugs.
94 
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Figure 12. Netropsin is an example of a polypyrrole which binds to A/T-rich sites, and acts as 
potent inhibitor of Werner and Bloom helicases.
94
 
 
Figure 13. Hoechst 33258 (pibenzimol) is example of a bis-(benzimidazole) which binds to AT-
sites, and acts as potent cytotoxic drug by inhibition of topoisomerase and DNA helicase.
94
 
  
 
  
Figure 14. SN 6999 is example of bis-quaternary ammonium heterocycles which bind to AT 
tracts with at least 4 base pairs, related to polyamidines, and causes significant distortion of the 
DNA structure as well as inhibition of DNA and RNA polymerases.
91, 94
 
  
In addition the pyrrole-imidazole (Py-Im) polyamides show high binding affinity and specificity to 
the specific DNA sequences. They are effective inhibitors of RNA transcription, and modulate gene 
expression by modifying chromatin structure. This compound has been linked with the DNA-
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alkylating agent chlorambucil (Chl) which then reacts covalently with specific sites of DNA. For 
example. polyamide 1R-Chl (Figure 16).
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Figure 15. Structure of 1R-Chl which binds to a specific sequence of DNA and acts as inhibitor 
of cell proliferation in different cancer cell lines with no apparent cytotoxicity.
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1.3.3.4. Intercalating binding agents  
The interaction between DNA base pairs and the acridine proflavione agent was described by Leman 
as intercalation. Intercalation is the selected binding manner of flat polyaromatic ligands of 
adequately large surface area and suitable steric properties (Figure 16). Intercalators stack between 
adjacent DNA base pairs leading to significant π-electron overlap, aligning perpendicular to the 
DNA backbone without breaking up the hydrogen bonds between the DNA bases. Van der Waals, 
hydrogen bonding, hydrophobic, and/or charge transfer are the known forces that maintain the 
stability of the DNA–intercalator complex, even more than DNA alone.83,96 In addition the DNA 
intercalators complex is less sensitive to the ionic strength compared to DNA groove binding 
complexes due to the stabilization by π-π interaction.  
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Figure 16. Intercalation of a planar aromatic molecule in the DNA base pairs by hydrophobic 
interaction and van der Waals forces. 
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When an intercalating agent is inserted between DNA base pairs, a decrease in the DNA helical twist 
and lengthening of the DNA occurs that causes delay in cell replication. Therefore such compounds 
used in chemotherapeutic treatment to inhibit DNA replication in rapidly growing cancer cells.  
The binding mode can be determined by the size and nature of intercalating chromophore. For 
effective intercalation, at least a two-ring fused system is necessary, for example naphthalene- type, 
but these intercalate only if they have pendant cationic side chain, having similar affinities 
irrespective of the presence of charged or uncharged nitrogen atoms in the aromatic system. In 
comparison fused three-ring systems such as acridines have adequate stacking interactions to 
intercalate without the need for appended side chains.
93 
Figure 17 shows some examples of 
intercalating clinical drugs. 
  
 
Figure 17. Example of DNA-intercalating agents 
93 
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1.3.4. Techniques used to study drug–DNA interactions 
There are a number of different techniques which can be used to study the interaction of DNA with 
ligand molecules such as infrared (IR), UV–Visible, and nuclear magnetic resonance (NMR) and 
fluorescence spectroscopies, as well as macromolecular X-ray crystallography. Atomic force 
microscopy (AFM), electrophoresis, mass spectrometry, viscosity measurements, thermal 
denaturation studies,  differential pulse voltammetry, Raman and circular dichroism, have also all 
been employed. All these techniques can be used as methods to characterise drug–DNA complexes, 
and effect of binding on DNA structure. In this study UV–Visible and fluorescence spectroscopies 
were used as these are of common use. Macromolecular x-ray crystallography was also attempted to 
see if co-crystals of DNA-drug addicts could be grown. In addition, some antibacterial activity also 
studied against one Gram negative strain (E. coli) and one gram positive strain (Staphylococcus 
aureus). 
1.3.4.1. UV–Visible absorption spectroscopy 
UV–Visible absorption spectroscopy is one the simplest and commonly employed instrumental 
techniques for studying both the stability of DNA and its interactions with small ligand molecules. In 
this technique, UV–Visible absorption spectra of the free drug are compared with drug–DNA 
complexes, which are usually different. If a small molecule has intercalated between DNA base pairs 
hypochromism (reduced absorbance) and bathochromism (red shift) should occur which is due to the 
stacking interaction between an aromatic chromophore of intercalator and a base pair of DNA.  In 
terms of bathochromism (red shift) the π-orbitals of the DNA base pairs couple with π*-orbital of the 
small molecules which causes an energy decrease and a decreasing of π → π* transition energy. 
Therefore the absorption of the small molecule shows a red shift. Simultaneously, the empty π*-
orbital is partly filled by electrons, reducing the transition probability, which leads to hypochromism. 
In case of electrostatic attraction between the DNA and small molecules, a hyperchromic effect 
should occur, which is due to the corresponding changes of DNA in its conformation and structure 
after the complex–DNA interaction has occurred. The hyperchromic effect is the exceptional 
increase in absorbance of DNA upon denaturation.
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1.3.4.2. Fluorescence spectroscopy 
Fluorescence spectroscopy is another common technique which can indicate interactions between 
small ligand molecules and DNA. The advantages of this technique compared to other techniques are 
high sensitivity, selectivity and large linear concentration range. Compounds containing aromatic 
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functional groups with low-energy π-π transition levels have large number of possible transitions 
compared to compounds containing aliphatic and alicyclic carbonyl structures or conjugated double-
bond structures, and absorp strongly. Such rigid structures can often re-emit the excess energy as 
light in the form of fluorescence. Therefore aromatic systems usually give the most intense and the 
most useful fluorescence signals. Also using this technique based on fluorescence emission the mode 
of drug-DNA binding can often be determined. In the case of intercalation interactions, drugs bound 
to DNA enhance deactivation through fluorescence emission so a significant increase in the 
fluorescence emission will usually be observed.  
But in other interactions like groove binding, electrostatic, hydrogen bonding or hydrophobic 
interactions drugs are close to the sugar-phosphate backbone; therefore it is possible to observe a 
decrease in the fluorescence intensity due to non-radiative energy loss. The quenching fluorescence 
assay is one method which provides further information about the binding mode of drugs to DNA. 
Ethidium bromide (EB) is one of the common fluorophore probes. It can insert to the DNA base pair 
and bind to DNA strongly as an intercalator, which causes an increase in the fluorescence intensity.  
The improved fluorescence in presence of EB can be quenched by the addition of a second molecule. 
Therefore by intercalating a second molecule into DNA, the fluorescence intensity of the EB-DNA 
will decrease, because it will compete with EB in binding with DNA. In addition the extent of 
interaction between the drug and DNA can be determinate by the extent of fluorescence quenching 
of EB bound to DNA.
86 
Figure 18, describes the interaction of  Ni complex [Ni2(L)2(NO3)2] with EB-
DNA. The KSV values of compound is (7.0 ± 0.097) x 10
3
 M
-1
  
 
  
 
Figure 18. Emission spectra of EB bound to CT-DNA in the presence of free Ni complex [Ni2 
(L)2(NO3)2] (a) Fluorescence quenching curves of EB bound to CT-DNA Ni complex (b). 
(Plots of I0/I vs. [Compound]). 
86
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1.3.4.3. Macromolecular X-ray crystallography  
One of the useful and important methods which is used to determine the three dimensional structure 
of DNA-drug complex is macromolecular X-ray crystallography. This method involves growth of a 
co-crystal of DNA and the drug of interest and X-ray diffraction data collection.  There are different 
methods to grow suitable crystals which all have the aim of bringing the biological macromolecules 
solution to a supersaturated state. The crystallization process can be affected by different factors 
which include biophysical and physico-chemical parameters. Biophysical parameters include 
stabilization, purification, storage and handling of macromolecules, as bacterial contamination are 
very significant in crystallization of the DNA. Fundamental physico-chemical parameters such as 
supersaturation (concentration of macromolecules and precipitants), temperature, pH, purity, ionic 
strength, pressure, magnetic and electric field, viscosity effects and the difference in concentration 
between DNA/drug solutions crystallizing solution also are significant factor in DNA crystallization. 
In addition, nucleation and crystal growth can be affected by the method used. Therefore it better to 
attempt different methods to achieve optimum crystallization. The most common method is the 
vapour diffusion technique which was investigated in this study.
98,99
 
1.3.4.4. Vapour diffusion crystallization 
This technique is suitable for small volumes less than 2 µl and was used for the first time to 
crystallize transfer ribonucleic acid (tRNA). In this technique the vapour pressure of a droplet 
containing biological macromolecule, buffer, crystallizing agent, additives, and any drug expected to 
bind, and the vapour pressure of a reservoir (containing a solution of crystallizing agent which is 
more concentrated than the droplet) are allowed to reach to equilibrium by diffusion of the volatile 
substances such as organic solvent or water molecules from the droplet. Vapour diffusion 
crystallization can involve different methods which include, hanging drop, sitting drop and sandwich 
drop as seen in (Figure 19).
99,37
 In the present study the hanging drop method was employed. 
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Figure 19. Vapour diffusion crystallization methods. a) Sitting drop, b) hanging drop, c) 
sandwich drop.
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1.4. Fluorinated heterocyclic compounds as protein kinases inhibitors 
Due to toxicity of many anticancer drugs to normal tissues and various side effects of them the 
medicinal chemist is constantly trying to design and develop new therapeutic agents for the treatment 
of cancers with high selectively. An important area where selectivity is hoped for is inhibition 
against protein kinases and receptors.
100-102
. Inhibition of receptors or kinases is one of the greatest 
pathways to treat cancers due to their significant role of them in cell proliferation.
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Cancer cells vary from normal cells in their way of communicating with their neighbours because of 
abnormality in their signalling network. Therefore the understanding of abnormal signal transduction 
as the source of the altered phenotype of cancer cells has led to more attention to emerging therapies 
targeting this abnormality,
104 
and identification of these signalling pathway is very important in 
signal transduction therapy.
105
 One of the most important signalling elements are protein tyrosine 
kinases (PTKs) which were recognized as key drivers of cancer cells in the late 1980s. Protein 
tyrosine kinases (PTKs) show a crucial role in the regulation of cell proliferation, differentiation, 
metabolism, migration, and survival. They are classified as receptor PTKs and non-receptor PTKs. 
Selective receptor and non-receptor PTK inhibitors are known to function as anti-tumor agents. 
These agents are indicated to prevent various features of cancer cell development, including 
propagation, survival, incursion, and angiogenesis.
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Also the groups of serine /threonine kinases, cyclin dependent kinase (CDKs), Erks, Raf,and 
PKB/Akt, are very important in cell proliferation, cell division, and anti-apoptotic signalling. In 
addition EGFR (epidermal growth factor receptor), PDGFR (platelet derived growth factor receptor), 
and VEGFR (vascular endothelial growth factor receptor), were targeted having established their 
involvement in various malignancies.
107
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For example, the Ras-Raf-Mek-Erk pathway is one significant pathway in the hallmark of many 
cancers which can be activated by receptor-linked tyrosine kinases such as the epidermal growth 
factor receptor (EGFR). Therefore the inhibition of Raf, Mek, and Erk are very significant and useful 
for treatment of many cancers as their activities are highly improved because of the extensive 
oncogenic mutations in ras (Figure 18).
108-110
 For example sorafenib (a Raf kinase inhibitor) can be 
useful in preventing activating mutations in B-Raf which occur in 66% of human melanomas.
111
 
Selumetinib (AZD6244) (a Mek kinase inhibitor) is used to treat various types of cancer, such as 
non-small cell lung (Figure 20). 
112
 
 
 
Figure 20. On cogene activation of the ERK MAPK cascade. 
Mutationally activated B-Raf, Ras and mutationally activated and/or overexpressed EGFR causes 
persistent activation of the ERK MAPK cascade in human cancers. Activated ERKs translocate to 
the nucleus, where they phosphorylate and control various transcription factors causing changes in 
gene expression. Especially, ERK-mediated transcription can result in the upregulation of EGFR 
ligands, such as transforming growth factor alpha (TGF-α), therefore generating an autocrine 
feedback loop that is critical for Ras-mediated transformation and Raf-mediated gene expression 
changes.
108
 
Also epidermal growth factor receptor (EGFR) is a tyrosine kinase cell-surface receptor for members 
of EGF-Family which contains an extracellular ligand-binding domain, a transmembrane lipophilic 
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region and an intracellular protein tyrosine kinase domain. EGFR triggered by binding of a specific 
substrate which leads to cell propagation, invasion and metastasis by activation of signal transduction 
pathways. By binding EGFR inhibitors to epidermal growth factor receptor the EGFR pathway will 
be blocked, resulting in inhibition of the proliferation of malignant cells.
113-116 
Therefore the role of 
EGFR in treatment of many cancers is found to be very significant. For example, Iressa and Tarceva 
are active epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) which prevent the 
growth and spread of non-small cell lung cancer and pancreatic cancer by blocking the EGFR 
pathway.
117-119
 Although they show some side effects. Quinazoline AG 147829 is another example of 
EGFR inhibitor which is in clinical development for the treatment of glioblastoma multiforme 
(GBM) (Figure 20). 
115
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Figure 21. Protein kinase inhibitors in the clinic and in development 
In general this study was aimed at the synthesis of new heteroarene and fluorinated heteroarene 
compounds with potential bioactivity. In particular for the synthesis of new heterocycles, we planned 
to exploit the easy SNAr reaction of fluorinated arenes such as hexafluorobenzene and 
pentafluropyridine to introduce a range of groups, specially bisimidazole and bisbenzoimidazole 
derivatives which will allow subsequent ring fusion processes to be carried to generate polycyclic 
structures, or allow biaryl type links to be set up to generate conformationally flexible polyaryl 
systems. A further aim was to introduce different water solubilising group into the successfully 
synthesised polycyclic structures to increase water solubility of the compounds for further 
45 
 
consideration and investigation of the biological activity. The binding properties of the synthesised 
compounds will be carried out using UV absorption, and ethidium bromide (EB) fluorescence 
displacement experiments to evaluate interactions between the synthesised compounds as groove or 
intercalating binding agents with DNA by different binding modes including hydrogen bonding and 
electrostatic interactions. Biological properties will be assessed by antimicrobial activity assay, and 
anticancer activity of the synthesised compounds will be investigated against different cancer cell 
lines. Continuing work should be undertaken to improve biological and anticancer activity of 
synthesised compounds and to develop the new drugs needed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
2. Results and discussion 
As mentioned before fluorinated compounds have shown important improvement in the biological 
activity of pharmaceutical compounds and drugs in medicinal chemistry. The introduction of a 
fluorine atom into organic compounds can change the biological properties of the compound and 
make significant improvement on the biological activity of them by influencing its metabolism.  On 
the other hand N-heterocycles are very important scaffolds found in many biologically active 
compounds, and drugs containing nitrogen atom play a significant role in interaction of small 
molecules and drugs target. These compounds have application and their utilization in organic 
synthesis is important. Therefore this research involves the use of perfluoroarenes, as convenient 
starting materials to different heterocycles compound especially N-heterocycles for synthesis of 
novel fluorinated heterocyclic compounds by SNAr reaction. 
  
2.1. Outcome of organic synthesis 
2.1.1. Synthesis of perfluoro heterocyclic compounds 
The aim of this study was the synthesis of a range of perfluorobiheteroaryl compounds containing 
dissimilar heterocyclic rings in order to have possible interaction with DNA and potential biological 
activity. It was hoped that hetero atoms such as N or S could function as effective nucleophiles to 
promote SNAr of the fluorine atoms in a perfluoroarene, and that this would provide an easy and 
flexible method to rapidly assemble linked multi-ring heterocycles as possible DNA binding agents. 
2.1.1.1. Reaction of pentafluoropyridine with imidazole 
The aim of this reaction (Scheme 25) was the synthesis of a biheteroaryl compound containing 
imidazole and a perfluoropyridine ring in order to develop scaffolds with potential to interact with 
DNA. It was hoped that nitrogen heterocycles such as imidazole could function as effective 
nucleophiles to promote SNAr of the fluorine atoms in a perfluoropyridine. The reaction of 
pentafluoropyridine with imidazole in presence of NaH as base and THF as solvent did not 
successfully afford the desired product. TLC and NMR revealed that some starting materials were 
still present with several products formed. Optimization of reaction conditions showed that a large 
excess of pentafluoropyridine (3 equiv.) was essential to complete consumption of starting material 
and formation of 2,3,5,6-tetrafluoro-4-(1H-imidazol-1-yl)pyridine 108. The structure of compound 
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108, formed in 89% yield, was established by its 
1
H NMR spectrum, with accurate mass 
measurement of  m/z MS (ESI) (MH
+
), 218.0335 matching C8H3F4N3. In addition the 
19
F NMR 
spectrum showed signals for two pairs of fluorine atoms indicating that the tetrafluoropyridine ring 
was intact. Several crystallization methods were tried to crystallize the product but the compound did 
was not crystallize, and remained as a yellow oily liquid. 
 
 
Scheme 25. Reaction of pentafluoropyridine with imidazole. 
 
2.1.1.2. Reaction of pentafluoropyridine with benzimidazole 
Initial attempts to make compound 109 using benzimidazole instead of imidazole (Scheme 26) led to 
its formation in a moderate 55% yield. To try to improve the yield slow addition was investigated. 
The reaction of pentafluoropyridine with benzimidazole in presence of NaH as base and THF as 
solvent was completed in 24 h at room temperature using a syringe pump to add the benzimidazole 
slowly. TLC and 
1
H NMR spectroscopy indicated the compound 109 was made successfully as a 
shiny solid in a much improved 98% yield with accurate mass measurement m/z of 268.0491 (MH
+
) 
for C12H5F4 N3.The 
19
F NMR spectrum showed signals for two pairs of fluorine atoms. The m.p. of 
the crystals was found to be 138-143 °C and the structure confirmed by x-ray crystallography (Figure 
22). Therefore the yield was then improved to 98% by use of a syringe pump allowing a more 
controlled addition. 
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Scheme 26. Reaction of pentafluoropyridine with benzimidazole. 
 
 
Figure 22. X-ray crystal structure of compound 109 which crystallises with one molecule of 
water with hydrogen bonds to the N-9 atoms of two benzimidazole rings. 
 
2.1.1.3. Reaction of benzimidazolyltetrafluoropyridine derivative 109 with Benzimidazole 
The aim of this reaction was formation of di-product 110 in order to form a linked three ring 
molecule with better potential as a groove binder for DNA (Scheme 27). 
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Scheme 27. Reaction of compound 109 with benzimidazole. 
Therefore reaction of compound 109 (1 equiv.) with benzimidazole 31 (1 equiv.) was carried out 
under different conditions (Table 2) 
Table 2. Different reaction conditions of compound 109 with benzimidazole 
Entry Reagents Conditions Results 
1 NaH THF, RT, 24 h. N2 
Starting material, unknown compound and 
product 36% 
2 NaH DMF, RT, 24 h. N2 Starting material and product 30% 
3 NaH THF, reflux, 24 h. N2 
Starting material, unknown compound and 
product 16% 
3 NaH 
Dioxane, reflux, 22 h. 
N2 
Starting material, product 13% 
 
As seen in table 2 entry 1, reaction in THF at room temperature indicated the best yield of target 
compound 110 which afforded by column chromatography. The structure was confirmed by 
1
H 
NMR spectroscopy and accurate mass measurement (ESI) (MH
+
), m/z 366.0953 for C12H5F4N3 as 
expected. 
The m.p. of the crystals was 186-190 °C. In addition the exact structure of compound 110 was 
confirmed by X-ray crystallography (Figure 23).  
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Figure 23. Crystal structure of compound. 110. 
 
2.1.1.4. Reaction of pentafluoropyridine with triazole 
The aim of this reaction (Scheme 28) was to complete the synthesis of another biheteroaryl 
compound containing 1,2,3-triazole and a perfluoropyridine ring as a scaffold with possible 
interaction with DNA. The reaction of pentafluoropyridine with triazole (ratio 2:1) in presence of 
NaH as base and THF as solvent for 24 h at RT was carried out successfully. 
19
F and 
1
H NMR 
spectra indicated the presence of two different compounds in the product. The product mixture was 
purified by column chromatography using 6:4 light petrol:ethyl acetate as eluting solvent to give X 
isomer 111 as white shiny solid (40%) and 100% ethyl acetate to give Y isomer 112 as shiny light 
yellow solid (15%). The structures of both isomers were confirmed by 
1
H NMR and 
19
F NMR 
spectroscopy. The 
1
H NMR perfectly proved the difference between each isomer as the 
1
H NMR 
spectrum of isomer X 111 indicated two signals each integrating for 1H, whereas the spectrum of 
isomer Y 112 showed only 1 signal which integrated for 2H. Also accurate mass measurement of 
each isomer confirmed the correct structure. Isomer X 111 indicated MS (ESI) (MH
+
), m/z 219.0287 
for C7H3F4N4 and isomer Y 112 showed MS (ESI) (MH
+
), m/z 219.0289 for C7H3F4N4 as expected. 
In addition the exact structure of compound 111 (X isomer) was confirmed by X-ray crystallography 
(Figure 24). 
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Scheme 28. Reaction of pentafluoropyridine with 1,2,3-triazole. 
 
Figure 24. Crystal structure of compound 110. 
 
2.1.1.5.  Reaction of pentafluoropyridine with benzotrizole 
The aim of this reaction (Scheme 29) was to achieve the synthesis of another heteroaryl compound 
containing benzotriazole and a perfluoropyridine ring in order to have possible interaction with DNA 
and potential biological activity, as benzotrizole derivatives indicated usefull activity in medicinal 
chemistry. The reaction of pentafluoropyridine with benzotriazole (ratio 2:1) in presence of NaH as 
base and THF as solvent for 24h at RT was carried out successfully.  The target compound 113 was 
precipitated by adding the water to give a white solid in 88% yield. The structure was confirmed by 
the 
19
F and 
1
H NMR spectra with the 
19
F NMR spectrum displaying two signals, each corresponding 
to 2 F as expected. Also accurate mass measurement (ESI) (MH
+
), m/z 269.0443 confirmed the 
expected formula, C12H5F4N4. 
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Scheme 29. Reaction of pentafluoropyridine with benzotriazole. 
 
2.1.1.6. Reaction of pentafluoropyridine with carbozle 
Reaction of pentafluoropyridine 74 with carbazole 29 was carried out at RT in the presence of NaH 
as base and a mixture of THF and DMF as solvents (Scheme 30). TLC analysis showed the presence 
of the starting carbazole 29, and column chromatography purification allowed us to get the target 
product 114 as white crystals in 45 % yield. 
1
H NMR and 
19
F NMR spectroscopy proved the 
presence of the compound 114 with the 
19
F NMR spectrum displaying 3 signals, each corresponding 
to 1 F as expected. Also mass spectrometry found the expected mass of the compound MS (ESI) 
(MH
+
), C29H17F3N3 requires m/z 464.1369 found m/z 464.1370.  In addition the exact structure of 
compound 114 was confirmed by X-ray crystallography (Figure 25). 
 
 
 
Scheme 30. Reaction of pentafluoropyridine with carbazole. 
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Figure 25. Crystal structure of compound 114. 
 
2.1.1.7. Reaction of 2-bromophenol with compound 109 
The aim of this reaction was the synthesis of polycyclic compounds with more than one heteroatom 
in their chemical structure in order to have potential interaction with DNA and useful biological 
activity. The reaction of compound 109 with 2-bromophenol in the presence of NaH as base and 
THF as solvent at room temperature for 24 h did not successfully afford the expected compound 116 
(Scheme 31). The 
1
H NMR and GC mass spectra did not show the product formed. Optimization of 
reaction condition showed that changing the solvent to DMF was essential to complete reaction and 
formation of product, although the TLC and NMR analysis showed presence of small quantity of 
impurity. After recrystalliztion, the product 115, in which two molecules of bromophenol had added, 
was formed in 53% yield and confirmed by 
1
H NMR spectroscopy and accurate mass measurement 
with m/z of 573.9383 for C24H15Br2 F2 N3O2. Moreover, the 
19
F NMR spectrum showed one signal for 
one pair of fluorine atoms indicating that 2,6-disubstitution had occurred. Also product showed a m.p 
of 178-181 °C. 
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Scheme 31. Reaction of 2-bromophenol with compound 109. 
2.1.1.8. Reaction of 2-aminothiophenol with compound 109 
The aim of this reaction was synthesis of higher polycyclic compounds with more than one 
heteroatom in their chemical structure in order to have good interaction with DNA and enhance 
biological activity. The reaction of compound 109 with 2-aminothiophenol 117 in the presence of 
NaH as base and THF as solvent at room temperature for 24 h did not successfully afford the 
expected tricyclic compound 119 (Scheme 32). TLC revealed that some starting material was still 
present with two products being formed. 
After column chromotographic purification the compound 118 was obtained in 29% yield as dark red 
solid which was confirmed by its 
1
H NMR spectrum and high resolution mass spectrum (scheme 32). 
The accurate mass of 374.0728 matched the expected formula of C18H12F3N4S. While the 
19
F NMR 
spectrum showed three signals for three fluorine atoms as expected. Also IR spectroscopy indicated 
the presence of a NH group by the signal at 3355 cm
-1
. 
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Scheme 32. Reaction of the 2-aminothiophenol with compound 109. 
 
2.1.1.9. Reaction of 2-aminobenzenethiol with 4-nitrobenzoyl chloride 
The aim of this reaction was the synthesis of target compound 121 as a starting compound for further 
reaction with pentafluoropyridine. It was hoped acylating the amino group would render the NH 
group more acidic and allow deprotonation to activate the nitrogen to nucleophilic attack leading to 
formation of the desired tricyclic thiazine derivative 124 (Scheme 33).  
To synthesise target, N-(2-mercaptophenyl)benzamide 121, 2-aminobenzenethiol was reacted with 4-
nitrobenzoyl chloride 120 in the presence of Et3N (base) and THF (solvent) at room temperature for 
24 h. The 
1
H NMR and mass analysis indicated some impurity and product was formed only in very 
low yield. Optimization of reaction conditions showed that changing the solvent to acetonitrile 
(CH3CN) was essential to give complete reaction and formation of target product in 57% yield, 
which was confirmed by 
1
H NMR spectroscopy and accurate mass measurement of 273.0339 for 
C13H10 N2O3S. In addition the IR data proved the presence of NH and carbonyl groups with peaks at 
3348.54 and 1681.98 cm
-1
.  Also the m.p. of the product was 178-181 °C. The thiol 121 was found to 
undergo easy oxidation in air to the disulfide. This then meant that an additional step to reduce the 
disulfide bond would be required for the proposed reactions with fluoroarenes. 
56 
 
2-(4-Nitrophenyl)benzothiazole 122 was formed when the reaction of 2-aminobenzenethiol with 4-
nitrobenzoyl chloride was carried out in pyridine (as base and solvent) at room temperature for 24 h, 
showing it was unsuitable as a solvent to form 121 leading to dehydration and ring closure. The 
structure was confirmed by 
1
H NMR spectroscopy and accurate mass measurement with m/z of 
257.0377 for C13H8 N2O2S. In addition in the IR spectrum, disappearance of the NH and carbonyl 
peaks at 3348.54 and 1681.98 cm
-1
 proved that cyclization of compound 121 had occurred, and 
compound 122 had formed. The m.p of the product was 224-229 °C. Due to the difficulty in 
preparing 121 and its easy aerial oxidation to the corresponding disulfide, it was not possible to study 
its reaction with 109 to make fused products such as 124. 
.  
Scheme 33. Reaction of 2-aminobenzenethiol with 4-nitrobenzoyl chloride. 
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2.1.1.10. Reaction of 2-bromothiophenol with compound 109  
The aim of this reaction was the synthesis of condensed polycyclic compounds which contain more 
than one electronegative atom such as nitrogen, fluorine, or sulphur in their chemical structure. 
Introduction of a 2-bromophenylthio- or 2-bromophenoxy-groups has been shown to be a viable 
method to effect fusion of a benzothiophene or benzofuran ring by bromine-lithium exchange, and 
intermolecular SNAr reaction. The reaction of 2-bromothiophenol 125 with compound 109 in 
presence of NaH as base and THF as solvent was thus carried out over 24 h at room temperature. 
TLC and NMR revealed that some starting material (compound 109) was still present. However after 
recrystallization from hot ethanol the formation of difluoropyridine derivative 126 in 65% yields was 
confirmed by 
1
H NMR spectroscopy and accurate mass measurement at 603.8952 for C24H13 
Br2F2N3S2. The 
19
F NMR spectrum showed two signals for two fluorine atoms as expected for the 
2,4,5 trisubstituted pyridine. Also the m.p. of the crystals was 166-170 °C. In addition the exact 
structure of 126 was confirmed by X-ray crystallography (Figure 26). 
Cyclisation of dipyridine derivative 126 (Scheme 34) was attempted with the hope of forming the 
bis-benzothiophenopyridine 128 but this could not be achieved by using BuLi to effect bromin-
lithium exchange. 
To minimize the formation of the difluoropyridine derivative 126 and encourage formation of target 
compound 127, the reaction was repeated under different conditions. Increasing the amount of 
tetrafluoropyridine derivative 109 (2 equiv.), and decreasing the time of reaction at 0 ºC was studied. 
The NMR spectra and accurate mass indicated that even under these conditions still compound 126 
was still the main product and compound 127 did not form. 
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Scheme 34. Reaction of 2-bromothiophenol with compound 109. 
 
 
Figure 26. crystal structure of compound 126. 
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2.1.2. Synthesis of Bis N-heterocyclic compounds as starting materials for reaction with 
fluoroarenes 
2.1.2.1. Reaction of glyoxal with ammonium acetate 120 
The aim of this reaction was synthesis of a bis-imidazole derivative by the condensation of glyoxal 
129 (an α-dicarbonyl aldehyde compound) with two equivalents of ammonium acetate in order to use 
as starting material for further reaction with perfluorinated arenes.
(2)
 The known 1H,1’H-2,2’-
biimidazole 130 was formed in a low 5% yield. The structure was confirmed by 
1
H NMR 
spectroscopy and by its mass spectrum with m/z 135.0668 for C6H7N4. Also IR spectroscopy 
indicated the present of a NH group by showing a signal in the region 3000-3500 cm
-1
. Although the 
yield is low, the product was easy to isolate by simple filtration and the starting materials were 
cheap. 
 
Scheme 35. Reaction of glyoxal with ammonium acetate 
 
2.1.3.  Synthesis of 2,2-(1,4-butanediyl)-bis-1H-imidazole and 2,2-(1,4-butanediyl)-bis- 1H-
benzimidazole  
As the 1H,1H-2,2’-biimidazole  130 did not dissolve in most organic solvents and showed low 
reactivity towards perfluorinated compounds, it was decided to prepare a linked bis-imidazole with a 
flexible spacer as such compounds were of interest as possible cross-linking agents. 2,2-(1,4-
butanediyl)-bis-1H-imidazole, 132 with long chain hydrocarbon linker to increase their solubility 
were thus prepared. 
2.1.3.1. Reaction of adipoyl chloride with aminoacetaldehyde dimethyl acetal  
The aim of this reaction was to synthesise intermediate compound 131 and to investigate cyclisation 
with acid to prepare target compound 132. The reaction of adipoyl chloride with aminoacetaldehyde 
dimethyl acetal in the presence of Et3N as base and THF as solvent for 5 h at room temperature 
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successfully afforded the desired product. The compound 131 was formed in 75% yield as white 
solid and its structure confirmed by its 
1
H NMR spectrum and by its mass spectrum with m/z 
321.2019 (MH
+
) for C14H29O6N2. Also the IR spectrum indicated the present of NH group by 
showing the signal in area 3000-3500 cm
-1
 (broad peak). The compound 131 had an m.p of 93-95 °C. 
The reaction was followed by treating the successfully made compound 132 with different acid 
conditions (Table 3) with the aim of converting the acetyl groups to aldehydes and promoting 
cyclisation to the imidazole target compound 132. Unfortunately the reactions were unsuccessful, 
and none of the conditions tried led to formation of target compound132 as seen in (Scheme 36). 
Table 3. different reaction conditions for cyclization of compound 132 
Entry Reagents Conditions Results 
1 AcOH / NH4OAc 80 °C, 24 h. N2 Unsuccessful 
2 PPA / NH4OAc 80 °C, 24 h. N2 
Unsuccessful 
3 H2SO4/AcOH / NH4OAc 80 °C, 24 h. N2 
Unsuccessful 
 
 
Scheme 36. Reaction of adipoyl chloride with aminoacetaldehyde dimethyl acetal 
2.1.3.2. Reaction of adipoyl chloride with o-phenylenediamine 
The aim this reaction was the synthesis of the linked bis-amide compound 133 and its cyclisation 
with acid to prepare the target linked benzimidazole 134. The reaction of adipoyl chloride with o-
phenylenediamine in the presence of Et3N as base and THF as solvent for 24 h at room temperature 
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successfully afforded compound 133 which was formed in 68% yield as a white solid. The structure 
was confirmed by 
1
H NMR spectroscopy and by its mass spectrum with m/z 327.1814 (MH
+
) for 
C18H23O2N4. Also the IR spectrum indicated the presence of an NH group by signals in the area 
3000-3500 cm
-1
 (broad peak). The compound 133 had a m.p. of 155-165 °C. 
The reaction was followed by treating the compound 134 with polyphosphoric acid (PPA) at 85 °C 
for 48 h. 
1
H NMR spectroscopy indicated presence of both cyclised and non-cyclised compounds 
which unfortunately could not be separated to isolate the target compound due to the high polarity of 
both compounds.  
 
Scheme 37. Reaction of adipoyl chloride with aminoacetal aldehyde methyl ester. 
 
2.1.3.3. Reaction of adiponitrile with aminoacetaldehyde dimethyl acetal 
As synthesis of compound 132 by using the adipoyl chloride was not successful as shown in scheme 
36, it was decided to study the reaction of adiponitrile, to change the carbonyl group in compound 
131 to an imine which might help cyclisation and allow preparation of target compound 132. 
Therefore the reaction of adiponitrile with aminoacetaldehyde dimethyl acetal was carried out under 
different conditions (Table 4). However, the reactions did not work at all and 
1
H NMR spectroscopy 
indicated only the presence of starting material (adiponitrile) and the target compound 135 did not 
formed.(Scheme 38). 
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Table 4. different reaction conditions attempted for the formation of compound 135. 
Entry Reagents Conditions Results 
1 
Cu(OTf)2 
 
THF /reflux, 24 h, N2 no reaction 
2 - THF/reflax, 24 h, N2 
no reaction 
3 - reflux, 24 h, N2 
no reaction 
 
 
Scheme 38. Reaction of adiponitrile with aminoacetaldehyde dimethyl acetal. 
 
2.1.3.4. Synthesis of imidate and formation of the target compound 132 and 134 
The aim of these reactions was formation of imidate 136 as starting material to react with 
aminoacetaldehyde dimethyl acetal and o-phenylenediamine to allow synthesis of target compounds 
132 and 134 which could not be formed using the conditions above. 
The reaction of adiponitrile with ethanol and acetyl chloride in DCM was completed in 3 days at 4 
°C. The imidate salt 136 formed as white solid in 80% yield and was confirmed by 
1
H NMR 
spectroscopy. Also the IR spectrum indicated the present of a NH group by showing a signal at 3000-
3500 cm
-1
. Compound 136 had a m.p. of 135-136 °C. 
The intermediate compound 136 then reacted successfully with aminoacetaldehyde dimethyl acetal 
in methanol as solvent at 65 °C for 3 h. The compound 135 was formed as a yellow syrup in 98% 
yield, and was confirmed by its 
1
H NMR spectrum and accurate mass measurement with m/z of 
319.2315 (MH
+
) for C14H31O4N4. Also the IR spectrum indicated the present of the NH group with a 
signal at 3000-3500 cm 
-1
. 
Compound 135 was treated successfully with 37% HCl at 65 °C for 24 h to synthesise target bis-
imidazole 132 as a brown solid in 60% yield (Scheme 39). The structure was confirmed by 
1
H NMR 
and 
13
C NMR spectroscopy. However, the 
1
H NMR spectrum recorded in DMSO showed two singlet 
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signals at 6-7 ppm for 4H atoms and one singlet signal for NH at 12 ppm (Figure 27) whereas the 
1
H 
NMR in methanol only indicated one singlet signal at 6.8 ppm for 4H atom and did not show any 
signal for NH (Figure 28), which could be caused by hydrogen exchange between two nitrogens in 
methanol. Accurate mass measurement confirmed the correct molecular formula with m/z of 
191.1296 (MH
+
) for C10H13N4. The compound 132 failed to melt, but decomposed at 168 °C. 
Reaction of the imidate salt with o-phenylenediamine was carried out successfully in the presence of 
methanol for 6 h at 80 °C (Scheme 38). The linked benzimidazole 134 formed as a light yellow solid 
in 75% yield and was confirmed by 
1
H NMR and 
13
C NMR spectroscopy and accurate mass 
measurement with m/z of 291.1581 (MH
+
) for C18H18N4. Also IR spectrum indicated the presence of 
NH group with a signal in area 3000-3500 cm 
-1
. The compound 134 m.p. was 258-260 °C in 
agreement with the literature value of 258 °C.
 31
 In addition the exact structure of 134 was confirmed 
by X-ray crystallography (Figure 29). 
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Scheme 39. Synthesis of bis-imidate to form linked imidazole and benzimidazoles 132 and 134. 
. 
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Figure 27. 
1
H NMR (400 MHz, DMSO-d6) spectrum of compound 132. 
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Figure 28. 
1
H NMR (400 MHz, methanol-d4) spectrum of compound 132. 
 
 
Figure 29. Crystal structure of compound 134. 
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2.1.4. Synthesis of bis-imidazole and bis-benzimidazole containing perfluoro heterocyclic 
derivatives 
Nitrogen containing heterocyclic aromatic compounds such as bis-imidazole and bis-benzimidazole 
are an important type of nitrogen containing heterocyclic aromatic substances in drug design and 
synthesis. Also they are of importance  in medicinal chemistry due to their biological activity.  
Moreover, several functional groups are easily introduced into the structurally rigid of bis-imidazole 
and Bis-benzimidazole ring and alter the biological activities allowing using as cross linking agents 
for double-stranded DNA.
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We planned to synthesize compounds which contain more than one bio labile constituent, namely 
bis-imidazole or bis-benzimidazole and fluorinated containing heterocyclic substances to provide a 
biologically active DNA binding structure as lead scaffolds.  
2.1.4.1. Reaction of the pentafluoropyridine with 1H,1H-2,2’-biimidazole  
The reaction of pentafluoropyridine 74 with 1H,1H-2,2’-biimidazole 130 in the presence of NaH as 
base and dry DMF as solvent was conducted over 24 h at room temperature. TLC revealed that two 
compounds formed and some starting material was still present. By adding water compound 138 
(0.14 g, 33%) was preciptated and collected as white solid. After an extraction process compound 
137 (0.08 g, 31%) was isolated. Their structures confirmed by 
1
H NMR spectroscopy and accurate 
mass measurement with m/z of 264.0413 (MH
+
) for C11H5F3N5 for 137, and 433.0441 (MH
+
) for 
C16H5F8N6 matching 138. The 
19
F NMR spectra showed three signals (1 F for each signal) for 
compound 137 and 2 signals (4 F atom for each signal) for compound 138 as expected. Compound 
137 had m.p. of 288-295 °C which is much higher than compound 138 (158-164 °C). The structure 
of 138 was confirmed by X-ray diffraction analysis (Figure 30). 
 
Scheme 40. Reaction of the pentafluoropyridine with 1H,1H-2,2’-biimidazole. 
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Figure 30. Crystal structure of compound 134. 
 
2.1.4.2. Reaction of the hexafluorobenzene with 1H,1H-2,2’-biimidazole 
The reaction of hexafluorobenzene 48 (2 equiv.) with 1H,1H-2,2’-biimidazole 130 (1 equiv.) in the 
presence of NaH as base and dry DMF as solvent was conducted over 24 h at room temperature. 
According to the 
1
H NMR spectrum and TLC the target compound did not form and starting material 
was present as the main compound. However, the reaction worked at 80 °C in the presence of NaH 
as base and dry DMF in 1:3 ratio of starting biimidazole and hexafluorobenzene.
  
After 
recrystallization from hot ethanol the product 139 was obtained as a brown solid (18% yield) and the 
structure confirmed by 
1
H NMR spectrum and accurate mass measurement with m/z of 281.0433 
(MH
+
) for C12H5 F4 N4. The 
19
F NMR spectrum showed two signals (2F for each environment) as 
expected. No evidence for the formation of 140 was obtained. 
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Scheme 41. Reaction of the pentafluoropyridine with 1H,1H-2,2’-biimidazole. 
 
2.1.4.3. Reaction of the pentafluorobenzaldehyde with 1H,1H-2,2’-biimidazole. 
The reactions of pentafluorobenzaldehyde 68 with 1H,1H-2,2’-biimidazole 130 in 1:1 and 2:1 ratios 
were attempted with NaH as base and dry DMF as solvent and were conducted over 24 h at room 
temperature. TLC and NMR of both reactions revealed mixtures of different compound formed. 
Attempts to separate and purify the products by repeated recrystallization methods were 
unsuccessful. Attempts to isolate pure product by column chromatography afforded five fractions, 
but the 
1
H NMR spectra of all fractions indicated they were still not pure. However, the reaction 
worked after heating the reactants in DMF at 80 °C for 24 h in the presence of NaH as base and in a 
1:1 ratio.
  
After recrystallization from DCM and light petrol the product 141 was obtained as a yellow 
solid in 10% yield, and the structure confirmed by 
1
H NMR spectroscopy and accurate mass 
measurement with m/z of 291.476 (MH
+
)  for C13H6 F3N4. The 
19
F NMR spectrum showed three 
signals (1F for each signal) indicating cyclisation had occurred to form 141 rather than 142.  
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Scheme 42. Reaction of pentafluorobenzaldehyde with 1H,1H-2,2’-biimidazole. 
 
2.1.4.4. Reaction of pentafluoropyridine with Bis-benzoimidazole 134 
The reaction of pentafluoropyridine 74 (3 equiv) with bis-benzimidazole 134 (1 equiv.) was studied 
under two conditions; the first was with NaH as base and dry DMF as solvent over 24 h at room 
temperature. TLC and 
1
H NMR spectroscopy indicated a mixture of different compounds. Therefore 
different crystallization methods were tried to isolate pure product, but they were unsuccessful and 
the 
1
H NMR spectrum of the product mixture was messy and complicated.  
The second condition employed DMSO as solvent instead of DMF and bis-benzimidazole was added 
dropwise by syringe pump. TLC revealed one main compound formed with only a trace impurity. 
After recrystallization from hot toluene, the product 143 (95%) was obtained as a white solid, and the 
structure assigned by 
1
H NMR spectroscopy and accurate mass measurement with m/z of 589.1376 
(MH
+
) for C28H17F8N6. The 
19
F NMR spectrum showed 2 signals (4 F atom for each signal) as 
expected. Compound 143, had a m.p of 197-198 °C. 
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Scheme 43. Reaction of the pentafluoropyridine with bis-benzimidazole 134. 
 
2.1.4.5. Reaction of the hexafluorobenzene with bis-benzimidazole 134 
The reaction of hexafluorobenzene 48 with bis-benzimidazole 134 was tried under two conditions; 
firstly with NaH as base and dry DMF as solvent over 24 h at room temperature using a 10:1 ratio of 
hexafluorobenzene and bis-benzoimidazole. TLC indicated very polar products were formed and the 
1
H NMR spectrum showed broad complex signals in the aromatic region. A different 
recrystallization method were tried but was unsuccessful and neither 144 nor 145 could be obtained. 
The second experiment used syringe pump addition of the bis-benzimidazole. This time TLC showed 
many spots which indicated many compounds formed. Recrystallization was attempted but was 
unsuccessful. Preparative TLC was then employed but only one component of the mixture was 
isolated pure, but proved to be in a negligible amount to characterise, while other spots were very 
close together and could not be separated. Also at the base line, preparative TLC showed a 
fluorescent compound formed, which was isolated but has not yet proved possible to identify. 
72 
 
 
Scheme 44. Reaction of the pentafluoropyridine with bis-benzimidazole 134. 
2.1.4.6. Reaction of pentafluorobenzaldehyde with bis-benzimidazole 134 
The reaction of pentafluorobenzaldehyde (2 equiv.) with bis-benzimidazole 134 (1 equiv.) was 
carried out in the presence of NaH as base and dry DMF as solvent over 24 h at room temperature 
using a syringe pump to ensure slow addition. The compound formed was a red solid which tailed on 
the TLC plate, and 
1
H NMR spectroscopy showed only broad, messy peaks in the aromatic reaction. 
Attempts to isolate a pure product by recrystallization or chromatography were unsuccessful and no 
evidence for the formation of 146 could be obtained. (Scheme 45) 
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Scheme 45. Reaction of pentafluorobenzaldehyde with bis-benzimidazole 134. 
 
2.1.4.7. Reaction of compound 134 with methyl pentafluorobenzoate 
The reaction of methyl pentafluorobenzoate 147 (2 equiv.) with bis-benzimidazole 133 (1 equiv.) 
was carried out in present of NaH as base and DMSO as solvent over 24 h at room temperature. TLC 
revealed one main compound formed with only a trace impurity. After recrystallization from hot 
ethanol, the product 148 (58%) was obtained as a white solid, and the structure assigned by 1H NMR 
spectroscopy and accurate mass measurement with m/z of 703.1569 (MH
+
) for C34H23F8O4N6. The 
19
F NMR spectrum showed 2 signals (4 F atoms for each signal) as expected. Compound 148, had a 
m.p of 195-198 °C  
 
Scheme 46. Reaction of compound 134 with methyl pentafluorobenzoate. 
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2.1.5. Synthesis of bis-linked binding agents via formation of an amide bond 
Organic bis-linked binding agents are compounds that interact with double stranded DNA, usually 
reversibly. Bis-linked binding compounds contain two possible intercalating ring systems connected 
together by a linker. Bis-linked binding agents have higher DNA binding constants due to more than 
one intercalating unit and can exhibit sequence selectivity and show slower dissociation than mono 
compounds.  
Therefore it was planned to exploit the reactivity of the acyl halide group in derivatives of 
pentafluorobenzoyl chloride towards di-amide formation by reaction with long chain diamines. It 
was hoped that diamide compounds would act as bis-nucleophiles and allow two potential binding 
compounds to be linked together to increase their DNA binding potency. The pentafluorophenyl 
benzamides could also be used as starting compounds for further functionalization to improve 
activity. 
2.1.5.1. Reaction of pentafluorobenzoyl chloride with 2,2-(ethylenedioxy)bis(ethylamine) 
In order to synthesise fluorinated bis-intercalating compounds, reaction of 
pentafluorobenzoylchloride 149 with the aliphatic amine 2, 2-(ethylenedioxy)bis(ethylamine) 150 
was investigated in a 2:1 ratio at RT in THF as solvent and with Et3N as base. The target compound 
151 was afforded in 75% yield (Scheme 47). 
19
F NMR spectroscopy displayed the expected fluorine 
signals for the target compound, δF (376 MHz, CDCl3) 21.14-21.22 (4F, m), 11.04-11.20 (2F, m), 
1.79-1.81(4F, m) and mass spectrometry gave the mass of the expected compound 151, MS (ESI) 
(MH
+
), C20H14O4F10N2 requires m/z 537.0867, found m/z 537.0867. The structure of 151 was 
confirmed by X-ray diffraction analysis (Figure 31), m.p. 128 - 129 °C. 
 
 
Scheme 47. Reaction of pentafluorobenzoyl chloride and 2,2-(ethylenedioxy)bis(ethylamine). 
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Figure 31. crystal structure of compound 151. 
 
2.1.5.2. Substitution reaction of benzimdazole 31 with fluorinated bis-linked scaffold 151 
After successful synthesis of the fluorinated bis-link binder 151 it was planned to investigate the 
possibility introducing different heterocyclic groups into the compound 151 by SNAr reaction to 
make larger agents with increased surface area to interact with DNA as potential bis-intercalators. 
Therefore the reaction of benzimidazole 31 with compound 151 was carried out in a 2:1 ratio at RT 
in the THF as solvent and NaH as base. The workup procedure gave a white solid which TLC 
indicated to be a mixture of two compounds. Therefore column chromatography was used to separate 
the mixture to give target compound 152 (62%) and compound 153 (15%) (Scheme 44). 
19
F NMR 
spectroscopy of the compound proved the di-substituted derivative 152 had formed by exhibiting two 
signals for eight fluorine atom each signal cantaining 4 F atoms.  
 and mass spectrometry was in accord with the expected formula, MS (ESI) (MH-), C34H23O4F8N6 
requires m/z 731.1659, found m/z 731.1657. Similarly 
19
F NMR spectroscopy of the compound 153 
proved mono substitution had occurred in one ring only, by exhibiting five signals for nine fluorine 
atoms, δF (376 MHz, CDCl3) 22.48 (2F, dd, J, 22.93, 11.65), 22.07-21.01 (2F, m), 16.59 (2F, dd, J, 
23.31, 11.65), 11.1 (1F, t, J 20.3), 1.83-1.70 (2F, m). 
The mass spectrum confirmed the required formula, MS (ESI) (MH
-
), C27H18O4F9N4 requires m/z 
633.1190 found m/z 633.1192. Also the structure of 152 was confirmed by X-ray diffraction analysis 
(Figure 32). 
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Scheme 48. Reaction of benzimdazole with fluorinated bis-linked scaffold 151. 
 
Figure 32. Crystal structure of compound 152. 
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2.1.5.3. Substitution reaction of carbazole with fluorinated bis-linked scaffold 151 
The reaction of carbazole 29 with compound 151 was carried under different conditions as shown in 
table 5, hoping to displace the 4-position fluorine atom in compound 151 to form the target 
compound 154 by nucleophilic substitution reaction (Scheme 49). Unfortunately the reactions did 
not work and only the starting material was recover according to TLC and 
1
H NMR spectroscopy, 
which showed only signal s in the aromatic region. 
Table 5. Different reaction conditions attempted for the of carbazole with Fluorinated bis-
linked scaffold 151. 
Entry Reagents Conditions Results 
1 NaH THF, RT, 22 h. N2 Starting material 
2 NaH THF, 65 °C, 22 h. N2 Starting material 
3 NaH DMF, RT, 22 h. N2 Starting material 
4 NaH DMF, 85 °C, 22 h. N2 Starting material  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 49. Attempted reaction of carbazole with fluorinated bis-linked scaffold 151. 
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2.1.5.4. Substitution reaction of 2-mercaptobenzimidazole with fluorinated bis-linked scaffold 
151 
After the unsuccessful reaction of carbazole 29 with compound 151 the reaction of 2-
mercaptobenzimidazole 155 with compound 151 was investigated using different conditions as 
shown in table 6, hoping to displace the 4-fluorine atom in compound 151 with formation of 
intermediate compound 156 by nucleophilic substitution reaction which may then cyclize to form the 
linked tetracyclic compound 157 (Scheme 50). Unfortunately the reactions did not work and only 
starting material was recovered according to TLC and 
1
H and 
19
F NMR spectroscopy. The 
1
H 
spectroscopy did not show any signal at aromatic region and 
19
F NMR spectroscopy indicated the 
same signals as compound 151. 
Table 6. Different reaction conditions of 2-mercaptobenzimidazole with fluorinated bis-linked 
scaffold 151 
Entry Reagents Conditions Results 
1 NaH THF, RT, 22 h. N2 Starting material 
2 NaH THF, Reflux (65 °C), 22 h, N2 Starting material 
3 NaH DMF, RT, 22 h, N2 Starting material 
4 NaH DMF, 85 °C, 22 h, N2 Starting material 
 
79 
 
 
Scheme 50. Reaction of 2-mercaptobenzimidazole with fluorinated bis-linked scaffold 151. 
 
2.1.5.5. Substitution reaction of imidazole with fluorinated bis-linked scaffold 151 
After the failed efforts to synthesis potential bis linked binding agents using carbazole or 2-
mercaptobenzimidazole it was decided to try imidazole derivatives as nucleophiles as the 
benzimdazole had worked well before (section 2.1.5.2). Thus reaction of imidazole with synthesis 
compound 151 was carried out in 2:1 ratio at RT in THF as solvent and with NaH as base. The 
workup procedure gave an oily product and TLC indicated the presence of a mixture of two 
compounds plus some starting material. Therefore column chromatography purification was carried 
to give target compound 158 (26%) and compound 159 (19%) (Scheme 51). The 
19
F NMR spectrum 
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of the compound proved di-substituent 158 had occurred by exhibiting two signals for eight fluorine 
atoms each signal containing 4F atoms. Also mass spectrometry confirmed the expected formula 
with (ESI)(MH
-
), C26H21F8N6O4 requires m/z 633.1491, found m/z 633.1473. Also 
19
F NMR 
spectroscopy proved mono substitution 159 had occurred in by exhibiting five signals for nine 
fluorine atoms, δF (376 MHz, CDCl3) 22.39-22.48 (2F, q, J, 12.03),  21.07-21.01 (2F, m), 16.59-
16.67 (2F, q, J, 11.65), 11.1 (1F, t, J 20.3),  1.70-1.83 (2F, m). and mass spectrometry confirmed the 
formula, (ESI)(MH
-
), C23H16F9N4O4 requires m/z 583.1033, found m/z 583.1040. it is worth 
mentioning that the benzimdazole show better reactivity than imidazole and gave much higher yields 
of mono and di-substituted products as seen in Scheme 44 with the same reaction conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 51. Reaction of imdazole with fluorinated bis-linked scaffold 151. 
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2.1.5.6. Substitution reaction of indole with fluorinated bis-linked binding scaffold 151 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 52. Reaction of indole with fluorinated bis-linked binding scaffold 151 
The reaction of indole 32 with compound 151.(Scheme 52) was next carried out under the conditions 
shown in table 7 in a 2:1 ratio of reactants. Disappointingly again the reactions did not work and only 
the starting materials were identified as proved by TLC and NMR spectroscopy. 
Table 7. Different reaction conditions for the attempted reaction of indole with fluorinated bis-
linked scaffold 151 
Entry Reagents Conditions Results 
1 NaH THF, RT, 22 h, N2 Starting material 
2 NaH THF, Reflux ( 65 °C), 22 h, N2 Starting material 
3 NaH  DMF, RT, 22 h, N2 Starting material 
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2.1.5.7.  Substitution reaction of benzotrizole with fluorinated bis-intercalator scaffold 151 
After the failed effort to synthesis a potential bis-linked binding using indole and successful reaction 
of benzimidazole it was planned to attempt reaction with benzotrizole as it is known to be a good 
nucleophile. Thus reaction of benzotriazole 30 with compound 151 (Scheme 53) was carried out 
under different conditions as shown in table 8, of these the reaction which was carried in a 2:1 ratio 
at RT in DMSO as solvent and NaH as base indicated the highest yield of target compound (entry 3). 
The workup procedure gave a colourless oily product. The 
1
H NMR spectrum indicated the presence 
of some impurities.Column chromatography purification was therefore carried to give target 
compound 161 (54 %) as a white solid.
19
F NMR spectroscopy showed two signals (4 F for each 
signal) as expected for target compound 161 and mass spectrometry displayed the expected mass of 
the compound, MS (ESI) (MH+), C32H23F8N8O4 requires m/z 735.1709, found m/z 735.1705. 
Table 8. Different reaction conditions for the attempted reaction of benzotrizole with 
fluorinated bis-linked scaffold 151. 
.Entry Reagents Conditions Results 
1 NaH THF, RT, 22 h, N2 Starting material 
2 NaH DMF, 65 °C, 22 h, N2 Starting material, product 161 (29%) 
3 NaH  DMSO, RT, 22 h, N2 Starting material, product 161 (54%) 
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Scheme 53. Reaction of benzotriazole with fluorinated bis-intercalator scaffold 159. 
 
2.1.5.8. Substitution reaction of 1,2,4-trizole with fluorinated bis-intercalator scaffold 151 
After the successful effort to synthesis a potential bis intercalator using benzotrizole it was planned 
to attempt to make the 1,2,4-triazole derivative. Thus reaction of 1,2,4-triazole 28 with synthesised 
compound 151 was carried out in a 2:1 ratio at RT in DMSO as solvent and NaH as base. The 
workup procedure gave colourless oily product. The 
1
H NMR spectrum indicated the presence of 
some starting material. Therefore column chromatographic purification was carried to give target 
compound 162 (28 %) as white solid (Scheme 54). 
19
F NMR spectroscopy showed the expected 
fluorine signals for the target compound, δF (376 MHz, CDCl3) 22.74-22.64 (2F, q, J, 11.65), 21.15-
21.05 (2F, m), 14.49-14.40 (2F, q, J, 11.28), 11.4 (1F, t, J 20.68), 1.95-1.81 (2F, m). Mass 
spectrometry displayed the expected mass of the compound, MS (ESI) (MH
-
), C22H15F9N5O4 
requires m/z 584.0986, found m/z 584.0994 
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Scheme 54. reaction of 1,2,4-triazole with fluorinated bis-intercalator scaffold 151. 
 
2.1.6. Synthesis of bis-linked binding agents by introducing of aliphatic hydrophilic link to 
synthesised fluorinated heterocyclic compounds. 
In this part of the investigation we planned to make another series of novel bis-linked binding agent 
by introducing an aliphatic hydrophilic link to synthesised fluorinated heterocyclic compounds with 
better water solubility, and to investigate their DNA binding properties. 
2.1.6.1. Reaction of compound 109 with 2,2-(ethylenedioxy)bis(ethylamine). 
The aim of this reaction was formation of compound 163 by replacement of the 2-fluorine atom in 
compound 109 with 2,2′-(ethylenedioxy)bis(ethylamine) to make another bis-linked binding agent by 
formation of an aryl amine bond by SNAr reaction (Scheme 55).  
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Scheme 55. Reaction of compound 109 with 2,2′-(ethylenedioxy)bis(ethylamine). 
Therefore reactions of compound 109 (2 equiv.) with 2,2′-(ethylenedioxy)bis(ethylamine) 150 
(1 equiv.) were carried with the different conditions shown in table 9. However the reaction which 
was carried in the present of THF as solvent and Et₃N as base under reflax ( 65 °C ) for 24 h 
indicated highest yield of target compound (entry 3).  
 
Table 9. Different methods for synthesising target compound 163. 
Entry Reagents Conditions Results 
1 None THF, RT, 24 h, N2 Starting material  
2 None THF, Reflux (65 °C), 24 h, N2 Starting material, product 163 ( 31%) 
3 Et₃N THF, Reflux (65 °C), 22 h, N2 Starting material, product 163 (55%) 
 
TLC revealed a mixture of two polar compounds one of which only just moved with ethyl acetate as 
eluent, while the other remained on the base line. Also some starting material was still present. After 
column chromatography purification processes the target product 163 was obtained in 55% yield and 
the structure was confirmed by its 
1
H NMR spectrum and accurate mass measurement with m/z of 
641.1845 (MH
-
) for C30 H23 F6N8O2. The 
19
F NMR spectrum showed three signals (2F for each 
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signal) as expected. Also IR spectroscopy indicated the presence of an NH group by a signal in the 
region 3000-3500 cm
-1
.  
2.1.6.2. Reaction of further perfluoropyridine derivatives with 2,2′
(ethylenedioxy)bis(ethylamine) 
After optimizing the conditions for the reaction of 1-(perfluoropyridin-4-yl)-1H-benzo[d]imidazole 
109 with 2,2′-(ethylenedioxy)bis(ethylamine), we were decided to try different perfluoropyridine 
derivatives to synthesise a series of more polar fluorinated heterocyclic compounds using 2,2′-
(ethylenedioxy)bis(ethylamine) as aliphatic hydrophilic linker as shown in Table 10. 
 
Table 10. Reaction of different perfluoropyridine derivatives with 2,2′-
(ethylenedioxy)bis(ethylamine). 
Reactant  Reactant Conditions Expected product Yield% 
 
 
 
 
 
THF as solvent, 
Et₃N as base, 
Reflux (65 °C), 22 
h, N2 
 
 
 
 
 
70% 
 
 
 
 
THF as solvent, 
Et₃N as base, 
Reflux (65 °C), 22 
h, N2 
 
 
 
 
 
30% 
87 
 
 
 
 
 
 
 
 
THF as solvent, 
Et₃N as base, 
Reflux (65 °C), 22 
h, N2 
 
 
 
 
 
65% 
 
As seen in table 10 reaction of compound  113 with 2,2′-(ethylenedioxy)bis(ethylamine) in THF as 
solvent, and Et₃N as base under reflux (65 °C) for 22 h worked well and the target compound 164 
was afforded in 70% yield. The 
19
F NMR spectrum showed three signals (2F for each signal) as 
expected. Also mass spectrometry confirmed the expected mass for the target product 164, MS (ESI) 
(MH
+
), C28H23F6N10O2 requires m/z 645.1904, found m/z 645.1908. 
Compound 111 was reacted with 2,2′-(ethylenedioxy)bis(ethylamine) under the same conditions as 
for the preparation of compound 164 (table 10) but the desired compound 165 was afforded in only 
30% yield which is much less then compound 164 therefore the benzotriazolyl perfluoropyridine 
derivative appears more reactive than the triazolyl perfluoropyridine. 
19
F spectroscopy proved the 
presence of six fluorine atoms in the product by detecting three signals which each signal contain 2 F 
as expected. In addition mass spectrometry found the expected mass for target product 165, MS 
(ESI)(MH
+
), C20H29F6N10O2 requires m/z 545.1591, found m/z 545.1576. 
Also target compound 166 was afforded (65% yield) in a similar way (Table 10). The 
19
F spectrum 
proved the product was formed and displayed three signals (2F atoms for each signal as expected. 
Moreover the mass spectrum displayed a signal for the expected molecular formula for the target 
compound 166, MS (ESI) (MH
+
), C22H21F6N8O2 requires m/z 543.1686, found m/z 543.1686 
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2.1.6.3.  Reaction of different perfluoropyridine derivatives with 2-(2-aminoethoxy) ethylamine  
The aim of these reactions was formation of an alternative series of polar fluorinated heterocyclic 
novel compounds with a shorter linker. Varying the length of the linker could allow different binding 
modes with duplex DNA to be probed. Replace most of a fluorine atom in perfluoropyridine 
derivatives with 2-(2-aminoethoxy) ethylamine was expected again to proceed readily by SNAr 
reaction. 
After optimization of the conditions for reaction with 2,2′-(ethylenedioxy)bis(ethylamine) 148 
(section 2.1.6.2), we were decided to test the same conditions for reactions of  perfluoropyridine 
derivatives with 2-(2-aminoethoxy)ethylamine 165 as an alternative aliphatic hydrophilic linker 
(Table 11). 
But as can be seen in table 11 reaction of compound 109 and 113 with 2-(2-aminoethoxy)ethylamine 
165 resulted in lower yields compared to reactions with 2,2′-(ethylenedioxy)bis(ethylamine) 148 in 
table 10 Therefore was decided to try reaction of compound 111 with 2-(2-aminoethoxy)ethylamine 
in the more polar DMF instead of THF as solvent. The result indicated the reaction worked much 
better in DMF by showing higher % yield of product. Thus, reaction of compound 108 with 2-(2-
aminoethoxy) ethylamine was also carried out in DMF.  
 
Table 11. Reaction of different perfluoropyridine derivatives with 2-(2-aminoethoxy) 
ethylamine. 
Reactant  Reactant Conditions Expected product Yield 
 
 
 
 
THF as solvent, 
Et₃N as base, Reflux 
(65 °C), 22 h, N2 
 
 
 
 
 
23% 
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THF as solvent, 
Et₃N as base, Reflux 
(65 °C), 22h. N2 
 
 
 
 
 
15% 
 
 
 
 
 
 
 
DMF as solvent, 
Et₃N as base, 65 °C, 
22 h, N2 
 
 
 
 
55% 
 
 
  
 
 
 
 
 
DMF as solvent, 
Et₃N as base, 65 °C, 
22 h, N2 
 
 
 
 
50% 
 
As seen in table 11, reaction of compound 109 with 2-(2-aminoethoxy) ethylamine in THF as 
solvent, and Et₃N as base under reflux (65 °C) for 22 h worked and the target compound 168 was 
afforded in 23% yield. The 
19
F NMR spectrum showed three signals (2F for each signal) as expected. 
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Also mass spectrometry showed the expected mass for target product 168, MS (ESI) (MH
+
), 
C28H21F6N8O1 requires m/z 599.1737, found m/z 599.1720 
Compound 113 was reacted with 2-(2-aminoethoxy)ethylamine under the same conditions as for 
compound 109 (Table 11) and target compound 169 was afforded in 15% yield. 
19
F spectroscopy 
proved the product formed by detecting three signals (2F atoms for each signal as expected).. Also 
mass spectrometry found the expected mass for target product 169, MS (ESI) (MH
+
), C26H19F6N10O1 
requires m/z 601.1642, found m/z 601.1637 
Due to the low yield of compounds 168 and 169, reaction of compound 111 with 2-(2-
aminoethoxy)ethylamine was carried out in DMF as solvent, using Et₃N as base but at the same 
temperature (65 °C) for 22 h. The reaction was successful affording the target compound 170 in 55% 
yields. 
19
F spectroscopy proved the product formed by detecting three signals (2F atoms for each 
signal as expected). Also mass spectrometry found the expected mass for the target compound 170, 
MS (ESI) (MH
+
), C18H15F6N10O1 requires m/z 501.1329, found m/z 501.1320. 
In addition target compound 171was afforded (50% yield) in similar conditions as for compound 170 
(Table 11), and its structure proved by 
19
F spectroscopy which found three signals (2F atoms for 
each signal as expected). Mass spectrometry showed the expected mass for target compound 171, 
MS (ESI) (MH
+
), C20H17F6N8O1 requires m/z 499.1424, found m/z 499.1409. 
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2.1.7. Further functionalization to make bis-linked binding agent 
Another approach taken was the design and synthesis of a series of potentially fluorinated bis-
intercalating compounds involving potential cyclization of ester derivatives to make bi- or tri-cyclic 
bis-intercalators. 
2.1.7.1. Reaction of compound 148 with hydrazine 
 
Scheme 56. Reaction of compound 148 with hydrazine. 
The reaction of hydrazine with compound 148 (Scheme 56) was carried out under different 
conditions as shown in table 12 in a 4:1 ratio of reactants. As in entry 1 the hydrazine hydrate did not 
dissolve very well in THF and only starting material was recovered. Therefore in entry 2, methanol 
was added to dissolve the hydrazine and form a homogeneous reaction mixture.  Unfortunately the 
reactions did not work and only the starting materials were recovered. Only in entry 3 did the 
19
F 
NMR spectrum indicate reaction had occurred but it was such a complex spectrum and nothing was 
recovered, even after several different purification methods. 
 
Table 12. Different condition attempted for synthesising target compound 172. 
Entry Reagents Conditions Results 
1 None  THF, RT, 22 h, N2 Starting material 
2 None 
THF and 2 ml of methanol, RT, 
22 h, N2 
Starting material  
3 None 
methanol, 1 h, 65 °C and RT, 22 
h, N2 
Starting material, unknown compounds 
formed 
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2.1.7.2. Reaction of compound 148 with 2-aminopyridine  
 
Scheme 57. Reaction of compound 148 with 2-aminopyridine. 
After the unsuccessful reaction of hydrazine with ester compound 148 and the poor solubility of 
hydrazine in nonpolar solvents, it was decided to try 2-aminopyridine as a nucleophilic reagent 
which might form both an amide bond to the ester in 148 and cyclise by effecting SNAr reaction of 
the adjacent fluorine to form tricyclic compound 174 (Scheme 57). Reactions of 2-aminopyridine 
with the successfully synthesised ester compound 148 were conducted with a higher ratio of  2-
aminopyridine (4:1) under different conditions as shown in table 12 Unfortunately all the reactions 
did not work and only starting materials was recovered. 
 
Table 13. Different condition attempted for synthesising target compound 174. 
Entry Reagents Conditions Results 
1 NaH THF, RT, 22 h, N2 Starting material 
2 None Dioxane, 10 h, RT and 10 h 80 °C, 22 h, N2 Starting material, 
3 None Acetic acid, 24 h, 100 °C and RT, 22 h. N2 Starting material 
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2.1.7.3. Reaction of ester compound 148 with acetamidine hydrochloride  
 
 
Scheme 58. Reaction of ester compound 148 with acetamidine hydrochloride. 
After unsuccessful reaction of 2-aminopyridine with compound 148 it was decided to try another 
more reactive nucleophile like acetamidine (Scheme 58).  The reactions of ester compound 148 and 
acetamidine hydrochloride were carried in a 1:2 ratio as shown in table 14,  As seen in entry 4 the 
reaction which was carried at 85°C, in DMF as solvent and NaH as base indicated highest yield of 
target compound 176 (entry 3). The workup procedure gave yellow solid product. The 
1
H NMR 
indicated the presence of some impurities. Therefore column chromatography purification was 
carried out to give compound 176 (28%) as a white solid. 
19
F and 
1
H NMR spectroscopy indicated 
that the acetamidine had added and cyclised on only one of the fluoroarene rings, leaving the ester 
intact on the other as seen in (Scheme 58). Also mass spectrometry displayed the expected mass of 
the compound 176, MS (ESI) (MH
+
), C35H24F7N6O3 requires m/z 709.1793 found m/z 709.1775. The 
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formation of 176 showed the reaction to be viable, and further investigation to effect reaction on both 
rings should be continued. 
 
Table 14. Different condition for synthesising target compound 176. 
Entry Reagents Conditions Results 
1 None 
Pyridine and 1 ml of methanol,  
80 °C, 22 h, N2 
Starting material 
2 Sodium acetate Methanol, reflux, 24 h, N2 Starting material  
3 NaH THF, RT, 22 h, N2 Starting material,  
4 NaH DMF, RT, 22 h, N2 
Starting material, product 176 
(10%) 
5 NaH DMF, 85°C, 22 h, N2 
Starting material, product 176 
(28%) 
6 NaH DMSO, RT, 22 h, N2 
Starting material, complex NMR 
spectrum of unknown compound. 
 
2.1.8. Addition of hydrophilic side chains to the successfully synthesised fluorinated heterocyclic 
compounds. 
Throughout the biological assays it had been found that some of synthesised compounds had poor 
solubility in the buffers employed. For the purpose of improving the water solubility of the novel 
synthesised compounds it was planned to introduce hydrophilic side chains to the compounds. 
Therefore the aim of these reactions is to replace a fluorine atom in the successfully prepared 
fluorinated heterocycls with different side chains by an aromatic nucleophilic substitution reaction. 
Hopefully the aliphatic side chain bearing polar groups should make the compound more water-
soluble and could improve DNA binding activity. 
2.1.8.1. Reaction of compound 138 with cysteine 
The aim of this reaction was to increase the water solubility and improve DNA binding activity of 
compound 138 by adding the amino acid cysteine 177 (protected as its methyl ester) as a side chain 
through reaction of its thiol side group. (Scheme 59)  
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Scheme 59.Reaction of the compound 138 with cysteine. 
Therefore reaction of compound 138 (1 equiv) with methyl cysteine 177 (2 equiv) was carried under 
different conditions as shown in table15. TLC and mp point indicated only the presence of 
compound 138 as starting material. The reaction had not worked and the target compound 178 was 
not formed. 
Table 15. different reaction conditions for compound 138 with cysteine. 
Entry Reagents Conditions Results 
1 Et3N THF, RT, 22 h, N2 Starting material 
2 Et3N DMF, RT, 22 h, N2 Starting material 
3 Et3N DMF and THF, RT, 22 h, N2 Starting material 
 
2.1.8.2. Reaction of the compound 143 with cysteine 
As the successfully synthesised compound 143 did show positive activity against some cancer cell 
lines, but had low water solubility, we decided to use this compound as a core biological agent and 
introduce different hydrophilic side chains by replacing the F atoms with further nucleophiles. It was 
hoped to synthesise a set of more water soluble fluorinated heterocycles with potential biological 
activity using this strategy. Therefore reaction of compound 143 with cysteine 177 was carried out in 
ratio 1:2 in the presence of Et3N as base and DMF as solvent was carried out for 24 h at room 
temperature under N2 in an attempt to form target compound 179. Unfortunately NMR spectroscopy 
indicated only the presence of starting material and the target compound was not afforded.  
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Scheme 60. Reaction of the compound 143 with cysteine.  
 
2.1.8.3. Study of the reaction of compound 143 with 2,2-(ethylenedioxy)bis(ethylamine) 
The aim of this reaction is improve the biological activity of compound 143 by replacement of two 
fluorine atoms of compound 143 with two amine chains and hopefully synthesising target compound 
180 as a possible DNA groove binding agent. (Scheme 61) 
The reaction of compound 143 (1 equiv.) with 2,2-(ethylenedioxy)bis(ethylamine) 150 (2 equiv.) in 
THF as solvent was conducted over 24 h at 65 °C under N2. TLC revealed a mixture of starting 
material and a new compound. Therefore column chromatographic purification was carried out 
affording the interesting and unexpected macro-cyclized compound 181 in 22% yields, instead of the 
target compound 180. The structure was confirmed by 
1
H and 
13
C NMR spectroscopy and accurate 
mass measurement with m/z of 697.2469 (MH
+
) for C34H31F6N8O2. The
 19
F NMR spectrum showed 
three signals (2F for each signal) as expected. Also the structure of 181 was confirmed by X-ray 
diffraction analysis (Figure 33). 
 
97 
 
 
Scheme 61. Reaction of compound 143 with 2,2-(ethylenedioxy)bis(ethylamine). 
 
 
.  
Figure 33. X-ray crystal structure of 181∙2½H2O showing the 24-membered macrocycle with 
2½ hydrogen bonded water molecules. The molecule lies on a 2-fold axis. O(3) and O(3A) are 
each ¼ occupied. 
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2.1.8.4. Investigation of the Reaction of compound 143 with 2-(2-Aminoethoxy)ethylamine 
After synthesis of the unexpected macro cyclized compound 181 it was planned to try the shorter 
linker 2-(2-aminoethoxy)ethylamine to find out if this would still lead to a cyclized compound. 
Therefore reaction of compound 143 (1 equiv) with 2-(2-aminoethoxy)ethylamine 167 (2 equiv)  in 
THF as solvent and with Et₃N as base was conducted over 24 h at 65°C under N2 (scheme 62) TLC 
revealed a mixture of starting material and a new compound. After column chromatographic 
purification the macro cyclized compound 183 was obtained in 35% yield. As seen, even with a 
shorter linker macrocyclisation occurred, and target compound 182 was not formed. Compound 183 
was confirmed by 
1
H, 
19
F and 
13
C NMR spectroscopy and accurate mass measurement with m/z of 
653.2207 (MH
+
) for C32H26F6N8O. The 
19
F NMR spectrum showed three signals (2 F for each 
signal) as expected. Also the structure of 183 was confirmed by X-ray diffraction analysis (Figure 
34). 
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Scheme 62. Reaction of compound 143 with 2-(2-aminoethoxy)ethylamine. 
 
 
 
Figure 34. X-ray crystal structure of 183 showing the 21-membered macrocycle with a 
hydrogen-bonded ethanol solvate molecule. 
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2.1.8.5. Study of the reaction of perfluoro bis-benzimidazole derivative 143 with 
hexamethylenediamine 
After successfully synthesising macro cyclized compounds 181 and 183 it was decided to try 
hexamethylenediamine in order to make further examples of such macro cycles. Thus reaction of 
perfluoro bis-benzimidazole derivative 143 with hexamethylenediamine 184 in 1:1 ratios was carried 
out in THF as solvent and in the presence of Et₃N as base at RT for 24 h (scheme 63). After 
purification the target macro cyclized compound 185 was again afforded in 20% yield. The structure 
was confirmed by 
1
H, 
19
F and 
13
C NMR spectroscopy and accurate mass measurement with m/z of 
655.2570 (MH
+
) for C34H31F6N8. The 
19
F NMR spectrum showed three signals (2 F for each signal) 
as expected. Formation of a 22-membered ring in this case, confirms the relative ease of macrocycle 
formation in these systems, which is likely due to the hindered rotation of the aryl benzimidazole 
groups increasing the probablitiy of the final amino group encountering the other fluoropyridine ring, 
rather than reacting with a second molecule to form oligomers or polymers. 
 
 
Scheme 63. reaction of perfluoro bis-benzimidazole derivative 143 with hexamethylenediamine.  
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2.1.8.6. Study of the reaction of compound 143 with ethylenediamine 
Next it was planned to study the possibility of adding two molecules of ethylenediamine 186 
perfluoro bis-benzimidazole derivative 143 by treating it with two equivalents of ethylenediamine 
186 in THF at RT for 24 h (Scheme 64). The target compound 187 was afforded easily by addition of 
water to the reaction mixture in 85% yield. The structure was confirmed by its 
1
H NMR spectrum 
and accurate mass measurement with m/z of 669.2632 (MH
-
) for C32H31F6N10. The 
19
F NMR 
spectrum showed three signals (2F for each signal) as expected.  
 
 
 
Scheme 64. Reaction of compound 143 with ethylenediamine. 
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2.1.8.7. Investigation of the reaction of compound 143 with 2-(2-aminoethoxy) ethanol 
Two equivalents of 2-(2-aminoethoxy) ethanol 188 were then reacted with one equivalent of 
compound 143 in order to form a further target compound 189 that might possess potential biological 
activity or DNA binding activity. The reaction was carried out in THF at RT for 24 h. The target 
compound 189 was afforded in 42% by recrystallization from DCM and light petroleum (scheme 
65). The structure was confirmed by its 
1
H NMR spectrum and accurate mass measurement with m/z 
of 759.2836 (MH
+
) for C36H37F6N8O2. The 
19
F NMR spectrum showed three signals (2 F for each 
signal) as expected. Elemental analysis fitted with the expected composition for a molecular formula 
of C36H36F6N8O2.3H2O (785).  
 
 
 
Scheme 65. Reaction of compound 188 with 2-(2-aminoethoxy)ethanol. 
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2.1.8.8. Investigation of the reaction of compound 143 with (±)-3-amino-1,2-propanediol 
Reaction of two equivalents (±)-3-amino-1,2-propanediol 190 with one equivalent of compound 143 
was tried in THF at RT similar to previous reactions. Unfortunately this time the reaction did not 
work well and different conditions were therefore studied (Table 16). 
Table 16. different reaction conditions for compound 143 with (±)-3-amino-1,2-propanediol.  
Entry Reagents Conditions Results 
1 None THF, RT, 24 h. N2 Starting material 
2 None DMF, RT, 24 h. N2 
Starting material and product 
(30%) 
3 None DMF, 80 ᵒC, 24 h. N2 Product (82%) 
 
As seen in table 16, the reaction worked very well in DMF at 80 ᵒC and target compound 191 was 
afforded in 82% (Scheme 66). The structure was confirmed by NMR spectroscopy. The 
19
F NMR 
spectrum showed three signals (2 F for each signal) as expected. In addition accurate mass 
measurement gave m/z of 731.2523 (MH
+
) for C34H33F6N8O8  
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Scheme 66. Reaction of compound 143 with (±)-3-amino-1,2-propanediol. 
 
2.1.8.9. Reaction of compound 143 with ethanolamine 
In order to extend the number of novel hydrophilic fluorinated heterocyclic compounds as potential 
biological agents, two equivalents of ethanolamine 192 were reacted with one equivalent of 
compound 143 in order to form the target 193 (Scheme 67). The reaction was carried out in boiling  
THF at RT for 24 h and compound 193 was afforded in 50% after recrystallization from hot ethanol  
The structure was confirmed by its 
1
H NMR spectrum and accurate mass measurement with m/z of 
669.2161 (MH
-
) for C34H27F6O2N8. The 
19
F NMR spectrum showed three signals (2F for each signal) 
as expected.  
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Scheme 67. Reaction of compound 143 with ethanolamine. 
 
2.1.8.10. Reaction of pentafluoroprydine 74 with 2-mercaptobenzimidazole 
As scaffold 194 showed positive activity against Trypanosoma parasites 
127
 and as this scaffold 
would have potential for further modification to allow synthesis of diverse libraries of molecules that 
can be screened for biological activity, we decided to synthesise this scaffold again, and also attempt 
to improve the yield by modifying the existing method as the reported yield 
128
 was very low. 
Therefore reaction of pentafluoropyridine 74 with 1,3-dihydro-2H-benzimidazole-2-thione 155 was 
carried out in a mixture of DMF and THF as solvent, and with NaH as base, but in this case the 
solution of 2-mercaptobenzimidazole in DMF : THF (3:10) was added by slow addition to a stirred 
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mixture of NaH and pentafluoropyridine in THF using a syringe pump to control the rate of addition. 
This helped to improve the reaction by increasing the yield from 27% to 54%. 
 
Scheme 68. Reaction of pentafluoropyridine with 2-mercaptobenzimidazole. 
 
2.1.8.11. Investigation of further substitution of fluorine in scaffold 194 by ethanolamine 
As mentioned above the bis-tetrafluorypyridyl benzimidazole derivative 194 had shown positive 
activity against Trypanosoma parasites 
121
 it was therefore decided take this compound on for further 
modification, and to add hydrophilic side chains to improve water solubility and biological activity, 
by further SNAr reaction. 
Thus, ethanolamine 192 was chosen as the first nucleophile to be investigated, and two equivalents 
were reacted with one equivalent of compound 194 in an approach to form the target compound 195 
(Scheme 69). The reaction was carried out in THF as solvent and Et₃N as base for 24 h, at RT and 
the desired compound 195 was afforded in 80% after extraction as a shiny white sugary solid.  The 
structure was confirmed by the 
1
H NMR spectrum and accurate mass measurement with m/z of 
531.1028 (MH
-
) for C21H17F6N6O2S. The 
19
F NMR spectrum showed six signals (1F for each signal) 
as expected.  
 
Scheme 69. Reaction of scaffold 194 with ethanolamine. 
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2.1.8.12. Subsituation reaction of scaffold 194 with ethylenediamine 
Reaction of two equivalents of ethylenediamine 186 with one equivalent of scaffold 194 was next 
tried with the same conditions (Scheme 70). The target compound 196 was afforded in 72% as a 
yellow sugary solid.  The structure was confirmed by 
1
H NMR spectroscopy and accurate mass 
measurement with m/z of 529.1350 (MH
-
) for C21H19F6N8S.  The 
19
F NMR spectrum showed six 
signals (1F for each signal) as expected. 
 
 
Scheme 70. Reaction of scaffold 194 with ethylenediamine. 
 
2.1.8.13. Substitution Reaction of scaffold 194 with morpholine 
Similarly reaction of morpholine 197 with compound 194 in ratio 2:1 was investigated in THF as 
solvent and Et₃N as base at RT for 24 h. pleasingly the target compound 198 was again afforded in 
good yield (67%) after chromatographic purification. The structure was confirmed by NMR 
spectroscopy and accurate mass measurement with m/z of 583.1345 (MH
-
) for C25H21F6N6O2S1. The 
19
F NMR spectrum showed six signals (1F for each signal) as expected for the two differently 
substituted trifluoropyridine rings. 
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Scheme 71. Reaction of scaffold 194 with Morpholine. 
 
2.1.8.14. Investigation of reaction of morpholine with the tethered bis-benzimidazolyl pyridine 
163 
After successful substitution of fluorine by morpholine 197 in compound 194 and synthesis of 
tethered compound 198  it was decided to try reaction of compound 163 with morpholine 197 in the 
hope of replacing a third fluorine in the pyridyl rings to form compound 199 Therefore reaction of 
morpholine with compound 163 in ratio 2:1 was undertaken in THF as solvent and Et₃N as base at 
RT for 24 h. After separation by column chromatography the compound 200 was afforded in 15% 
yield. However compound 199 was not afforded as shown in (Scheme 72), and in this reaction 
morpholine had added to only one of the pyridine rings and mono-substitution occurred. The 
structure of compound 200 was confirmed by 
1
H NMR and 
19
F NMR spectroscopy with tiny 
impurity which could not be more purify due to lack of the time and polarity of the compound. The 
19
F NMR spectrum showed five signals (1F for each signal) as expected. Reaction at only one 
pyridine ring illustrates the decreasing reactivity of the remaining fluorines on increasing 
substitution, particularly with electron donating groups such as amines. Reaction at higher 
temperature may lead to morpholine adding to both pyridine end groups to form the symmetrical 
compound 199. 
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Scheme 72. Reaction of morpholine with tethered compound 163. 
 
2.1.9. Investigation of reaction of perfluoroarenes with aliphatic side chains which contain thiol 
After successfully reaction of perfluroarenes with aliphatic containing hydrophilic amino and make 
series of novel linked and fused heterocyclic scaffolds containing amine group. We was decided to 
try another aliphatic side chain which contain thiol to make series of novel linked and fused 
heterocyclic scaffolds containing thiol group and compare the biological activity of each series. 
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2.1.9.1. Reaction of compound 109 with 3,6-dioxa-1,8-octanedithiol 
To start we decided try to react compound 109 with 201 to make bis-linked binding agent containing 
sulphur group therefore reaction of compound 109 (2 equiv.) with 3,6-dioxa-1,8-octanedithiol 201 
(1equiv.) was carried under different conditions. As seen in table 17,  the reactions did not work well 
and only the reaction which was carried at 65 °C, in THF as solvent and NaHCO3 as base indicated 
presence of compound 202 which was afforded by column chromatography as white solid in 41 % 
yield (entry 5). However the 
1
H NMR spectrum was not completely clean and still showed some 
impurity, and the compound could therefore not be fully characterised. Although 
19
F NMR 
spectroscopy showed 3 signals as expected, each signal contained 1 F atom. Also mass spectrometry 
displayed the expected mass of the compound 202. MS (ESI) (MH
+
), C18H19F3N3O2S2 requires m/z 
430.0871 found m/z 430.0869. Although the target bis linked intercalator compound 203 not formed, 
the formation of compound 202 showed the reaction to be viable and further investigation to effect 
reaction on both rings should be continued. 
Table 17. different reaction conditions for compound 109 with 3,6-dioxa-1,8-octanedithiol. 
Entry Reagents Conditions Results 
1 Et3N 
THF, reflux (65 °C), 
22 h. N2 
Complex NMR spectrum of unknown 
compound. 
2 Et3N THF, RT, 22 h. N2 Still complex NMR spectrum  
3 No base   THF, RT. 22 h. N2 
Starting material 
 
4 
NaHCO3 
 
THF, RT, 22 h, N2 Starting material 
5 NaHCO3 THF, 65 °C, 22 h, N2 Starting material and compound 202 
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Scheme 72. Reaction of compound 109 with 3,6-dioxa-1,8-octanedithiol. 
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2.2. DNA binding studies 
2.2.1. UV absorption spectroscopy experiment 
The interaction of the synthetic compounds prepared with DNA was determined by a UV absorption 
spectroscopy which is a simple and useful method for analysing binding. In the UV absorption assay 
the change in the absorbance of the test compound with and without SS-DNA gives an idea about the 
interaction of the substance with DNA. Known compounds, Actinomycin D (an intercalator) and 
naproxen (a groove binder) were used as controls. Compounds binding with DNA through 
intercalation usually result in hypochromism and bathochromism (red shift). As the intercalative 
mode involving a stacking interaction between an aromatic chromophore and the base pair of DNA, 
the extent of the hypochromism is usually consistent with the strength of intercalative interaction.
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In the case of electrostatic attraction between the compound and DNA, a hyperchromic effect is 
observed that reflects the corresponding changes of DNA in its conformation and structure after the 
complex–DNA interaction has occurred. The hyperchromic effect is the noticable increase in 
absorbance of DNA upon denaturation.  
All spectral characteristics indicated some change which were causedby change in conformation and 
structure of DNA after the compounds binds to it.  Also the association/ binding constants of all 
DNA-complexes were determinate by Benesi-Hildebrand equation, Eq. (1) 
 
𝐴𝑜
𝐴−𝐴0
=  
∈𝐺
∈𝐻−𝐺−∈𝐺
+
∈𝐺
∈𝐻−𝐺−∈𝐺
 ×
1
𝐾[𝐷𝑁𝐴]
                                                                                (1) 
Where K is the binding constant, Ao is absorbance of drug without any DNA, and A is absorbance of 
the DNA-Drug complex. εG and εH-G are the absorption coefficients of the drug and DNA-Drug 
complex, respectively. The K value was determined from the intercept-to- slope ratio of Ao/A-Ao vs. 
1/ [DNA] plot. 
In addition the Gibbs free energy (ΔG) was used to calculate for each complex using Eq. (2) 
ΔG = -RT lnK                                                                                                                          (2) 
Where R is general gas constant (8.314 JK
-1
mol
-1
) and T is room temperature (298 K). 
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2.2.1.1. UV-visible spectroscopy of ACTD as known intercalate agent and naproxen as known 
groove binder 
ACTD is a known DNA-interacting transcription blocker with anti-cancer activity.it interferes with 
both DNA replication and transcription by intercalation between bases.  Also it acts as a cytotoxic 
inducer of apoptosis in tumour cells. Therefore it was used as reference in this study (Figure 35) 
 
 
Figure 35. Absorption spectra of 1 x 10
-5
 M ACTD in absence (a) and presence of 9.6 µM (b), 
18 µM (c), 27 µM (d), 35 µM (e), 43 µM (f) and 50 µM (g) of DNA. 
The arrow shows increasing DNA concentration. Inside graph is plot of Ao/ (A-Ao) vs. 1/ 
[DNA] for determination of binding constant (K) and Gibbs free energy (ΔG) of ACTD. (R2 = 
0.9926 for six point) 
According to Figure 35, the ACTD as known intercalator control showed strong absorption in the 
region (440-460 nm) which is accredited to the long-living triplet excited state of aromatic system. 
Also the spectra indicated that by increasing concentration of DNA, the absorption bonds of the 
complex were decreased which resulting in the tendency of hypochromism as expected due to the 
intercalation of ACTD with DNA. Hypochromism is caused by contraction of DNA helix, as well as 
from conformational change of DNA. The binding constant value for ACTD is 0.5x10
5 
M
-1
 which 
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indicated strong affinity of the drug to SS-DNA. The Gibbs free energy is -11.6 kJmol
-1
. The 
negative value of ΔG shows a spontaneous process in this interaction.  
Naproxen is another known DNA binding agent which was used as possible groove binder control. 
As seen in (Figure 36) it showed strong absorption at300 nm.The spectra indicated that by increasing 
concentration of DNA, the absorption decreased therefore in the case of groove binding still we have 
the hypochromism as well as the intercalation interaction. The K value (1 x 10
5 
M
-1) and the Gibb’s 
free energy (-12.3 kJmol
-1
) of naproxen was higher than the K value and the Gibbs free energy of 
ACTD ( figure 14) which indicated that naproxen has higher affinities to SS-DNA  than  AD. The 
negative value of ΔG shows a spontaneous process.  
 
 
Figure 36. Absorption spectra of  1 x 10
-5
 M of naproxen in absence (a) and presence of 9.6 µM 
(b), 18 µM (c), 27 µM (d), 35 µM (e), 43 µM (f) and 50 µM (g) DNA. 
The arrow shows increasing of DNA concentration. Inside graph is plot of Ao/ (A-Ao) vs. 1/ 
[DNA] for determination of binding constant (K) and Gibbs free energy (ΔG) of.naproxen (R2 
= 0.8614 for six points) 
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2.2.1.2. Studies of UV absorption results and cooperation of binding constant data 
 
Table 18. Absorption changes caused by synthesised compounds intraction with DNA. 
Compounds Absorption  K value (M
-1
) 
108 Decrease (hypochromism) 0.5 x 10
4
 
111 Decrease (hypochromism) 2.9 x 10
4
 
113 Decrease (hypochromism) 1.1 x10
5
 
114 Decrease (hypochromism) 1.5 x 10
5
 
137 Decrease (hypochromism) 0.1 x 10
5
 
138 Decrease (hypochromism) 0.3 x 10
4
 
143 Decrease (hypochromism) 0.6 x 10
5
 
151 Decrease (hypochromism) 4.7 x 10
4
 
152 Decrease (hypochromism) 1.4 x 10
5
 
161 Decrease (hypochromism) 6.9 x 10
4
 
162 Decrease (hypochromism) 2.5 x 10
4
 
163 Decrease (hypochromism) 0.8 x 10
4
 
164 Decrease (hypochromism) 1.5 x 10
3
 
165 Increase (hyperchromic effect) 1.5 x10
5
 
166 Decrease (hypochromism) 8.9 x 10
4
 
169 Decrease (hypochromism) 4.4 x 10
4
 
170 Decrease (hypochromism) 9.8 x 10
4
 
171 Decrease (hypochromism) 8.8 x 10
4
 
181 Decrease (hypochromism) 1.1 x 10
5
 
183 Decrease (hypochromism) 7.6 x 10
4
 
187 Decrease (hypochromism) 4.4 x 10
4
 
189 Decrease (hypochromism) 1x10
5
 
191 Decrease (hypochromism) 3 x 10
4
 
195 Decrease (hypochromism) 2.4 x 10
5
 
196 Decrease (hypochromism) 1.8 x 10
5
 
198 Increase (hyperchromic effect) 2.1 x 10
5
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According to the above table the K values (bonding constant) more than 1x10
-5
 indicates good 
binding affinity, the K values between  1x10
-4
 – 1x10-5 indicate moderate binding affinity and the K 
values below 1x10
-4
  indicate poor binding affinity. Also most of the compounds on adding the DNA 
in different concentrations showed a decrease in the absorption which indicated a hypochromic effect 
due to the intercalative interaction. Only compounds 165 and 198 showed an increase in the 
absorption due to a hypochromic effect which can be result of electrostatic attraction between the 
compounds and DNA.  
 
Figure 37. UV absorption of synthesised compounds with different concentrations of DNA. 
Each bar in this graph represents the binding constant of different synthesised compounds. 
According to figure 37, all of the synthesised compounds showed some affinity to SS-DNA in the 
UV absorption assay, although in comparison to the reference compounds and each other, binding is 
very different. Interestingly compounds 165, 196 and 198 showed the greatest k values compared to 
the other compounds and even references which indicated highest bonding affinity to SS-DNA than 
other synthesised compounds. In addition compound 195 and 198 showed closest and higher binding 
constants in comparison to 196 which might be because of presence of oxygen in both structure, as 
seen in below. 
0
0.5
1
1.5
2
2.5
n
ap
ro
xe
n
A
C
TD 1
0
8
1
1
1
1
1
2
1
1
4
1
3
7
1
3
8
1
4
3
1
4
8
1
5
1
1
5
2
1
6
1
1
6
2
1
6
3
1
6
4
1
6
5
1
6
6
1
6
9
1
7
0
1
7
1
1
8
1
1
8
3
1
8
7
1
8
9
1
9
1
1
9
5
1
9
6
1
9
8
B
a
n
d
in
g
 c
o
n
st
a
n
t 
(k
) 
1
0
5
 M
-1
 
Test compounds  
117 
 
Compounds 114 and 165 have the  second largest binding constant values which are  still higher then 
reference’s K value. Compounds 113, 170, 181 and 189 indicated very similar K values to naproxen. 
Along with the K value of compounds 169 and 187, which was very close to ACTD, compounds 
108, 112, 137, 143, 162, 163, 164, and 191, showed very weak DNA binding affinity compared to 
the referece and the other compounds. 
2.2.2. Ethidium bromide (EB) fluorescence displacement experiment 
Ethidium bromide (EB) fluorescence displacement assay was another useful method for studying the 
interaction of the synthetic compounds prepared with DNA. In this method the EB fluorescence 
intensity will increase in the presence of DNA by intercalation of EB into the double helix (Figure 
38). It is quenched by addition of another compound as the quencher then displaces EB from DNA. 
Therefore if the fluorescence intensity decreased on adding the compound it means that the test 
compound binds to the DNA and displaces the EB.  If no change in intensity occurs it does not mean 
the compound does not bind to DNA as it may bind in another non-intercalating way. 
 The linear Stern-Volmer quenching constant Ksv was calculated from the linear Stern-Volmer 
equation (3), by considering the quenching of EB bound to DNA by different concentration of 
quencher or compound. 
Io/I = 1 + Ksv[Q]                                                                                                                       (3) 
Where Io and I represent the fluorescence intensities in absence and presence of the compound and Q 
is the concentration of the compound. Kvs values were calculated from the slope of the regression line 
in the derived plot of Io/I vs compound concentration. 
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Figure 38. ) Emission spectra of EB 1 x 10-6 M in the absence of DNA and b) Emission spectra 
in presence of DNA  3.17 x 10-5 M 
 
2.2.2.1.  EB fluorescence displacement assay of Actinomycin D as intercalating agent  
 
Figure 39. Emission spectra of SS-DNA-EB in tris-HCl buffer on titration of ACTD. 
Kex = 480 nm; [EB] = 1 x 10
-6
 M; [DNA] = 3.17 x 10
-5
 M;[ACTD] (a) 0.0, (b) 1 x 10
-6
, (c) 2 x 10
-
6
, (d) 4 x 10
-6
, (e) 6 x 10
-6
, (f) 8 x 10
-6
, (g) 10 x 10
-6
 M. The arrow shows the increase of the 
complex concentration. Inside graph is plot of Io/ I vs. [DNA] for determination of K and ΔG 
values. (R
 2
= 0.9782 for six points) 
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According to figure 39, by increasing of the ACTD concentration, the fluorescence intensity at 605 
nm decreased significantly, which indicated the ACTD had displaced the EB completely and bound 
to DNA by intercalation interaction as expected. Also the Kvs value for ACTD complex was found to 
be 1.6 x 10
5
 which indicated a very strong affinity of ACTD complex to SS-DNA. The Gibbs free 
energy is -12.8 kJ.mol
-1. The negative value of ΔG shows a spontaneous process in this interaction.  
2.2.2.2. EB fluorescence displacement assay of naproxen as groove binding agent reference. 
 
 
Figure 40. Emission spectra of SS-DNA-EB in tris-HCl buffer on titration of naproxen. 
Kex = 480 nm; [EB]= 1 x 10
-6
 M; [DNA] = 3.17 x 10
-5
 M;  [AD] (a) 0.0, (b) 1 x 10
-6
, (c) 2 x 10
-
6
,(d) 4 x 10
-6
, (e)  6 x 10
-6
, (f) 8 x 10
-6
, (g) 10 x 10
-6
 M. The arrow shows the increase of the 
complex concentration. Inside graph is plot of Io / I vs. [DNA] for determination K and ΔG 
values. (R 
2
= 0.9782 for six points) 
According to Figure 40, by increasing of the naproxen concentration the fluorescence intensity 
decreased which indicated naproxen complex interact with DNA as groove binder and releasing 
some EB from EB-DNA system. Another possibility is naproxen binds to DNA in different binding 
sites and changes the conformation of DNA which causes a decrease in the fluorescence intensity. 
Also the Kvs value for naproxen complex was found to be 5.1 x 10
4
 M
-1 
which indicated affinity of 
naproxen complex to compete at binding site of SS-DNA which EB binds as an intercalating agent is 
much less then ACTD (Figure 39) as expected. The Gibbs free energy is -12.8 kJ. mol
-1
. The 
negative value of ΔG again shows a spontaneous process. 
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2.2.2.3. Binding constant comparison of synthesis compound using EB quenching assay 
 
 
Figure 41. EB displacement assay of synthesis compound. Each bar in this graph represents 
binding constant of different synthesised compounds. ACTD and naproxen were used as 
references. 
According to Figure 41, all the synthesised compounds showed some affinity to SS-DNA in this 
assay, although in comparison to the intercalating reference compound ACTD binding was very 
weak. Compounds 111, 169,and 191, indicated the greater K values compared to others. Therefore 
theses compound showed stronger affinity to SS-DNA than other synthesised compound and their 
Kvs values are closest to the Kvs value of naproxen. 
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2.3. Anticancer activity in vitro  
The anticancer activities of synthesis compounds (143, 148, 151, 152, 181, 183, 187, 189, 
191, 193 and 194) were determined against breast carcinoma MCF-7 and leukemia K562 cell 
lines after 72 h of incubation using the Calcein assay, and the CDK inhibitor, roscovitine, as a 
control compound. The results obtained (Table 19), show that compounds  143, 187, 183 and 
194 display cytotoxicity in which IC50 values reached low micromolar ranges.  
 
Table 19. Cytotoxicity of fluoroarylbenzimidazole derivatives 
.Compound Cell line IC50 (M) 
 K-562 MCF-7 
143 2.8 ± 0.4 7.8 ± 2.0 
148 >12.5 >12.5 
152 >12.5 >12.5 
183 7.2 ± 1.5 4.8 ± 0.4 
187 3.4 ± 0.1 8.0 ± 2.6 
189 >12.5 >12.5 
191  >12.5 >12.5 
193 >12.5 >12.5 
194 13.2 ± 1.3 >25 
Roscovitine 42 ± 3 11 ± 1 
 
These four compounds were further screened by collaborating partners against melanoma 
G361 and osteosarcoma HOS cell lines to expand information about selectivity towards 
various types of cancers (Table 20). Concentration-dependent activity it was observed in all 
cases with these four compounds. Three of the active compounds contained the 
tetramethylene bis-benzimidazole linker group 134 with tri- or tetrafluorinated pyridine rings, 
whilst the smaller molecule 194 also contains two fluorinated pyridine rings, separated by the 
benzimidazole ring. This suggests that two fluorinated pyridine rings separated by 4-6 Å is 
desirable for activity. However the mechanism of the activity is not yet clear. 
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Table 20. Cytotoxicity of lead derivatives. 
Compound IC50 (µM) 
G361 HOS 
143 2.0 ± 0.1 1.8 ± 0.1  
183 6.0 ± 0.1 8.3 ± 2.0  
 
187 19.9 ± 1.2 16.3 ± 3.0 
194 4.4 ± 0.6 2.5 ± 0.9  
 
Roscovitine 22.4 ± 0.2 24.3 ± 0.2 
 
Further experiments were conducted to gain information about the mechanism underlying the 
observed cytotoxicity. Firstly, the effect of compounds 183, 187 and 194 on the cell cycle of 
K562 and MCF-7 cells was analysed. Asynchronously growing cells were treated for 24 h 
with compounds in two doses, corresponding to 1× and 3× IC50 values, followed by analysis 
by flow cytometry. As shown in Figure 42, the compounds markedly influenced cell cycle 
profiles in both cell lines although each compound demonstrated this effect in a different 
way. Treatment of MCF-7 cells with a low dose of 143 led to a decrease in the S phase, 
whilst a higher dose significantly decreased G1-phase population and increased sub-G1 
population in both K562 and MCF-7 cell lines. Compound 187 had no effect at the lower 
dose used, but the higher dose significantly increased G2/M population in MCF-7 cells. 
Interestingly, treated K562 cells completely altered the profile, with apparent block of 
S phase. Macrocyclic compound 183 markedly reduced S and G2/M phases in MCF7 cells, 
while the cell cycle profile in K562 was not changed at all. 
 
Figure 42. Effect of studied compounds on the cell cycle of MCF7 and K562 cells treated for 
 24 h. 
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Flow cytometric analysis revealed that some compounds increase sub-G1 population, which 
is a well accepted indicator of ongoing apoptotic cell death. We therefore analyzed treated 
K562 cells for activity of caspases 3 and 7, proteases that are activated during apoptotic cell 
death. (Figure 43) shows the results of biochemical assay of caspase 3/7 activity in cells 
treated for 24 h with the studied compounds at doses corresponding to 1× and 3× IC50 values. 
While 187 was inactive in the assay, compounds 183 and 194 significantly stimulated 
activation of the caspases, with the increase in activity more than twenty-fold, and five-fold, 
over untreated control cells respectively. Based on flow cytometric results and biochemical 
assay of caspases we conclude that 183 and 194 induce apoptosis in treated cells. However, 
the flow cytometric experiments suggest that the active compounds exhibit their toxicity 
through different cellular targets. Further work is ongoing to identify the mode of action of 
these fluorinated compounds. 
 
 
Figure 43. Fluorimetric caspase activity assay. K562 cells treated with studied compounds for 
24 h were lysed and the activities of caspases were measured using the fluorogenic substrate 
Ac-DEVD-AMC and normalised to untreated control. 
. 
2.4. Antibacterial activity of synthesised compounds 
The synthesised compounds were examined against a gram positive (Staphylococcus aureus) and a 
gram negative (Escherichia coli) bacterium in vitro by using the disc diffusion method with each 
experiment performed in triplicate. Amoxicillin was used as reference antibiotic in this assay. 
Criteria for activity is based on the diameter of the inhibition zone (mm); an inhibition zone more 
than 20 mm indicates significant activity, for 18-20 mm inhibition is good, 15-17 mm is low, and 
below 11-14 mm is non-significant activity.
35, 66
   The following compounds at 10
-3 
M  were tested, 
108, 114, 137, 138, 143, 148, 161, 162, 163, 164, 165, 171, 181, 183, 198 , but showed no zone 
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inhibition at all. Compounds 111, 113, 251, 252, 166, 169, 170, 187, 189, 191, 195 and 196 showed 
an inhibition zone and reading of the zone inhibition represents the mean value of these readings, 
which are shown in Table 21. 
Unfortunately the antibacterial activity assay confirmed that the tested compounds showed non-
significant activity against the bacteria, because the inhibition zones were below 11-14 mm. As the 
high concentration 10
-3 
M did not show a significant inhibition we did not study any lower 
concentrations of the compounds. Although the compound 191 showed highest activity against E. 
coli and compound 187 showed the highest activity against S. aureus. Therefore the fluorinated 
synthesized compounds in the present study did not show good antibacterial activity against either 
Escherichia coli or Staphylococcus aureus strains, despite the evidence for DNA binding. Further 
studies would be required to understand the exact interaction of the compounds with bacterial cells.  
Table 21.Antimicrobial activity of some fluorinated synthesized compounds 
 
Compound 
Average zone of inhibition (mm) 
Escherichia coli Staphylococcus aureus 
Amoxicillin 19 40 
111 9 0 
113 9 0 
151 11 0 
152 10 7 
166 10 8 
169 7 9 
170 9 0 
187 0 14 
189 10 0 
191 12 0 
195 0 7 
196 0 9 
 
2.5. Hanging drop DNA crystallization  
In DNA crystallization assay a piece of melting point tube was used to hold a drop of DNA-
compound mixture in a cacodylate buffer solution. This was attached to wall of sample vial above 
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cotton wool wetted with the more concentrated buffer solution to help to absorb solvent from the 
drop to concentrate it, leading to crystallisation. The sample tube containing the drop was left at RT 
for a prolonged time to form crystals. Cacodylate buffer was used to dissolve the short synthetic 
oligonucleotide CGCGAATTCGCG by adding 600 µl of the buffer to DNA to prepare conc. 0.5 mM 
of DNA. Synthesised compounds were dissolved in DMSO (0.01 mol, 10 ml) in separate vials and 
the drop was making by mixing 2 µl of each compound stock solution with 20 µl of 
CGCGAATTCGCG DNA. Unfortunately to date no crystals have formed and this method has given 
no information about the DNA-compound complexes formed.  
 
3. Conclusions and future work 
Over fifty new composite, linked and fused heterocyclic scaffolds have been successfully 
synthesised using SNAr substitution reactions of perfluorinated arene building blocks including 
pentafluoropyridine, hexafluorobenzene, and methyl pentafluorobenzoate with different nucleophile 
hetarenes  such as imidazole, triazole, benzimidazole, benzotriazole, and carbazole. Furthermore, 
these scaffolds would have potential for further modification by introducing different water 
solublising side chains to allow synthesis of diverse libraries of molecules which are more water 
souluble and have improved potential for biological activity. X-ray crystal structures of ten 
compounds were obtained including those of two macrocyclic compounds 181 and 183 containing 
24- and 21-membered rings. 
Cyclization of ester derivative 148 to make bi- or tri-cyclic bis-intercalators by using different 
nucleophiles reagent such as hydrazine, 2-aminopyridineas and acetamidine did not prove successful. 
Only compound 176 cyclised on just one of the fluoroarene rings, leaving the ester intact on the 
other, by using acetamidine which was a more reactive nucleophile than the other reagents tested. 
A number of compounds synthesised have been shown to bind to DNA by a combination of UV 
absorption and fluorescence measurement, although the exact nature of binding has not been 
determined. 
From UV absorption most of the test compounds showed decrease in the absorption which indicated 
a hypochromic effect due to the intercalative interaction. Only compounds 195 and 168 showed a 
hypochromic effect by an increase in the UV absorption, which can be result of electrostatic 
attraction between the compound and DNA. 
In addition, interestingly compounds 195, 196 and 198 showed the greatest K values in binding 
constant  compared to the other compounds and known references which indicated higher bonding 
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affinity to SS-DNA than other synthesised compounds. Compounds 113, 170, 181 and 189 indicated 
very similar K values to naproxen. Along with K value of compounds 169 and 187 was very close to 
ACTD. 
In terms of fluorescence assay, only compounds 191, 169 and 112 indicated greater K values 
compared to other scaffolds, which showed stronger affinity to SS-DNA than the other synthesised 
compounds, although in comparison to the K value of intercalating reference compound ACTD are 
still much lower. 
For anticancer activity of the test compounds, only three compounds 143, 183 and 187 demonstrated 
micromolar inhibition against K-562 and MCF-7 cell lines. These compounds, in addition to 194, 
also demonstrated micromolar inhibition against G361 and HOS cell lines. Compounds 143 and 183 
were found to activate caspases leading to apoptosis. 
Attempts to co-crystallize the compounds with a synthetic oligonucleotide to allow X-ray diffraction 
studies to determine binding were unsuccessful. Also studies on the antimicrobial activity of a range 
of the new compounds indicated non-significant activity against the bacteria because the inhibition 
zones were below 11-14 mm. However, compound 187 showed the highest activity against of S. 
aureus and compound 191 showed highest activity against E. coli. 
The synthetic work has generated several areas where additional study would be desirable. The 
formation of 176 showed the cyclization of ester derivatives to make bi- or tri-cyclic bis-intercalators 
to be viable, and further investigation to effect reaction on both rings should be continued. Also 
cyclization of ester derivative using more reactive nucleophiles reagents could be explored. Further 
development of methods to foresee and control the stepwise addition of nucleophiles to 
perfluoroarenes should be undertaken to study the orientation effects of the added groups, and to 
improve reactivity as the number of available fluorine atoms falls with progressive substitution. To 
improve biological activity of the compounds further work could be carried out to replace the 
remaining fluorine atoms in the ring systems synthesised with alternative aromatic or aliphatic 
containing hydrophilic amino, hydroxyl and thiol groups. Also synthesis of positively charged 
derivatives should be undertaken to improve binding to DNA. 
Additional attempts to co-crystallize the products synthesised with the DNA strands of known 
composition should be carried out, to allow a more detailed understanding of the molecular 
interaction involved in binding activity. A number of the successfully synthesised compounds in this 
work are being taken forward in a further project to test for anticancer and anti-parasitic activity. 
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4. Experimental  
4.1. General 
All starting materials and solvents were obtained commercially. THF was distilled under a nitrogen 
atmosphere from sodium/benzophenone ketyl radical. Anhydrous conditions were obtained by using 
oven/flame-dried glassware purged with nitrogen prior to the addition of chemical reagents. A 
nitrogen atmosphere was maintained throughout reactions where necessary through the use of a 
nitrogen balloon. NMR spectra were recorded on a Bruker DPX 400 operating instrument or a Jeol 
ECS-400 at 400 MHz for 
1
H or 376 MHz for 
19
F NMR spectra or 100 MHz for 
13
C spectra were 
recorded in CDCl3, DMSO-d6 or methanol-d4. Chemical shifts are given in parts per million (ppm) 
and coupling constants are recorded in hertz. Tetramethylsilane was used as internal standard for 
1
H 
and 
13
C spectra. 
19
F NMR spectra re referenced to hexafluorobenzene. DEPT was used to assign 
environment (CH, CH2, and CH3) to each carbon atom in the 
13
C spectra. Mass spectra were 
recorded on a Thermo Scientific Exactive (Orbi) ESI (Ethanol) via nanomate (Advion) or were 
recorded at the EPSRC National mass Spectrometry Facility. The solvent used for all samples was 
methanol. GC-MS was performed on a Fisons 8060 with a DB5MS column of 30 m length and 
splitless injection. 
IR spectra were obtained using a Perkin-Elmer spectrum 65 FT-IR spectrophotometer.  Sodium 
chloride plates were used to acquire thin film spectra, or samples were recorded as KBr discs. 
Melting points were recorded using an Electrothermal-IA 9100 melting point instrument and are 
uncorrected. Elemental analysis was determined using a Perkin-Elmer 2400 analyser.  
The reactions were checked using thin layer chromatography (TLC) on Merck TLC silica gel 60 
F254 aluminum backed plates. UV radiation at a wavelength of 254 nm using a U.V.P chromate-vue 
cabinet model CC-60 used to visualise TLC plates. Column chromatography was carried out on 
Merck Kiesel 60 silica gel.  
 For biological activity assays salmon sperm (SS) DNA, naproxen, ACTD and EB were purchased 
from Sigma. A Spectra UV-2550 instrument was used for UV absorption assay and a Perkin Elmer 
Luminescence Spectrometer S50B was used for fluorescence assay. For DNA crystallization 
experiments the DNA sequence CGCGAATTCGCG was purchased from Sigma.  Cacodylate buffer 
was pH 6.5; 50 mM-isopropanol 15% solution. Gram-positive Staphylococcus aureus and Gram-
negative Escherichia coli strains were used for antibacterial studies. Muller Hinton agar, petri dish 
90 × 14 mm (diameter and height respectively) and Townson + Mercer incubator was used to 
incubate the bacteria in anti-microbial activity studies. 
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4.2. Organic synthesis 
4.2.1. 2,3,5,6-Tetrafluoro-4-(1H-imidazol-1-yl)pyridine 108129 
 
A solution of imidazole 27 (2 mmol, 0.136 g) in THF (4 mL) was added dropwise to a stirred 
suspension of sodium hydride NaH (60% dispersion in mineral oil) (2.5 mmol, 0.1 g) in THF (5 mL). 
The mixture was reacted at room temperature for 30 min. A solution of pentafluoropyridine 74 (6 
mmol, 0.7 mL) in THF (3 mL) was added dropwise to the mixture and the reaction left to stir at room 
temperature overnight. The solvent was evaporated and water (20 mL) was added to the residue. The 
reaction mixture was extracted with DCM (25 mL × 3) and the combined organic layers dried over 
MgSO4, filtered and evaporated to give compound 108 (0.39g, 89%) as yellow oil. 
vmax /cm
-1
 (film)  2986, 1645, 1479, 1265, 1189, 1078, 968, 832, 738 ; MS (ESI) (MH
+
), C8H3F4N3 
requires m/z 218.0328; found m/z 218.0335; δH (400 MHz, CDCl3) 8.01 (1H, s), 7.43 (1H, t, J 1.6 
Hz), 7.32 (1H, s); δF (376 MHz, CDCl3) 175.54-75.70 (2F, BB’), 13.13-13.23 (2F, AA’)  
4.2.2.  1-(Perfluoropyridin-4-yl)-1H-benzo[d]imidazole 109130 
 
A solution of pentafluoropyridine 74 (10 mmol, 1.1 mL) in THF (3 mL) was added dropwise to a 
stirred suspension of sodium hydride NaH (60% dispersion in mineral oil) (15 mmol, 0.6g) in THF 
(10 mL). A solution of benzimidazole 31 (10 mmol, 1.2 g) in THF (15 mL) was added dropwise to 
the mixture by using a syringe pump and the reaction left to stir at room temperature for 24 h under 
129 
 
N2. The solvent was evaporated and water (20 mL) was added to the residue. The reaction mixture 
was extracted with DCM (25 mL × 3) and the combined organic layers dried over MgSO4, filtered 
and evaporated to give compound 109 (2.62g, 98%) as a shiny, creamy solid. 
 m.p. 136-140°C; vmax /cm
-1
 (film) 2988, 1712, 1478, 1265, 1222, 969, 896, 748; MS (ESI) (MH
+
), 
C12H5F4N3 requires m/z 268.0469 found m/z 268.0491; δH (400 MHz, CDCl3,) 8.11 (1H, s), 7.94-7.90 
(1H, m), 7.47-7.44 (2H, q, J, 7.2, 4.4) 7.34-7.33 (1H, m); δF (376 MHz, CDCl3) 75.98-76.14 (2F, 
BB’), 16.34-16.15 (2F, AA’); δC (100 MHz, CDCl3) 144.3 (td, J, 240, 11, C-F ), 143.2 (Cq), 141.1 
(N-CH=N), 136.9 (dd, J, 270, 37, C-F), 132.3 (Cq), 127.0-127.2 (m, Cq-N), 125.2 (CH), 124.4 (CH), 
121.3 (CH), 110.9 (CH).  
4.2.3. 1,1'-(3,5,6-Trifluoropyridine-2,4-diyl)bis(1H-benzo[d]imidazole) 110 
 
A solution of tetrafluoropyridine derivative 109 (2 mmol, 0.53 g) in THF (5 mL) was added 
dropwise to the stirred suspension of sodium hydride NaH (60% dispersion in mineral oil) (2.5 
mmol, 0.1 g) in THF (5 mL). A solution of benzimidazole 31 (2 mmol, 0.24 g) in THF (5 mL) was 
added dropwise to the mixture using pressure compensating dropping funnel and the reaction left to 
stir at room temperature overnight. The solvent was evaporated and water (20 mL) was added to the 
residue. The reaction mixture was extracted with DCM (25 mL × 3) and the combined organic layers 
dried over MgSO4, filtered and evaporated to give brown sticky solid (0.6 g).Purification was carried 
out by column chromatography and 1-(2-(benzo[d]imidazol-1-yl)-3,5,6-trifluoropyridin-4-yl)-1H-
benzo[d]imidazole 110 was obtained as a brown solid (0.08 g, 36%). 
m.p. 186-190 °C ; MS (ESI) (MH
+
), C12H5F4N3 requires m/z 366.0953; found m/z 366.0960; δH (400 
MHz, CDCl3,) 8.43 (1H, d, J 2.8), 8.11 (1H, t, J 2), 8.01 (2H, d, J 7.6), 7.90-7.88 (1H, m), 7.85-7.83 
(1H, m), 7.41-7.38 (4H, m), 7.33 -7.31 (1H, m); δF (376 MHz, CDCl3) 79.3 (1F, t, J 23.3 ), 27.8 (1F, 
d, J 28.9),  18.4 (1F, d, J 23.3). 
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4.2.4. 2,3,5,6-Tetrafluoro-4-(1H-1,2,3-triazol-1-yl)pyridine 111 and 2,3,5,6-tetrafluoro-4-(2H-
1,2,3-triazol-2-yl)pyridine 112 
 
A solution of pentafluoropyridine 74 (40 mmol, 4.4 mL) in THF (4 mL) was added dropwise to a 
stirred suspension of sodium hydride NaH (60% dispersion in mineral oil) (30  mmol, 1.2 g) in THF 
(10 mL). A solution of 1,2,3-triazole 28 (20 mmol, 1.38 g) in THF (15 mL) was added dropwise to 
the mixture and the reaction left to stir at room temperature for 24 h under N2. The solvent was 
evaporated and water (20 mL) was added to the residue. The reaction mixture was extracted with 
DCM (25 mL × 3) and the combined organic layers dried over MgSO4, filtered and evaporated to 
give oily semi solid compound (3.5 g).
 19
F and 
1
H NMR spectra indicated the presence of two 
different compounds in the product. The mixture was separated by column chromatography using 6:4 
light petrol: ethyl acetate as eluting solvent to give isomer X 111 as a shiny white solid (1.72 g, 40%) 
and 100% ethyl acetate to give isomer Y 112 as shiny light yellow solid (0.66 g, 15%). 
X isomer 111: 
m.p. 63-65 °C; vmax /cm
-1
 (film) 1643, 1465, 1257, 1180, 956, 848, 671. MS (ESI) (MH
+
), C7H3F4N4 
requires m/z 219.0288 found m/z 219.0287; δH (400 MHz, CDCl3,) 8.61 (1H, s ), 8.28 (1H, s); δF 
(376 MHz, CDCl3) 77.48-77.32 (2F, BB’), 14.41-14.25 (2F, AA’); δC (100 MHz, CDCl3) 154.5 
(CH), 145.2 (CH), 144.1 (td , J  270, 23, C-F), 136.7 (dd, J 210, 30 C-F), 127.15-127.98 (m, Cq-N); 
Analysis (%) for C7H2F4N4 (218) required: C, 38.55; H, 0.92; N, 25.69 Found: C, 38.34; H, 0.83; N, 
25.08. 
Y isomer 112: 
m.p. 150-152°C; vmax /cm
-1
 (film)  1651, 1427, 1265, 1057,  956, 833; MS (ESI) (MH
+
), C7H3F4N4 
requires m/z 219.0288 found m/z 219.0289; δH (400 MHz, CDCl3) 8.64 (2H, t, J 2 ); δF (376 MHz, 
CDCl3) 76.14-75.68 (2F, BB’), 15.00-18.84 (2F, AA’); δC (100 MHz, CDCl3) 144.5 (td, J 190, 11 C-
F), 141.0 (t, J, 4 CH) , 135.3 (dd, J 200, 10, C-F),  124.5-124.7 (m, Cq-N); Analysis (%) for 
C7H2F4N4 (218) required: C, 38.55; H, 0.92; N, 25.69 Found: C, 38.37; H, 0.85; N, 25.04 
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4.2.5. 1-(Perfluoropyridin-4-yl)-1H-benzo[d][1,2,3]triazole 113131 
 
A solution of pentafluoropyridine 74 (40 mmol, 4.4 mL) in THF (5 mL) was added dropwise to a 
stirred suspension of sodium hydride NaH (60% dispersion in mineral oil) (30 mmol, 1.2 g) in THF 
(10 mL). A solution of benzotriazole 30 (20 mmol, 2.4 g) in THF (15 mL) was added dropwise to the 
mixture by syringe pump and the reaction left to stir at room temperature for 24 h under N2. The 
solvent was evaporated and distilled water (10 mL) was added to the residue. A white solid was 
precipitated and was collected by suction filtration to give compound 113 (4.72 g, 88%) as white 
solid. 
m.p. 135-138°C; vmax /cm
-1
 (film) 2924, 2854, 1695, 1473, 1249, 1041, 956, 840, 624; MS (ESI) 
(MH
+
); C12H5F4N4 requires m/z 269.0445 found m/z 269.0443; δH (400 MHz, CDCl3,) 8.22 (1H, d, J 
8.4), 7.67 (1H, t, J 7.2), 7.56-7.48 (2H, m); δF (376 MHz, CDCl3) 75.99-75.76 (2F, BB’), 17.24-
17.04 (2F, AA’); δC (100 MHz, CDCl3) 145.6 (Cq), 144.2 (dt, J 230, 14, C-F), 136.7 (dd, J  270, 37, 
C-F), 132.6 (Cq), 127.0-127.1 (m, Cq-N),  125.9 (CH), 130.0 (CH), 109.8 (CH), 121.0 (CH).  
4.2.6. 9,9'-(3,4,6-Trifluoropyridine-2,5-diyl)bis(9H -carbazole) 114 
 
A solution of pentafluoropyridine 74 (50 mmol, 8.85 g) in THF (3 mL) was added dropwise to to a 
stirred suspension of NaH (60% dispersion in mineral oil) (20 mmol, 0.8 g) in THF (5 mL). A 
solution of carbazole 29 (10 mmol, 1.67 g) in THF (10 mL) and DMF (2 mL) was added dropwise to 
132 
 
reaction mixture under N2 and left to stir at RT for 24 h. The solvent was evaporated and water (20 
mL) was added to the residue. a yellow solid precipitated and was filtered (3.47 g). The product was 
purified by column chromatography using 8:2 light petrol:diethyl ether eluting solvent to give 
compound 114 (4.1g, 45%) as white crystals. 
m.p. 203-205 °C; vmax /cm
-1
 (film)  1597, 1419, 1118, 972 , 856; MS (ESI) (MH
+
), C29H17F3N3 
requires m/z 464.1369 found m/z 464.1370; 𝛿H (400 MHz, CDCl3) 8.15 (1H, d, J  8), 8.11 (1H, d, J  
7.6), 7.54-7.45 (3H, m), 7.41-7.31 (3H, m); 𝛿F (376 MHz, CDCl3) 77.89 (1F, t, 28.95), 38.30 (1F, d, 
J 30.01), 22.84 (1F, d, J 26.32); δC (100 MHz, CDCl3),147.28 (dd, J 250, 20, C-F ), 146.0 (dd, J 260, 
10, C-F),139.2 (Cq), 139.0 (Cq), 139.8 (dd, J 220, 31, C-F), 132.01-132.85 (m, Cq-N), 127.45-
128.05 (m, Cq-N), 126.8 (CH), 126.5 (CH), 124.7 (Cq), 124.6 (Cq), 122.1 (CH), 121.8 (CH), 120.8 
(CH), 120.5 (CH), 110.9 (d, J 2.8, C-H), 110.3 (C-H); Analysis (%) for C29H16F3N3. (445) required: 
C, 75.16; H, 3.48; N, 9.07 Found: C, 74.93; H, 3.35; N, 9.02. 
4.2.7. 1-(2,6-bis(2-Bromophenoxy)-3,5-difluoropyridin-4-yl)-1H-benzo[d]imidazole 115 
 
A solution of 2-bromophenol 58 (1 mmol, 0.11 mL) in THF (3 mL) was added dropwise to a stirred 
suspension of sodium hydride NaH (60% dispersion in mineral oil) (1.5 mmol, 0.06 g) in THF (5 
mL) and left 30 min at room temperature. A solution of tetrafluoropyridine derivative 109 (1 mmol, 
0.267 g) in THF (5 mL) and was added dropwise to the reaction mixture and the reaction left to stir 
at room temperature overnight. The solvent was evaporated and water (20 mL) was added to the 
residue. The reaction mixture was extracted with DCM (3 × 25 mL) and the combined organic layers 
dried over MgSO4, filtered and evaporated to give cream colour solid (0.53 g). Recrystallization 
from DCM and hexane gave shiny white crystals of 1-(2,6-bis-(2-bromophenoxy)-3,5-
difluoropyridine-4-yl)-1H-benzo[d]imidazole 115 as shiny white crystals (0.31 g, 53%).  
m.p. 178-181 °C; vmax /cm
-1
 (film): 1712, 1635, 1519, 1435, 1350, 1287, 1080, 979, 871, 732;  
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MS (ESI) (MH
+
), C24H16
79
Br2F2N3O2 requires m/z 573.9387; found m/z 573.9383; δH (400 MHz, 
CDCl3,) 8.23 (1H, t, J 2), 7.85 (1H, dt, J 6, 1.6), 7.48-7.46 (5H, m), 7.17 (2H, dt, J 8, 1.2), 7.06-7.02 
(4H, m); δF (376 MHz, CDCl3) 14.9 (2F, s). 
4.2.8. 2-((4-(1H-benzo[d]imidazol-1-yl)-3,5,6-trifluoropyridin-2-yl)thio)aniline 118 
 
A solution of tetrafluoropyridine derivative 109 (1 mmol, 0.267 g) in THF (3 mL) was added 
dropwise to a stirred suspension of sodium hydride NaH (60% dispersion in mineral oil) (1.3 mmol, 
0.05 g) in THF (5 mL). 2-aminothiophenol 117 (1 mmol, 0.11 mL) was mixed with sodium 
borohydride (1 mmol, 0.038 g) in THF (5 mL) and was added dropwise to the mixture using a 
pressure compensating dropping funnel, and the reaction left to stir at room temperature overnight. 
The reaction was quenched with a few drops of methanol. Distilled water (10 mL) was added, and 
the mixture was extracted with DCM (3×20 mL). The organic extract was washed with aqueous 
sodium chloride and dried over MgSO4, filtrated and evaporated to give dark yellow sticky solid 
(0.41 g). Purification was carried out by column chromatography giving 2-((4-(1H- 
benzo[d]imidazol-1-yl)-3,5,6-trifluoropyridine-2 yl)thiol)aniline 118 as dark red solid (0.11 g, 29%).   
m.p. 60-64 °C; vmax /cm
-1
 (film) 3333 (broad, N-H), 1612, 1512, 1435, 1303, 1257, 802, 740 ; 
MS (ESI) (MH
+
), C18H11F3N4S requires m/z 374.0729, found m/z 374.0728; δH (400 MHz, CDCl3,) 
8.01 (1H, s), 7.86-7.82 (1H, m), 7.41-7.39 (1H, dd, J 7.6, 1.2), 7.36-7.32 (2H, m), 7.25-7.21 (2H, m), 
6.78 (2H, dd J 8, 1.2), 4.27 (2H, s, N-H); δF (376 MHz, CDCl3) 78.5 (1F, t, J 24), 35.1 (1F, d, J 29), 
14.9 (1F, d, J 24). 
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4.2.9. N-(2-Mercaptophenyl)-4-nitrobenzamide 121 
 
2-Aminothiophenol 116 (2 mmol, 0.22 mL) was mixed with sodium borohydride (2 mmol, 0.08 g) in 
CH3CN (5 mL) and was added dropwise to a stirred solution of Et3N (2 mmol, 0.28 mL) in CH3CN 
(4 mL). A solution of 4-nitrobenzoyl chloride 120 (2 mmol, 0.371 g) in CH3CN (5 mL) and was 
added dropwise to the reaction mixture and the reaction left to stir at room temperature overnight. 
After distilled water (10 mL) was added solid precipitated and was collected by suction filtration to 
give yellow solid (0.095 g). Recrystallization from hot ethanol gave shiny yellow crystals of N-(2-
mercaptophenyl)-4-nitrobenzamide 121 (0.31 g, 57%).  
m.p. 178-181 °C ; vmax /cm
-1
 (film) 3348 (N-H), 1681 (C=O), 1581 and 1519 (NO2), 1311, 1249, 
1103, 1010, 833, 756, 632, 540; MS (ESI) (MH
-
), C13H10N2O3S requires m/z 273.0348; found m/z 
273.0339; δH (400 MHz, CDCl3,) 8.91 (1H, s, N-H), 8.43 (1H, d, J 8.0), 8.34-8.31 (2H, m), 7.93 (1H, 
d, J, 8.8), 7.81 (1H, dd, J 2.4, 6.8), 7.56 (1H, dd J 7.6, 1.2), 7.33-7.30(1H, m ), 7.05 (1H, t J 6), 4.25 
(1H, s, SH). 
4.2.10. 2-(4-Nitrophenyl)benzo[d]thiazole 122 
 
 
2-Aminothiophenol 116 (2 mmol, 0.22 mL) was mixed with sodium borohydride (2 mmol, 0.076 g) 
in pyridine (5 mL) and left to stir at room temperature for 30 min. A solution of 4-nitrobenzoyl 
chloride 120 (2 mmol, 0.371 g) in pyridine (5 mL) and was added dropwise to the reaction mixture 
and the reaction left to stir at room temperature overnight. The solvent was evaporated and water (20 
mL) was added to the residue. The reaction mixture was extracted with DCM (3 × 25 mL) and the 
combined organic layers dried over MgSO4, filtered and evaporated to give yellow sticky solid  
135 
 
(0.54 g). The compound was washed with cold ethanol and collected by suction filtration to give 
compound 122 (0.25 g, 49%) as a shiny yellow solid.  
m.p. 224-229 °C; vmax /cm
-1
 (film) : 1597 and 1519 (NO2), 1342, 1219, 1111, 972, 848, 763, 732, 
686; MS (ESI) (MH
+
), C13H9N2O2S requires m/z 257.0371; found m/z 257.0377; δH (400 MHz, 
CDCl3,) 8.4 (2H, d, J 2), 8.29 (2H, d, J 8.8), 8.16 (1H, d, J 8.4), 7.99 (1H, d, J 8), 7.58(1H, t, J 7.6), 
7.49 (1H, d, J 7.2). 
4.2.11. 1-(2,5-bis((2-Bromophenyl)thio)-3,6-difluoropyridin-4-yl)-1H-benzo[d]imidazole 126 
 
A solution of 2-bromothiophenol 125 (1 mmol, 0.12 mL) in THF (3 mL) was added dropwise to 
stirred suspension of sodium hydride NaH (60% dispersion in mineral oil) (1.5 mmol, 0.05 g) in THF 
(5 mL). A solution of tetrafluoropyridine derivative 109 (1 mmol, 0.267 g) in THF (5 mL) added 
dropwise to the reaction mixture and left to stir at room temperature overnight. The solvent was 
evaporated and water (20 mL) was added to the residue. The reaction mixture was extracted with 
DCM (3 × 25 mL) and the combined organic layers dried over MgSO4, filtered and evaporated to 
give creamy solid (0.4 g). Recrystallization from hot ethanol gave shiny white crystals of 1-[2,6-bis-
(2-bromo-phenylsulfanyl)-3,5-difluoro-pyridin-4-yl]-1H-benzoimidazole 126 (0.39 g, 65%).  
m.p. 162-165 °C; vmax/cm
-1
 (film): 1581, 1450,  1333, 1149, 1018, 1080, 884, 740; MS (ESI) (MH
+
), 
C24H14Br2F2N3S2 requires m/z 603.8973; found m/z 603.8952; δH (400 MHz, CDCl3,) 7.79 (1H, s), 
7.72-7.67 (3H, m), 7.35 (1H, t, J 1.2), 7.28 (1H, dd, J 6, 2), 7.26-7.22 (3H, m), 7.03 (1H, d, J 4.8), 
6.83-6.81 (2H, m), 6.73-6.71 (1H, m); δF (376 MHz, CDCl3)  101.9 (1F, d, J 27), 33.30 (1F, d, J 27).  
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4.2.12.  1H,1’H-2,2’-Biimidazole 130 120 
 
 Aqueous glyoxal 129 (50%, 0.1 mol, 11.5 mL) was added dropwise to a stirred solution of 
ammonium acetate (0.26 mol, 20 g) in water (10 mL) and the reaction left to stir at room temperature 
overnight. The dark brown solid formed (0.71 g) was collected by suction filtration and washed with 
water (3 × 10 mL) and acetone (3 × 10 mL) to give 1H,1’H-2,2’-biimidazole 130 (0.7 g, 5%) 
m.p. 347-350 °C (literature value : > 300 °C) 
(27)
; MS (ESI) (MH
+
), C6H6N4 requires m/z 135.0668; 
found m/z 135.0662; vmax /cm
-1
 (film) 3368 (broad peak , H2O), 2922 and 2852 (2 N-H), 1651, 1402, 
1329, 1102, 937, 745; δH (400 MHz, DMSO-d6) 12.85 (2H, s, N-H), 7.18 (2H, s), 7.06 (2H, s).  
4.2.13. N1,N6-bis(2,2-Dimethoxyethyl)adipamide 131 
 
 
A solution aminoacetaldehyde dimethyl acetal (4 mmol, 0.46 g) in THF (2 mL) was added dropwise 
to a stirred solution of triethylamine (4 mmol, 0.61 mL) in THF (3 mL). The mixture was stirred at 
room temperature for 30 min. A solution of adipoyl chloride (2 mmol, 0.29 mL) in THF (2 mL) was 
added dropwise to the mixture and the reaction left to stir at room temperature overnight under N2. 
The reaction was quenched with distilled water (10 mL), and the mixture was extracted with DCM 
(3×20 mL). The organic extract was dried over MgSO4, filtered and evaporated to give compound 
131 (0.48 g, 75%) as a white solid. 
m.p. 93-95°C; vmax/cm
-1
 (film) 3315-3284 (broad peak) NH group, 1649 (C=O), 1423, 1384, 1138, 
1199, 966, 832, 738, 607; MS (ESI) (MH
+
), C14H29N2O6 requires m/z 321.2020; found m/z 321.2019; 
δH (400 MHz, CDCl3) 5.88 (2H, s), 4.38 (2H, t, J 5.2), 3.39-3.41(16H, m), 2.21-2.26 (4H, m), 1.64-
1.68 (4H, m). 
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4.2.14.  1,4-di(1H-imidazol-2-yl)butane 132  
 
The intermediate compound 135 (8.3 mmol, 1.58 g) was treated with HCl (40 mmol, 6 mL) and the 
mixture heated at 65 °C for 24 h under N2. After 24 h the reaction mixture was cooled and 
neutralized with dry sodium carbonate (Na2CO3). Addition of water precipitated the target compound 
132 (0.79 g, 50%) which was filtered as a light brown solid.  
mp: decomposed at 168 °C; vmax /cm
-1
 (film) 3000-3450 (broad peak, NH), 1639, 1577, 1423, 1342, 
1153, 1103, 991, 887, 763, 675; MS (ESI) (MH
+
), C10H15N4 requires m/z 191.1291 found m/z 
191.1296; MS (ESI) (MH
-
), C10H13N4 requires m/z 189.1146, found m/z 189.1147 
δH (400 MHz, DMSO-d6) 11.79 (2H, s), 6.95 (2H, s), 6.73 (2H, s), 2.57-2.54 (4H, m), 1.61-1.56 (4H, 
m); δH (400 MHz, Methanol-d4) 6.85 (4H, s), 2.66-2.70 (4H, m), 1.69-1.67 (4H, m); δC (100 MHz, 
Methanol-d4) 149.9 (Ar Cq), 120.1 (Ar CH), 27.6 (CH2), 27.3 (CH2). 
4.2.15. N1,N6-bis(2-Aminophenyl)adipamide 133  
 
A solution of o-phenylenediamine (4 mmol, 0.47 g) in THF (4 mL) was added dropwise to a stirred 
solution of triethylamine (4 mmol, 0.6 mL) in THF (3 mL). The mixture was stirred at room 
temperature for 30 min. A solution of adipoyl chloride (2 mmol, 0.29 mL) in THF (2 mL) was added 
dropwise to the mixture and the reaction left to stir at room temperature overnight under N2. The 
solvent was evaporated and water (20 mL) was added to the residue. A yellow solid precipitated and 
was filtered to give compound 133 (0.49 g, 75%) as white solid.  
m.p. 155-165°C; vmax/cm
-1
 (film) 3250 (broad peak) NH group, 1658 (C=O), 1643, 1512, 1481, 
1290, 1136, 1068, 966, 832, 752, 607; MS (ESI) (MH
+
), C18H22N4O24 requires m/z 327.1815 found 
m/z 327.1814; δH (400 MHz, DMSO-d6) 9.34 (1H, s), 9.15 (1H, s), 7.15 (2H, d, J 8), 6.89 (2H, t, J 
7.2) 6.70 (2 H, t, J 7.6), 6.54 (2 H, t, J 7.6), 4.32 (2H, s), 2.34-2.33- (4H, m), 1.64-1.63 (4H, m). 
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4.2.16. 1,4-bis(1H-benzo[d]imidazol-2-yl)butane 134 
 
 
 
 
A solution of o-phenylenediamine (4 mmol, 0.43 g) in methanol (6 mL) was added to a suspension of 
compound 18 (2 mmol, 0.55 g) in methanol (3 mL). The mixture was refluxed for 3 h under N2. 
After 3 h the reaction was stopped and treated with water (20 mL). Compound 134 precipitated and 
was collected by suction filtration as shiny light yellow solid (0.44 g, 75%). m.p. 258-260°C; 
vmax/cm
-1
 (film) 3441-3163 (broad, NH), 1620, 1535, 1415, 1141, 1006, 840, 744; MS (ESI) (MH
+
), 
C18H19N4 requires m/z 291.1592, found m/z 291.1581 
MS (ESI) (MH
-
), C18H17N4 requires m/z 289.1549 found m/z 289.1559; δH (400 MHz, DMSO-d6), 
12.2 (2H, s), 7.44 (4H, dd, J 6, 2.8), 7.16 (4H, dd, J 6, 3.2), 2.96-2.89 (4H, m), 1.85-1.77 (4H, m). δC 
(100 MHz, DMSO-d6) 155.5 (Ar Cq), 138.8 (broad Ar Cq), 127.14-127.7 (m, N-Cq=N), 114.5 (Ar 
CH), 120.4 (Ar CH), 28.7 (CH2), 27.5 (CH2). 
4.2.17. N1,N6-bis(2,2-Dimethoxyethyl)adipimidamide 135 
 
 
A solution of aminoacetaldehyde dimethyl acetal (0.0045 mol, 0.47 g) in methanol (3 mL) was added 
to stirred suspension of compound 136 (0.002 mol, 0.48 g) in methanol (3 mL). The reaction mixture 
was heated under reflux for 3 h.  The solvent was evaporated to give intermediate compound 135 
(0.6 g, 95%) as a yellow syrup.   
MS (ESI) (MH
+
), C14H31N4O4 requires m/z 319.2341 found m/z 319.2315; vmax/cm
-1
 (film) 3483, 
3051 (NH), 1656, 1452, 1502, 1237, 1195, 1066, 798, 742; δH (400 MHz, Methanol-d4) 4.54 (2H, t, J 
4.8 Hz), 3.44 (16H, m), 2.53 (4H, m), 1.74 (4H, m). 
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4.2.18.  Diethyl adipimidate dihydrochloride 136 
 
Ethanol (0.4 mol, 18.4 g) and acetyl chloride (0.25 mol, 17.8 mL) were added to a solution of 
adiponitrile (0.1 mol, 10.8 g) in DCM (10 mL). The mixture was stirred for 30 min then left at 4 ºC 
for 3 days. After this time, compound 136 had precipitated and was collected as white solid by 
suction filtration (23 g, 80%).  
m.p. 135-136°C; vmax /cm
-1
 (film) 3383 (broad peak) NH group, 1651, 1462, 1377, 1215, 1114, 879, 
777; δH (400 MHz, D2O) 4.66 (4H, q, J 6) 2.37-2.35 (4H, m), 1.58-1.59 (4H, m), 1.20 (6H, t, J 5.6 
Hz). (N-H, peak not detected) 
4.2.19.   5,7,8-Trifluorodiimidazo[1,2-a:2',1'-c]pyrido[3,4-e]pyrazine 137 and 1-(perfluorophenyl)-
1'-(perfluoropyridin-4-yl)-1H,1'H-2,2'-biimidazole 138 
 
 
      
 
 
 
A solution of pentafluoropyridine 74 (2 mmol, 0.22 g) in THF (5 mL) was added dropwise to stirred 
suspension of sodium hydride NaH (60 % dispersion in mineral oil) (2.5 mmol, 0.1 g) in THF (5 
mL). A solution of 1H,1’H-2,2’-biimidazole 130 (1 mmol, 0.134 g) in THF (5 mL) and was added 
dropwise at room temperature and the mixture stirred overnight. The reaction was quenched with a 
few drops of methanol. After distilled water (10 mL) was added some solid formed and was 
collected by suction filtration to give compound 138 (0.14 g, 33%) as a white solid. The aqueous 
filtrate was extracted with DCM (3×20 mL). The organic extract was dried over MgSO4, filtered and 
evaporated to give dark yellow sticky solid which recrystallized from hot ethanol to give the pure 
compound 137 (0.08 g, 31%) as yellow solid. 
140 
 
Compound 137  
m.p. 288-295 °C; vmax /cm
-1
 (film), 1681, 1243, 1187, 957, 787; MS (ESI) (MH
+
), C11H5F3N5 
requires m/z 264.0483; found m/z 264.0413; δH (400 MHz, DMSO-d6) 8.42-8.33 (2H, dd, J, 32, 1.2), 
7.74-7.69 (2H, dd, J 1.6, 18.4); δF (376 MHz, CDCl3) 8.31 (1F, dt, J 23.3, 2.6), 69.31 (1F, q, J 11.7), 
86.90 (1F, dq, J 13.5, 3.0). 
Compound 138 
m.p. 158-164 °C; vmax /cm
-1
 (film), 1651, 1203, 1087, 927, 717; MS (ESI) (MH
+
), C16H5F8N6 
requires m/z 433.0434; found m/z 433.0441; δH (400 MHz, CDCl3,) 8.13-8.08 (2H, m), 7.68-7.66 
(4H, dd, J 10.4, 1.2); δF (376 MHz, CDCl3) 74.70-74.53 (4F, BB’), 16.03-15.77 (4F, AA’). 
4.2.20.   5,6,7,8-Tetrafluorodiimidazo[1,2-a:2',1'-c]quinoxaline 140 
 
 
A solution of hexafluorobenzene 48 (2 mmol, 0.37 g) in DMF (3 mL) was added dropwise to a 
stirred suspension of sodium hydride NaH (60% dispersion in mineral oil) (2.5 mmol, 0.1 g) in DMF 
(5 mL). 1H,1H-2,2’-biimidazole 130 (1 mmol, 0.134 g) in DMF (3 mL) and was added dropwise to 
the mixture. The mixture was heated at 80°C overnight under N2. The solvent was evaporated and 
water (20 mL) was added to the residue. Some yellow solid precipitated and was filtered to give a 
brown solid which after recrystallization from ethanol afforded compound 140 (0.05 g, 18%) as a 
brown solid. m.p. decomposed at 240 °C 
vmax/cm
-1
 (film), 29.33, 1631, 1223, 1187, 957, 787; MS (ESI) (MH
+
), C12H5F5N4  requires m/z 
281.0445 found m/z 281.0433; δH (400 MHz, CDCl3,) 8.16 (2H, d, J 1),7.67 (2H, d, J 1); 
δF (376 MHz, CDCl3) 14.04-13.94 (2F, BB’), 4.57-4.54 (2F, AA’).  
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4.2.21.  5,7,8-Trifluorodiimidazo[1,2-a:2',1'-c]quinoxaline-6-carbaldehyde 141 
 
 
A solution of pentafluorobenzaldehyde 68 (1 mmol, 0.19 g) in DMF (3 mL) was added dropwise to a 
stirred suspension of sodium hydride NaH (60% dispersion in mineral oil) (1.5 mmol, 0.06 g) in 
DMF (5 mL). 1H,1H-2,2’-biimidazole 130 (1 mmol, 0.134 g) in DMF (3 mL) and was added 
dropwise to the mixture. The mixture was heated at 80 °C overnight under N2. The solvent was 
evaporated and distilled water (10 mL) was added. Solid formed which was collected by suction 
filtration to give impure brown solid after recrystelazaion by DCM and light petrol compound 141 
(10%) was isolated as yellow solid. vmax/cm
-1
 (film), 2923, 1709, 1646, 1500, 1260, 10.91, 796,  682; 
MS (ESI) (MH
+
), C13H6F3N5O  requires m/z 291.0488 found m/z 291.0476; δH (400 MHz, CDCl3,) 
10.46 (1H, s), 8.22 (2H, d, J 1.2), 7.69 (2H, d, J 1.6) ;δF (376 MHz, CDCl3) 13.21-13.11 (1F, m), 
20.16 (1F, d, J 21.8), 32.91 (1F, d, J 18.4). 
4.2.22.   1,4-bis-1-Tetrafluoropyrid-4-yl-1H-benzimidazol-2-ylbutane 143 
 
A solution of pentafluoropyridine 74 (1.5 mmol, 0.25 g) in DMSO (2 mL) was added dropwise to 
stirred suspension of sodium hydride NaH (60 % dispersion in mineral oil) (1.5 mmol, 0.06 g) in 
DMSO (2 mL). Compound 133 (0.5 mmol, 0.15 g) in DMSO (4 mL) and was added dropwise by 
syringe pump and the reaction mixture left for 24 h at room temperature under N2. The solvent was 
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evaporated and water (20 mL) was added to the residue. Solid precipitated and was collected by 
suction filtration to give compound 143 (0.28 g, 95%) as a white shiny solid.  
m.p. 195-198 °C; vmax/cm
-1
 (film), 2924, 1642, 1471, 1255, 1136,  972, 743; MS (ESI) (MH
+
), 
C28H17F8N6 requires m/z 589.1381 found m/z 589.1376; δH (400 MHz, CDCl3,) 7.81 (2H, d, J 7.6), 
7.36 (4H, m), 7.07 (2H, d, J 7.6), 2.87 (4H, m), 2.06 (4H, m); δF (376 MHz, CDCl3) 76.4-76.1 (4F, 
m), 18.2-17.9 (4F, m); δC (100 MHz, CDCl3) 153 ( Ar N-Cq=N), 144.2 (dd, J 230, 26, C-F), 142.8 
(Ar Cq), 136.8 (dd, J 267, 36, C-F),  134.2 (Ar Cq), 128.1-127.2 (m, Cq-N), 124.2 (Ar CH), 124.0 
(Ar CH), 120.1 (Ar CH),  109.4 (Ar CH), 29.8 (CH2-C=N), 26.4 (CH2-CH2-CH2); Analysis (%) for 
C28H16F8N6.½H2O (597) requires: C, 56.28; H, 2.85; N, 14.07, found: C, 56.38; H, 3.01; N, 13.86. 
4.2.23.   1,4-bis-1-(4-Methoxycarbonyltetrafluorophenyl)-1H-benzimidazol-2-ylbutane 148 
 
 
 
 
 
 
 
A solution of methyl pentafluorobenzoate 147 (2 mmol, 0.45 g) in DMSO (3 mL) was added 
dropwise to stirred suspension of sodium hydride NaH (60% dispersion in mineral oil) (2 mmol, 0.08 
g) in DMSO (3 mL). Compound 134 (1 mmol, 0.3 g) in DMSO (4 mL) was added dropwise to the 
reaction mixture after 30 min by syringe pump and it left 24 h at room temperature under a N2 
atmosphere. By adding distilled water (10 mL) to the mixture light yellow solid (0.8 g) precipitated 
and was collected by suction filtration which was recrystallized from hot ethanol to give compound 
148 (0.4 g, 58%) as white shiny crystals. 
m.p. 195-198 °C; vmax/cm
-1
 (film), 2924, 1642, 1471, 1255, 1136,  972, 743 
MS (ESI) (MH
+
), C34H23F8N6O4 requires m/z 703.1586 found m/z 703.1569; δH (400 MHz, CDCl3,) 
7.81 (2H, d, J 7.6), 7.30-7.38 (m, 4H), 7.04 (2H, d, J 8.0), 4.09 (6H, 2), 2.87 (4H, m), 2.06 (4H, m); 
δF (376 MHz, CDCl3) 25.3-25.2 (4F, m), 19.3-19.2 (4F, m); δC (100 MHz, CDCl3) 159.3 (C=O), 
154.0 (Ar N -Cq=N), 145.4 (dd, J 180, 21, C-F), 142.9 (Ar Cq), 142.8 ( dd, J 170, 13, C-F ), 135.0 
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(Ar Cq), 123.8 (Ar CH), 123.5 (Ar CH), 119.9 (Ar CH), 114.1 (t, J  17, Ar Cq-C=O), 109.3 (Ar CH), 
53.8 (CH3),  27.1 (CH2-C=N), 26.5 (CH2-CH2-CH2), (1 ArF Cq not detected). 
4.2.24.  2,2-(Ethylenedioxy)-bis-ethyl  pentafluorobenzamide 151 
 
A solution of 2,2-(ethylenedioxy)bis(ethylamine) 150 (1 mmol, 0.15 g) in THF (2 mL) was added 
dropwise to stirred solution of triethylamine (2 mmol, 0.20 g) in THF (2 mL). A solution of 
pentafluorobenzoyl chloride 149 (2 mmol, 0.46 g) in THF (2 mL) and was added dropwise to the 
reaction mixture and left for 24 h at room temperature under N2. The solvent was evaporated and 
water (10 mL) was added to the residue. Yellow orange solid precipitated, and was filtered (0.5 g). 
Recrystallization using DCM and light petroleum gave compound 151 (0.38 g, 71%) as white shiny 
crystals.  
m.p. 128-129 °C; vmax/cm
-1
 (film), 3279 (N-H), 2872, 1658 (C=O), 1501, 1135, 1119, 992, 731; MS 
(ESI) (MH
+
), C20H14O4F10N2 requires m/z 537.0867, found m/z 537.0867; δH (400 MHz, CDCl3) 6.55 
(2H, s, NH), 3.70-3.66 (8H, m), 2.87 (4H, m); δF (376 MHz, CDCl3) 21.2-21.1 (4F, m), 11.26 (2F, t, 
J 20.3), 1.74-1.90 (4F, m); δC (100 MHz, CDCl3) 157.6 (C=O), 144. 2 (dd, J 255, 12, C-F), 142.3 
(dd, J 260, 25, C-F), 137.5 (dd, J 230, 32. C-F), 111.5 (t, J 30, Ar Cq-C=O), 70.8 (CH2-O), 69.8 
(CH2-O), 40.1 (CH2-N). Analysis (%) for C20H14F10N2O4 (536) required: C, 44.79; H, 2.63; N, 5.22 
Found: C, 44.78; H, 2.44; N, 5.25. 
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4.2.25.  2,2’-(Ethylenedioxy)-bis-ethyl  4-benzimidazol-1-yltetrafluorobenzamide 152 and N-(2-(2-
(2-(4-(1H-benzo[d]imidazol-1-yl)-2,3,5,6-tetrafluorobenzamido)ethoxy)ethoxy)ethyl)-
2,3,4,5,6-pentafluorobenzamide 151 
 
 
A solution of benzimidazole 31 (2 mmol, 0.24 g) in THF (3 mL) was added dropwise to stirred 
suspension of sodium hydride NaH (60% dispersion in mineral oil) (2 mmol, 0.08 g) in THF (3 mL) 
after 30 min. A solution of compound 151 (1 mmol, 0.54 g) in THF (3 mL) was added dropwise to 
the reaction mixture. The reaction mixture was left to stir for 24 h at room temperature under N2. 
Distilled water (10 mL) was added to the reaction mixture and it was extracted with DCM (3×25 
mL). The organic extract was dried over MgSO4, filtered and evaporated to give white solid (0.65 g). 
TLC indicated presence of mixture of two compounds and traces of starting material in the product. 
Thus further purification was carried out by column chromatography. Compound 153 (0.1 g, 15%) 
was afforded by using 99:1 ethyl acetate and methanol eluting as a colourless oil. Compound 152 
(0.45 g, 62%) was eluted using 90:10 ethyl acetate and methanol to afford the compound 153 as a 
shiny white solid. 
vmax /cm
-1
 (film) 3279 (broad N-H), 2831, 1665 (C=O), 1496,1280, 1211, 1118, 987, 740 
MS (ESI) (MH
-
), C27H18F9N4O4 requires m/z 633.1190 found m/z 633.1192; δH (400 MHz, CDCl3,) 
8.04 (1H, s), 7.88 (1H, d, J 3.6), 7.42-7.40 (2H, m), 7.23-7.22 (1H, m), 7.12 (1H, s, NH), 6.82 (1H, s, 
NH), 3.75-3.64 (12H, m); δF (376 MHz, CDCl3) 22.48 (2F, dd, J 22.93, 11.65), 22.07-21.01 (2F, m), 
16.59 (2F, dd, J 23.31, 11.65), 11.1 (1F, t, J 20.3), 1.83-1.70(2F, m). 
Compound 152 
m.p. 115-117 °C; vmax /cm
-1
 (film) 3194 (N-H), 2877, 1666 (C=O), 1550, 1418, 1280, 1134, 987, 
710, 748; MS (ESI) (MH
-
), C34H23F8N6O4 requires m/z 731.1659 found m/z 731.1657; 
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δH (400 MHz, CDCl3,) 8.03 (2H, s), 7.91-7.89 (2H, m), 7.43-7.38 (4H, m), 7.22 (2H, d, J 6), 7.00 
(2H, s), 3.75-3.73 (12H, m); δF (376 MHz, CDCl3) 22.6-22.5 (4F, m), 17.8-17.7 (4F, m);δC (100 
MHz, CDCl3) 157.5 (C=O), 142.9 (Ar CH=N), 141.1 (Ar Cq), 133.0 (Ar Cq),  124.9 (Ar CH), 123.9 
(Ar CH), 120.9 (Ar CH), 110.4 (Ar CH), 70.5 (CH2-O), 69.4 (CH2-O), 40.2 (CH2-N) (C-F and C-N 
could not be detected); Analysis (%) for C34H24F8N6O4 (732) required: C, 55.74; H, 3.30; N, 11.47 
Found: C, 55.59; H, 3.37; N, 11.16. 
4.2.26.   N,N'-((Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(2,3,5,6-tetrafluoro-4-(1H-
imidazol-1-yl)benzamide) 158 and 2,3,4,5,6-pentafluoro-N-(2-(2-(2-(2,3,5,6-tetrafluoro-4-
(1H-imidazol-1-yl)benzamido)ethoxy)ethoxy)ethyl)benzamide 159 
 
  
A solution of imidazole 27 (1 mmol, 0.07 g) in THF (3 mL) was added dropwise to stirred 
suspension of sodium hydride NaH (60 % dispersion in mineral oil) (2 mmol, 0.08 g) in THF (3 mL). 
The reaction mixture was left to stir for 30 min at RT then a solution of compound 151 (0.5 mmol, 
0.26 g) in THF (3 mL) was added dropwise to the reaction mixture. The reaction mixture was left to 
stir for 24 h at room temperature under N2. Distilled water (10 mL) was added to the reaction 
mixture and it was extracted with DCM (3×25 mL). The organic extract was dried over MgSO4, 
filtered and evaporated to give colourless oil (0.3 g). TLC indicated the presence of mixture of two 
compounds and traces of starting material in the product. Thus further purification was carried out by 
column chromatography. Compound 158 (0.076 g, 26%) was afforded, after elution with 100% ethyl 
acetate, as a white oil. Compound 159 (0.05 g, 19%) was afforded using 99:1 ethyl acetate and 
methanol as eluent as a colourless oil. 
Compound 159 
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vmax /cm
-1
 (film) 3252 (NH), 2931, 1678 (C=O), 1498, 1349, 1294, 1118, 978, 746; MS (ESI) (MH
-
), 
C23H16F9N4O4 requires m/z 583.1033 found m/z 583.1040; δH (400 MHz, CDCl3,) 7.80 (1H, s), 7.27 
(2H, d, J 9.6), 6.99 (1H, s, NH), 6.82 (1H, s, NH), 3.75-3.64 (12H, m); δF (376 MHz, CDCl3) 22.39-
22.48 (2F, q, J 12.03),  21.07-21.01 (2F, m), 16.59-16.67 (2F, q, J 11.65), 11.1 (1F, t, J 20.3), 1.70-
1.83 (2F, m). 
Compound 158  
vmax /cm
-1
 (film) 3192 (NH), 2881, 1668 (C=O), 1481, 1309, 1138, 978, 810; MS (ESI) (MH
-
), 
C26H21F8N6O4 requires m/z 633.1491 found m/z 633.1473; δH (400 MHz, CDCl3,) 7.77 (2H, s), 7.26 
(4H, d, J 11.6),  3.74-3.65 (12H, m), 1.90 (2H, s, N-H); δF (376 MHz, CDCl3) 22.30-22.39 (4F, q, J 
11.65), 14.52-14.60 (4F,q, J 9.0); δC (100 MHz, CDCl3) 157.5 (C=O), 137.4 (Ar CH), 130.2 (Ar 
CH), 119.9 (Ar CH), 115.6 (Ar Cq-C=O), 70.4 (CH2-O), 69.3 (CH2-O), 40.1 (CH2-N), (C-F and C-N 
could not be detected). 
4.2.27.   N,N'-((Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(4-(1H-benzo[d][1,2,3]triazol-1-yl)-
2,3,5,6-tetrafluorobenzamide) 161 
 
A solution of benzotriazole 30 (0.2 mmol, 0.02 g) in DMSO (2 mL) was added dropwise to stirred 
suspension of sodium hydride NaH (60 % dispersion in mineral oil) (0.2 mmol, 0.02 g) in DMSO (2 
mL) and after 30 min a solution of compound 151.(0.1 mmol, 0.05 g) in DMSO (2 mL) was added 
dropwise to the reaction mixture. The reaction mixture was left to stir for 24 h at room temperature 
under a N2 atmosphere. 
Distilled water (10 mL) was added to the reaction mixture and it was extracted with DCM (3×25 
mL). The organic extract was washed with aqueous sodium chloride and dried over MgSO4, filtered 
and evaporated to give white oil (0.06 g). TLC indicated the presence of some impurity in the 
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product. Thus further purification was carried out by column chromatography. Compound 161 was 
afforded after elution with 6:4 ethyl acetate and petrol followed by recrystallization from DCM and 
petrol to give a shiny white solid (0.041 g, 54%). m.p. 206-208 °C 
vmax /cm
-1
 (film) 3248 (N-H), 2877, 1658 (C=O), 1489, 1280,1041,979, 740; MS (ESI) (MH
+
), 
C32H23F8N8O4 requires m/z 735.1709 found m/z 735.1705; δH (400 MHz, CDCl3,) 8.21 (2H, d, J 8.4), 
7.64 (2H, td, J 6.8, 0.8), 7.52 (2H, td, J 6, 0.8), 7.42 (2H, d, J 8), 7.13 (2H, s, NH), 3.76-3.68 (12H, 
m); δF (376 MHz, CDCl3) 22.70-22.61 (4F, q, J 11.28), 18.52-18.42 (4F, q, J 11.25,); δC (100 MHz, 
CDCl3) 157.5 (C=O), 145 (Ar Cq), 133.4 (Ar Cq), 129.6 (Ar CH), 125.9 (Ar CH), 120.6 (Ar CH), 
109.6 (Ar CH), 70.6 (CH2-O), 69.4 (CH2-O), 40.3 (CH2-N) (C-F and C-N could not be detected); 
Analysis (%) for C32H22F8N8O4.1/2H2O (743) required: C, 51.68; H, 3.09; N, 15.07 Found: C, 51.99; 
H, 3.08; N, 14.86. 
4.2.28.  2,3,4,5,6-Pentafluoro-N-(2-(2-(2-(2,3,5,6-tetrafluoro-4-(4H-1,2,4-triazol-4-
yl)benzamido)ethoxy)ethoxy)ethyl)benzamide 162 
 
 
A solution of 1,2,4-triazole 28 (1 mmol, 0.07 g) in DMSO (3 mL) was added dropwise to stirred 
suspension of sodium hydride NaH (60% dispersion in mineral oil) (2 mmol, 0.08 g) in DMSO (3 
mL). The reaction mixture was left to stir for 30 min at RT then a solution of compound 151 (0.5 
mmol, 0.26 g) in DMSO (3 mL) was added dropwise. The reaction mixture was left to stir for 24 h at 
room temperature under a N2 atmosphere. 
Distilled water (10 mL) was added to the reaction mixture and it was extracted with ethyl acetate 
(3×25 mL). The organic extract was washed with aqueous sodium chloride and dried over MgSO4, 
filtered and evaporated to give colourless oil (0.15 g). Purification was carried out by column 
chromatography, eluting with 9:1 ethyl acetate and petrol. Recrystallization from DCM and petrol 
then gave compound 162 (0.08 g, 28%) as a white solid. 
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 m.p. 92-94 °C; vmax /cm
-1
 (film) 3282 (NH), 2921, 1662 (C=O), 1503, 1519, 1323, 1131, 990, 739; 
MS (ESI) (MH
-
), C22H15F9N5O4 requires m/z 584.0986 found m/z 584.0994; δH (400 MHz, CDCl3,) 
8.47 (1H, s), 8.26 (1H, s), 6.90 (1H, s, NH), 3.71-3.65 (12H, m); δF (376 MHz, CDCl3) 22.69 (2F, q, 
J 11.65), 21.15-21.05 (2F, m), 14.45 (2F, q, J 11.28), 11.4 (1F, t, J 20.68), 1.95-1.81 (2F, m); 
Analysis (%) for C22H16F9N5O4 (743) required: C, 45.14; H, 2.75; N, 11.96 Found: C, 45.05; H, 
2.98; N, 11.37. 
4.2.29.  N,N'-((Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(4-(1H-benzo[d]imidazol-1-yl)-
3,5,6-trifluoropyridin-2-amine) 163 
 
A solution of compound 109 (2 mmol, 0.53 g) in THF (3 mL) was added dropwise to a stirred 
solution of 2,2-(ethylenedioxy)bis(ethylamine) 150 (1 mmol, 0.15 g) in THF (3 mL). The reaction 
mixture was refluxed at 65 °C for 24 h under N2. The solvent was evaporated and distilled water (10 
mL) was added to residue. The mixture was extracted with DCM (3×20 mL). The organic extract 
was dried over MgSO4, filtrated and evaporated to give a sugary shiny solid (0.4 g). 
19
F and 
1
HNMR 
spectrum indicated the presence of some impurities in the product. Therefore further purification was 
carried out by column chromatography and compound 163 (0.19 g, 30%) was afforded as shiny solid 
using 100% ethyl acetate as eluting solvent. 
m.p. 258-260 °C; vmax/cm
-1
 (film) 3302 (N-H), 2921, 1653, 1513, 1206, 744; MS (ESI) (MH
+
), 
C30H25F6N8O2 requires m/z 643.1999 found m/z 643.1953; MS (ESI) (MH
-
), C30H23F6N8O2 requires 
m/z 641.1843 found m/z 641.1845; δH (400 MHz, CDCl3,) 8.02 (2H, s), 7.89 (2H, d, J 6.8), 7.38-7.32 
(4H, m), 7.28-7.26 (2H, m), 5.25 (2H, s), 3.72-3.64 (12H, m); δF (376 MHz, CDCl3) 72.11(2F, t, J 
29), 11.2 (2F, dd, J 29, 9), 2.04 (2F, dd, J 23, 11); δC (100 MHz, CDCl3) 146.4 (dd, J 230, 11, C-F), 
143.1 (Ar CH=N) , 142.5 (t, J, 15, Ar Cq-NH), 142.1 (Ar Cq), 136.5 (dd, J 260, 7, C-F), 132.8 (Ar 
Cq), 129.6 (dd, J 260, 21, C-F) 124.5 (Ar CH),  123.7 (Ar CH), 123.1-122.9 (m, Cq-N), 120.8 (Ar 
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CH), 111.1 (Ar CH), 70.3 (CH2-O), 69.5 (CH2-O), 40.9 (CH2-N); Analysis (%) for C30H24F6N8O2 
(642) required: C, 56.08; H, 3.76; N, 17.44 Found: C, 56.09; H, 3.91; N, 17.35. 
4.2.30.  N,N'-((Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(4-(1H-benzo[d][1,2,3]triazol-1-
yl)-3,5,6-trifluoropyridin-2-amine) 164 
 
A solution of compound 113 (6 mmol, 1.6 g) in THF (6 mL) and DMF (2 mL) was added dropwise 
to a stirred solution of triethylamine (6 mmol, 0.8 mL) in THF (3 mL). A solution of  2,2-
(ethylenedioxy)bis(ethylamine) 150 (3 mmol, 0.437 g) in THF (6 mL ) was added dropwise to the 
mixture and the reaction left to stir at room temperature overnight under N2. The solvent was 
evaporated and water (10 mL) was added to the residue to give a sugary solid precipitate (1.56 g). 
TLC indicated the presence of some starting material in the product. Therefore further purification 
was carried out by column chromatography. Compound 164 (1.36 g, 70%) was afforded after elution 
with 1:1 ethyl acetate and petroleum ether as a white solid. 
 m.p.162-164 °C; vmax /cm
-1
 (film) 3394 (NH), 2921, 1651, 1427, 1257, 1057, 979, 740; MS (ESI) 
(MH
+
), C28H23F6N10O2 requires m/z 645.1904 found m/z 645.1908; δH (400 MHz, CDCl3,) 8.16 (2H, 
d, J 8), 7.58 (1H, t, J 7.2), 7.48-7.43 (4H, m), 5.25 (2H, s), 3.72-3.68 (12H, m); δF (376 MHz, 
CDCl3) 72.11 (2F, td, J 23, 7), 12.08  (2F, dd, J 29, 10), 1.51  (2F, dd, J 22, 9); δC (100 MHz, CDCl3) 
145.5 (Ar Cq),  133.1 (Ar Cq), 129.3 (Ar CH), 125.0 (Ar CH), 120.5 (Ar CH), 110.1 (Ar CH),  70.3 
(CH2-O), 69.5  (CH2-O), 40.9 (CH2-N), (C-F and C-N could not be detected); Analysis (%) for 
C28H22F6N10O2 (644) required: C, 52.18; H, 3.44; N, 21.73 Found: C, 52.21; H, 3.30; N, 21.94. 
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4.2.31.  N,N'-((Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(3,5,6-trifluoro-4-(1H-1,2,3-
triazol-1-yl)pyridin-2-amine) 165 
 
A solution of compound 111 (1 mmol, 0.218 g) in THF (3 mL) was added dropwise to a stirred 
solution of triethylamine (1 mmol, 0.13 mL) in THF (3 mL). A solution of 2,2-
(ethylenedioxy)bis(ethylamine) 150 (0.5 mmol, 0.07 g) in THF (3 mL ) was added dropwise to the 
mixture and the reaction left to stir at room temperature overnight under N2. The solvent was 
evaporated and distilled water (10 mL) was added. The mixture was extracted with DCM (3×20 mL). 
The organic extract was dried over MgSO4, filtrated and evaporated to give sugary solid (0.3 g) 
which was purified by column chromatography. Compound 165 (0.08 g, 30%) was afforded after 
elution with 100% ethyl acetate as a white solid.  
m.p. 111-113 °C; vmax/cm
-1
 (film) 3279 (NH), 2924, 1643, 1504, 1419, 1350, 1257, 1064, 927, 740 ; 
MS (ESI) (MH
+
), C20H29F6N10O2 requires m/z 545.1591 found m/z 545.1576; δH (400 MHz, CDCl3,) 
8.52 (2H, s), 8.24 (2H, s), 5.29 (2H, s), 3.69-3.62 (12H, m); δF (376 MHz, CDCl3) 71.26 (2F, t, J 
28.9), 10.13 (2F,dd, J 28.9, 11.6), 4.02 (2F, d, J  21.1); δC (100 MHz, CDCl3) 154.2 (Ar CH), 146.2 
(dd, J 240, 11 , C-F), 145.3 (Ar CH), 142 (t, J 13, Cq-NH),  135.5 (d, J 260, C-F), 128.3 (dd, J, 280, 
33, C-F),  124.2-123.8 (m, Cq-N), 70.3 (CH2-O), 69.6 (CH2-O), 40.9 (CH2-N). 
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4.2.32.  N,N'-((Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(3,5,6-trifluoro-4-(1H-imidazol-1-
yl)pyridin-2-amine) 166 
 
A solution of compound 108 (6 mmol, 1.3 g) in THF (6 mL) was added dropwise to a stirred solution 
of triethylamine (6 mmol, 0.8 mL) in THF (3mL). A solution of 2,2-(ethylenedioxy)bis(ethylamine) 
150 (3 mmol, 0.44 g) in THF (6 mL ) was added dropwise to the mixture and the reaction left to stir 
at room temperature overnight under the N2.The solvent was evaporated and distilled water (10 mL) 
was added to the residue. The mixture was extracted with DCM (3×20 mL). The organic extract was 
dried over MgSO4, filtrated and evaporated to give sugary shiny solid (1.26 g). Purification was 
carried out by column chromatography. The compound 166 (1.05 g, 65%) was afforded by using 50 
% Ethyl acetate and 50% Petroleum ether which washed with diethyl ether as creamy shiny solid.  
m.p.117-120°C; vmax /cm
-1
 (film) 3217, 31.24 (N-H), 2931, 1655, 1419, 1350, 1273, 1087, 927, 740, 
601; MS (ESI) (MH
+
), C22H21F6N8O2 requires m/z 543.1686 found m/z 543.1686; δH (400 MHz, 
CDCl3,) 7.89 (2H, s), 7.38 (4H, d, J 10.8), 5.28 (2H, s), 3.61-3.72 (12H, m); δF (376 MHz, CDCl3)  
71.62 (2F, t, J 24.4), 8.11  (2F, dd, J 7.14, 27.44 ), 4.68 (2F, dd, J 8.64 , 24.8); δC (100 MHz, CDCl3) 
146.6 (dd, J 180, 8.7 C-F), 142.2 (t, J 11, Ar Cq-NH), 137.4 (Ar N-CH=N), 135.1 (ddd, J 200, 4.6, 
1.7, C-F), 130.1 (Ar CH), 128.5 (dd, J 200, 26.3 C-F), 124.1-123.9 ( M, Cq-N), 111.1 (Ar CH), 
119.5 (Ar CH), 69.6 (CH2-O), 70.2 (CH2-O),40.8 (CH2-N); Analysis (%) for C22H20F6N8O2 (542) 
required: C, 48.71; H, 3.72; N, 20.66 Found: C, 48.80; H, 3.75; N, 20.05. 
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4.2.33.  N,N'-(Oxybis(ethane-2,1-diyl))bis(4-(1H-benzo[d]imidazol-1-yl)-3,5,6-trifluoropyridin-2-
amine) 168 
 
 
 
 
 
 
A solution of compound 109 (2 mmol, 0.43 g) in THF (3 mL) was added dropwise to a stirred 
solution of triethylamine (4 mmol, 0.52 mL) in THF (3 mL). A solution of 2-(2-
aminoethoxy)ethylamine) 167 (1 mmol, 0.178 g) in THF (3 mL) was added dropwise to the mixture 
and the reaction left to stir at room temperature overnight under N2. The solvent was evaporated and 
distilled water (10 mL) added to residue. The mixture was extracted with DCM (3×20 mL). The 
organic extract was dried over MgSO4, filtrated and evaporated to give a creamy solid (0.35 g) which 
was purified by column chromatography. Compound 168 (0.013 g, 23%) was afforded after elution 
with 100% ethyl acetate and recrystallization from DCM and petrol as a shiny white solid.  
m.p. 140-141 °C; vmax/cm
-1
 (film) 3299 (NH), 2941, 1681, 1532, 1459, 1226, 1157, 962, 695 
MS (ESI) (MH
+
), C28H21F6N8O1 requires m/z 599.1737 found m/z 599.1720; δH (400 MHz, CDCl3,) 
8.01 (2H, s), 7.89 (2H, d, J  7.2), 7.38-7.33 (4H, m), 7.28-7.24 (2H, m), 5.14 (2H, s), 3.75-3.70 (8H, 
m); δF (376 MHz, CDCl3) 72.11 (2F, t, J 23), 12.14 (2F, dd, J 30, 9), 1.16 (2F,dd, J 23, 9); δC (100 
MHz, CDCl3) 155.1 (Ar N-CH =N), 142.0 (Ar Cq), ), 136.5 (Ar Cq), 124.6 (Ar CH), 123.8 (Ar CH), 
120.5(Ar CH), 111.0 (Ar CH), 69.5  (CH2-O), 41.9 (CH2-N), (C-F, C-NH and C-N could not be 
detected). 
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4.2.34.  N,N'-(Oxybis(ethane-2,1-diyl))bis(4-(1H-benzo[d][1,2,3]triazol-1-yl)-3,5,6-
trifluoropyridin-2-amine) 169 
 
 
A solution of compound 113 (2 mmol, 0.54 g) in THF (3 mL) was added dropwise to a stirred 
solution of triethylamine (4 mmol, 0.52 mL) in THF (3 mL). A solution of 2-(2-
aminoethoxy)ethylamine) 167 (1 mmol, 0.18 g) in THF (3 mL) was added dropwise to the mixture 
and the reaction left to stir at room temperature overnight under N2. The solvent was evaporated and 
distilled water (10 mL) was added precipitating a creamy solid (0.43 g). Purification was carried out 
by column chromatography. Compound 169 was afforded as a white solid (0.09g, 15%) using 1:1 
ethyl acetate and petroleum ether as eluent followed by recrystallized from DCM and petrol. m.p. 
157-159 °C;vmax /cm
-1
 (film) 3279 (NH), 2931, 1651, 1512, 1419, 1265, 1057, 972, 617; MS (ESI) 
(MH
+
), C26H19F6N10O requires m/z 601.1642 found m/z 601.1637; δH (400 MHz, CDCl3,) 8.14 (2H, 
d, J, 8), 7.56 (2H, t, J 8), 7.50-7.41 (4H, m), 5.15 (2H, s), 3.76-3.69 (8H, m); δF (376 MHz, CDCl3) 
72.11 (2F, t, J 23), 11.29 (2F,dd, J 28, 7), 1.62  (2F, dd, J 23, 8); δC (100 MHz, CDCl3) 155.1 (Ar  
CH),146.3 (dd, J 240, 18, C-F), 145.5 (Ar Cq), 142.3 (t, J 13, Cq-NH), 136.5 (d, J, 260, C-F), 133.0 
(Ar Cq), 129.8 (dd, J 230, 21, C-F), 129.3 (Ar CH), 125.0 (Ar CH), 123.7-122.7 (m, Cq-N), 120.5 
(Ar CH), 111.0 (Ar CH), 69.5 (CH2-O), 40.9 (CH2-N); Analysis (%) for C26H18F6N10O1. 1/2H2O 
(609) required: C, 51.23; H, 3.11; N, 22.98 Found: C, 51.29; H, 2.81; N, 22.35. 
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4.2.35.  N,N'-(Oxybis(ethane-2,1-diyl))bis(3,5,6-trifluoro-4-(1H-1,2,3-triazol-1-yl)pyridin-2-amine) 
170 
 
A solution of compound 111 (1 mmol, 0.22 g) in DMF (3 mL) was added dropwise to a stirred 
solution of triethylamine (2 mmol, 0.26 mL) in THF (3 mL). A solution of 2-(2-aminoethoxy) 
ethylamine) 167 (0.5 mmol, 0.18 g) in THF (3 mL) was added dropwise to the mixture and the 
reaction was refluxed at 65 ᵒC for 24 h, under N2. The solvent was evaporated and distilled water (10 
mL) was added to give a cream solid (0.37 g) which was filtrated by suction filtration. The TLC plate 
indicated the presence of some starting material in the product. Thus the product was recrystallized 
by hot ethanol to cover compound 170 (0.138 g, 55%) as white solid. m.p. 127-129°C; vmax/cm
-1
 
(film) 3363, 3132 (N-H), 2947, 1658, 1519, 14350, 1265, 1126, 979, 67; MS (ESI) (MH
+
), 
C18H15F6N10O1 requires m/z 501.1329 found m/z 501.1320; δH (400 MHz, CDCl3,) 8.50 (2H, s), 8.22 
(2H, s), 5.12 (2H, s), 3.73-3.62 (8H, m); δF (376 MHz, CDCl3) 72.11(2F, t, J 29), 10.10 (2F, dd, J 29, 
11), 3.66  (2F, dd, J 23, 11); δC (100 MHz, CDCl3) 153.2 (Ar CH), 146.2 (dd, J 230, 21, C-F), 145.3 
(Ar CH), 142.3 (t, J 16, Cq-NH), 135.4 (d, J 250, C-F), 128.4 (dd, J 240, 33, C-F), 123.8-12.31 (m, 
Cq-N), 69.4 (CH2-O), 40.9 (CH2-N); Analysis (%) for C18H14F6N10O1. (500) required: C, 43.21; H, 
2.82; N, 27.99 Found: C, 43.15; H, 2.65; N, 26.93. 
4.2.36.  N,N'-(Oxybis(ethane-2,1-diyl))bis(3,5,6-trifluoro-4-(1H-imidazol-1-yl)pyridin-2-amine) 
171 
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A solution of compound 108 (1 mmol, 0.22 g) in DMF (3 mL) was added dropwise to a stirred 
solution of triethylamine (2 mmol, 0.26 mL) in THF (3 mL). A solution of 2-(2-aminoethoxy) 
ethylamine) 167 (0.5 mmol, 0.12 g) in THF (3 mL) was added dropwise to the mixture and the 
reaction was heated at 65 ᵒC for 24 h, under N2. The solvent was evaporated and distilled water (10 
mL) was added to the residue. The mixture was extracted with DCM (3×20 mL). The organic extract 
was dried over MgSO4, filtered and evaporated to give yellow sticky oil (0.31 g).  The product was 
triturated with diethyl ether to recover a white solid (0.16 g). TLC indicated the presence of some 
starting material in the product. Therefore the product was recrystallized from hot ethanol to give 
compound 171 (0.12 g, 50%) as a shiny white solid. 
m.p. 144-145 °C; vmax /cm
-1
 (film) 3333, 3225 (N-H), 2931, 1651, 1519, 1350, 1280, 1080, 979, 748, 
671; MS (ESI) (MH
+
), C20H17F6N8O1 requires m/z 499.1424 found m/z 499.1409 
δH (400 MHz, CDCl3,) 7.89 (2H, s), 8.29 (4H, d, J 20), 5.08 (2H, s), 3.73-3.64 (8H, m); δF (376 
MHz, CDCl3) 72.11(2F, t, 22.93), 8.14 (2F,d, J 28.95), 4.36 (2F,d, J 23.31); δC (100 MHz, CDCl3) 
144.5 (Ar N-CH=N), 153.2 (Ar C-H), 133.5 (Ar CH), 120.3 (Ar CH), 69.5  (CH2-O), 40.9 (CH2-N). 
(C-F, C-N and C-NH could not be detected); Analysis (%) for C20H16F6N8O1. (498) required: C, 
48.20; H, 3.24; N, 22.48 Found: C, 48.27; H, 3.20; N, 21.84. 
4.2.37.  Methyl2,3,5,6-tetrafluoro-4-(2-(4-(1-(5,6,8-trifluoro-2-methyl-4-oxo-1,4-
dihydroquinazolin-7-yl)-1H-benzo[d]imidazol-2-yl)butyl)-1H-benzo[d]imidazol-1-
yl)benzoate 176 
 
A solution of acetamidine hydrochloride 88 (0.2 mmol, 0.02 g) in DMF (3 mL) was added dropwise 
to a stirred suspension of sodium hydride NaH (60% dispersion in mineral oil) (0.3 mmol, 0.012 g) 
in DMF (3 mL). A solution of  compound 148 (0.1 mmol, 2.38 g) in DMF (3 mL) was added 
dropwise to the reaction mixture after 30 min by syringe pump and the reaction was refluxed at  
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85 ᵒC for 24 h under a N2 atmosphere. The solvent was evaporated and distilled water (10 mL) was 
added. The yellow solid partials precipitated and were collected by suction filtration (0.07 g). TLC 
plate indicated the presence of some starting material and impurity in the product therefore further 
purification was carried out by column chromatography. Compound 176 (0.02 g, 28%) as white 
crystal was afforded using 7:3 ethyl acetate: light petrol eluting solvent which was recrystallized 
from DCM and petrol. 
 m.p. 203-205 °C; vmax /cm
-1
 (film) 3394 (N-H), 2931, 1705 (C=O), 1620, 1489, 1280, 1157, 1003, 
748, 624; MS (ESI) (MH
+
), C35H24F7N6O3 requires m/z 709.1793 found m/z 709.1775; δH (400 
MHz, CDCl3,) 11.24 (1H, s, NH), 7.78 (2H, dd, J 7.6, 16.4 ), 7.28-7.21 (4H, m), 7.02 (2H, t, J 8.4), 
3.71 (3H, s, CH3), 2.81-2.71 ( 4H, m), 2.61 (3H, s, CH3), 1.85-2.03 (4H, m); δF (376 MHz, CDCl3) 
28.25 (1F, d, J 15.04), 24.57-24.46 (2H, m), 20.60 (1F, t, J 22.56),  15.72-15.66 (2F, m), 14.97 (1F, 
d, J 18.8). 
4.2.38.  Rection of 1,4-bis-1-tetrafluoropyrid-4-yl-1H-benzimidazol-2-ylbutane 143 with 2,2-
(ethylenedioxy)bis(ethylamine): macrocycle 181 
 
A solution of 2,2-(ethylenedioxy)bis(ethylamine) 150 (0.4 mmol, 0.06 g) in THF (3 mL) was added 
dropwise to stirred solution of compound 143 (0.4 mmol, 0.24 g) in THF (5 mL). The reaction 
mixture was refluxed at 65°C for 24 h under N2. The solvent was evaporated and distilled water (10 
mL) added to residue. The mixture was extracted with DCM (3×20 mL). The organic extract was 
dried over MgSO4, filtered and evaporated to give a white sugary solid (0.23 g). Column 
chromatography purification was carried using 1:1 ethyl acetate and light petroleum as eluting 
solvent give compound 181 (0.06 g, 22%) as white crystals.  
m.p. 133-135 °C; vmax /cm
-1
 (film) 3311 (N-H), 2925, 2840, 1652, 1508,1454,1263,1097, 990,  744; 
MS (ESI) (MH
+
), C34H31F6N8O2 requires m/z 697.2469 found m/z 697.2462; δH (400 MHz, CDCl3) 
7.79 (2H, d, J 7.6), 7.37-7.33 (2H, td, 7.2, 0.8), 7.30-7.26 (2H, td, J 8.0, 1.2), 7.04 (2H, d, J 7.6), 5.37 
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(2H, t, J 4.8), 3.83-3.59 (12H, m), 2.82-2.63 (4H, m), 2.03-1.87 (4H, m); δF (376 MHz, CDCl3) 72.9 
(2F, t, J 29.0), 11.95 (2F, d, J 35.0), -0.74 (2F, dd, J 19.9, 5.6); δC (100 MHz, CDCl3) 153.9 (Ar N-
Cq=N), 142.6 (Ar Cq),  134.7 (Ar Cq),  123.6 (Ar CH), 123.3 (Ar CH), 119.7(Ar CH),  109.4 (Ar 
CH), 69.9 (CH2-O), 69.0 (CH2-O), 40.7 (CH2-N) 26.9 (CH2-C=N), 26.2 (CH2-CH2-CH2), (C-F and 
C-N could not be detected). Analysis (%) for C30H30F6N8O2∙2H2O (732) requires: C, 55.74; H, 4.64; 
N, 15.30, found: C, 55.88; H, 4.37; N, 14.91. 
4.2.39.  Reaction of 1,4-bis-1-tetrafluoropyrid-4-yl-1H-benzimidazol-2-ylbutane 143 with 2-(2-
aminoethoxy)ethylamine: macrocycle 183 
 
 
A solution of 2-(2-aminoethoxy)ethylamine 167 (0.4 mmol, 0.07 g) in THF (3 mL) was added to 
stirred solution of triethylamine (0.8 mmol, 0.08 g) in THF (2 mL). After 15 min a solution of 
compound 143 (0.2 mmol, 0.12 g) in THF (3 mL) was added dropwise to the reaction mixture. The 
reaction mixture was heated at 65 °C for 24 h under N2.  
The solvent was evaporated and water (10 mL) was added to the residue. A yellow orange solid 
precipitated, and was filtered (0.12 g). Column chromatography purification using 9:1 ethyl acetate 
and light petroleum as eluting solvent gave compound 183 (0.04 g, 35%) as white sugary crystals. 
 m.p. 203-205 °C; vmax /cm
-1
 (film) 3434 (NH), 2099, 1648, 1550, 1453,1260,1126,1011, 744;  
MS (ESI) (MH
+
), C32H26F6N8O requires m/z 653.2207 found m/z 653.2196; δH (400 MHz, CDCl3,) 
7.75 (2H, d, J 8.0), 7.29-7.18 (4H, m), 6.99 (2H, d, J 8.4), 5.28 (2H, s), 4.05-4.00 (2H, m), 3.81-3.73 
(4H, m), 3.45-3.39 (2H, m), 2.93-2.82 (2H, m), 2.68-2.63 (2H, m), 2.04-1.87 (4H, m); δF (376 MHz, 
CDCl3) 72.6 (2F, t, J 29.0), 11.7 (2F, d, J 29.0), 0.55 (2F, d, J 17.3); δC (100 MHz, CDCl3) 153.8 (Ar 
N-Cq=N), 142.8 (Ar Cq),  142.1(t, J, 14 Ar Cq-NH), 138.0 (dd, J, 290, 11, C-F), 134.8 (Ar Cq), 
130.9 (dd, J, 250, 30, C-F), 123.5 (Ar CH), 123.3 (Ar CH), 123.5-123.0 (m  Ar Cq-N), 119.9 (Ar 
CH), 109.4 (Ar CH), 68.6 (CH2-O), 40.6 (CH2-N), 27.0 (CH2-C=N), 26.0 (CH2-CH2-CH2), (1 ArFCq 
not detected); Analysis (%) for C32H26F6N8O∙H2O (670) requires: C, 57.31; H, 4.17; N, 16.72, found: 
C, 57.38 H, 4.18; N, 16.41. 
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4.2.40.  Reaction of 1,4-bis-1-tetrafluoropyrid-4-yl-1H-benzimidazol-2-ylbutane 143 with 2-(2-
aminoethoxy)ethylamine : macrocycle 185 
 
A solution of hexamethylenediamine 184 (0.5 mmol, 0.06 g) in THF (3 mL) was added to a stirred 
solution of triethyleamine (1 mmol, 0.1 g) in THF (2 mL) after 15 min solution of compound143 (0.2 
mmol, 0.12 g) in THF (3 mL) was added dropwise to the reaction mixture. The reaction mixture was 
refluxed at 65 °C for 24 h under N2.The solvent was evaporated and water (10 mL) was added to the 
residue. A yellow orange solid precipitated and was filtered (0.3 g). Column chromatography 
purification using 8:2 light petrol and ethyl acetate eluting solvent gave compound 185 as yellow 
sugary crystals (0.03 g, 20 %). 
Decomposed at 180°C; vmax /cm
-1
 (film) 3279 (broad peak, NH), 2924, 1651, 1512, 1427, 1257, 
964,833; MS (ESI) (MH
+
), C34H31F6N8 requires m/z 655.2570 found m/z 655.2569; δH (400 MHz, 
CDCl3,) 7.72 (2H, d, J 8), 7.31-7.19 (4H, m), 6.98 ( 2H, d, J 8), 5.36 (2H, s), 3.82-3.72 (8H, m), 
3.65-3.51 (4H, m), 2.84-2.66 (4H, m), 2.02-2.15 (4H, m); δF (376 MHz, CDCl3) 72.32 (2F, t, J 
25.56), 12.71 (2F,dd, J 7.5, 30.08), 1.29 (2F, dd, J 8.6, 21.43) δC (100 MHz, CDCl3) 153.8 (Ar N-
Cq=N), 142.9 (Ar Cq), 134.8 (Ar Cq), 123.4 (Ar CH), 123.3 (Ar CH), 119.9 (Ar CH), 109.4 (Ar 
CH), 70.8 (CH2-CH2-CH2), 69.6. (CH2-CH2- CH2), 40.6 (CH2-N), 27.0 (CH2-C=N), 26.0 (CH2-CH2-
CH2), (C-F, C-NH and C-N could not be detected). 
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4.2.41.  1,4-bis-1-[2-(2-Aminoethylamino)-trifluoropyrid-4-yl-1H-benzimidazol-2-ylbutane 187 
 
A solution of ethylenediamine 186 (0.4 mmol, 0.025 g) in THF (2 mL) was added dropwise to a 
stirred solution of compound 143 (0.2 mmol, 0.12 g) in THF (3 mL) and the mixture stirred at room 
temperature for 24 h under N2. Distilled water (10 mL) was added and the mixture extracted with 
DCM (3×20 mL). The organic extract was dried over MgSO4, filtered and evaporated to give 
compound 187 (0.11 g, 85%) as a white shiny solid. 
m.p. 195-198 °C; vmax/cm
-1
 (film), 3400 (broad, NH), 2095, 1647, 1509, 1453, 1388, 1264; MS (ESI) 
(MH
-
), C32H31F6N10 requires m/z 669.2632, found m/z 669.2621; δH (400 MHz, CDCl3,) 7.80 (2H, d, 
J 7.6), 7.35-7.29 (4H, m), 7.11 (2H, d, J, 7.6), 5.50-5.38 (2H, td, J 8.4, 5.4), 3.57 (4H, dd, J 11.2, 
5.2), 3.05 (4H, t, J 5.6), 2.81 (4H, s), 1.99-1.95 (4H, m); δF (376 MHz, CDCl3) 72.3 (2F, m), 13.09 
(2F, dd, J 23.3, 8.6), 1.44 (2F, dd, J 23.3, 8.6). 
4.2.42.  1,4-bis-1-{2-[2-(2-Hydroxyethoxy)ethylamino)-trifluoropyrid-4-yl]}-1H-benzimidazol-2-
ylbutane 189 
 
A solution of 2-(2-aminoethoxy)ethanol 188 (0.2 mmol, 0.02 g) in THF (4 mL) was added dropwise 
to stirred solution of compound 143 (0.1 mmol, 0.06 g) in THF (4 mL) and the mixture stirred at 
room temperature for 24 h under N2. Distilled water (10 mL) was added to reaction mixture and it 
was extracted with ethyl acetate (3×25 mL). The organic extract was dried over MgSO4, filtered and 
evaporated to give white oily product (0.07 g) which was recrystallized from DCM and light 
petroleum to give compound 189 (0.03 g, 42%) as colourless shiny crystals.  
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m.p. 168-170 °C; vmax/cm
-1
 (film), 3333 (N-H), 2870,1651,1512, 1427, 1388, 1273, 1118, 1072, 987, 
740; MS (ESI) (MH
+
), C36H37F6N8O2 requires m/z 759.2836 found m/z 759.2829; δH (400 MHz, 
(CD3)2CO) 7.67 (2H, d, J 8.0), 7.46 (2H, s), 7.33-7.24 (6H, m), 4.68 (2H, t, J 4.8), 3.61 (8H, t, J 5.6), 
3.54-3.47 (8H, m (overlap with water peak)), 2.78 (4H, m), 1.84 (4H, m); δF (376 MHz, CDCl3) 72.2 
(2F, t, 11.7), 13.6-13.3 (2F, m), 1.93-(1.46) (2F, m); Analysis (%) for C36H36F6N8O2.3H2O (785) 
required: C, 55.03; H, 4.96; N, 14.26 Found: C, 55.37; H, 4.67; N, 13.87. 
4.2.43.  1,4-bis-1-[2-(2,3-Dihydroxypropylamino)-trifluoropyrid-4-yl]-1H-benzimidazol-2-ylbutane 
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A solution of (±)-3-amino-1,2-propanediol 190 (0.2 mmol, 0.018 g) in DMF (3 mL) was added 
dropwise to a stirred solution of compound 143 (0.1 mmol, 0.058 g) in DMF (mL) and the mixture 
heated at 80 ᵒC for 24 h under N2. Distilled water (10 mL) was added and some solid formed which 
collected by suction filtration to give compound 191 (0.08 g, 82%) as a white solid.  
m.p. 123-126 °C; vmax/cm
-1
 (film), 3417 (broad N-H), 2931, 1651,1427, 1257, 1057, 979,748; 
MS (ESI) (MH
+
), C34H33F6N8O8 requires m/z 731.2523 found m/z 731.2516; δH (400 MHz, CDCl3) 
1.92-1.86 (4H, m), 2.90-2.75 (4H, m), 3.47-3.42 (2H, m), 3.84 -3.56 (6H, m), 3.90 (4H, m), 4.25 
(2H, s), 7.28-7.18 (6H, m), 7.64 (2H, d, J 7.6); δF (376 MHz, CDCl3) 72.53 (2F, t, J 25.9), 14.02 (2F, 
dd, J 29.0, 8.6), 5.09 (2F, dd, J 25.9, 8.6); δC (100 MHz, CDCl3) 154.6 ( Ar N -Cq=N), 142.9 ( Ar 
Cq) , 135.1 (Ar Cq), 123.8 (Ar CH), 123.7 (Ar CH), 123.4(Ar CH), 119.5 (Ar CH), 110.7 (Ar CH), 
70.0 (CH-O), 64.5 (CH2-O), 44.8 (CH2-N), 26.6 (CH2-C=N), 26.4 (CH2-CH2-CH2), (Ar C-F and C-N 
could not be detected). 
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4.2.44.  1,4-bis-1-[2-(2-Hydroxyethylamino)-trifluoropyrid-4-yl]-1H-benzimidazol-2-ylbutane 193 
 
A solution of ethanolamine 192 (0.4 mmol, 0.024 g) in THF (4 mL) was added dropwise to stirred 
solution of synthesise compound 143 (0.2 mmol, 0.108 g) in THF (4 mL) at 80 ᵒC for 24 h under a 
N2 atmosphere. Distilled water (10 mL) was added and the mixture extracted with DCM (3×20 ml). 
The organic extract was dried over MgSO4, filtered and evaporated to give a white solid (0.14 g) 
which was recrystallized from hot ethanol to give the pure compound 193 (0.06, 50%) as white shiny 
crystals.  
m.p. 175-178 °C; vmax/cm
-1
 (film), 3425 (broad N-H), 2947, 1651, 1512, 1427, 1149, 1057, 987, 748. 
MS (ESI) (MH
-
), C34H27F6N8 O2 requires m/z 669.2161 found m/z 669.2175; 
δH (400 MHz, (CD3)2CO) 7.71-7.68 (2H, dd, J, 8.3, 1.6), 7.32-7.25 (4H, m), 6.60 (2H, s ), 4.12 (2H, 
broad s), 3.78 (4H, t, J 11.2), 3.60-3.58 (4H, m), 2.88 (4H, m), 1.99 (4H, m); δF (376 MHz, CDCl3) 
72.5 (2F, t, J 14.7), 13.9 (2F, dd, J 29.0, 11.7), 5.1 (2F, dd, J 22.9, 8.6). 
4.2.45.  1-Tetrafluoropyrid-4-yl-2-tetrafluoropyrid-4-ylsulfanyl-1H-benzimidazole 194 
 
 
A solution of pentafluoropyridine 74 (100 mmol, 16.9 g) in THF (3 mL) and was added dropwise to 
a stirred suspension of NaH (60 % dispersion in mineral oil) (40 mmol, 1.6 g) in THF (4 mL). A 
solution of 2-mercaptobenzimidazole 155 (20 mmol, 3.0 g) in DMF (3 mL) and THF (10 mL) was 
added to reaction mixture dropwise using a syringe pump under N2 atmosphere and left to stir at RT 
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for 24 h. The solvent was evaporated and water (20 mL) was added to the residue. The reaction 
mixture was extracted with DCM (3x25 mL) and organic extract was dried over MgSO4, filtered and 
evaporated to give compound 194 (4.8 g, 54%) as creamy white crystals. 
 m.p. 113-115 °C 
max /cm
-1
(film) 1630, 1474, 1246, 975, 952; MS (ESI) (MH-), C17H3F8N4S found m/z 446.9962 
requires m/z 446.9956; 𝛿H (400 MHz, CDCl3) 7.85-7.80 (1H, m), 7.49-7.47 (2H, m), 7.23-7.19 (1H, 
m); δF (376 MHz, CDCl3) 77.42-77.05 (2F, m), 74.37-73.97 (2F, m), 19.26-19.12 (2F, m), 27.03-
26.87 (2F, m); δC (125 MHz, CDCl3) 144.1 (dtd, J 248, 15, 4), 143.5 (dddd, J 247, 18, 13, 3), 143.4, 
142.0, 141.2 (dm, J 260), 138.1 (dm, J 266), 135.0, 126.1, 126.0 (tt, J 13, 5), 125.0, 124.9 (tt, J 18, 
3), 120.7, 110.1; Analysis (%) calculated for C17H4F8N4S (448): C, 45.55; H, 0.90; N, 12.50. Found 
C, 45.41; H, 0.92; N, 12.00 
4.2.46.  2-((3,5,6-Trifluoro-4-((1-(2,3,5-trifluoro-6-((2-hydroxyethyl)amino)pyridin-4-yl)-1H-
benzo[d]imidazol-2-yl)thio)pyridin-2-yl)amino)ethan-1-ol 195 
 
A solution of ethanolamine 192 (1 mmol, 0.06 mL) in THF (4 ml) was added dropwise to stirred 
solution triehylamine (1 mmol, 0.14 ml) in THF (3 mL). A solution of scaffold 194 (0.5 mmol, 0.22 
g) in THF (6 mL) was added dropwise to the mixture and the reaction left to stir at room temperature 
overnight under a N2 atmosphere. Distilled water (10 mL) was added to the mixture and it was 
extracted with ethyl acetate (3×20 mL). The organic extract was washed with aqueous sodium 
chloride and dried over MgSO4, filtrated and evaporated to give compound 195 (0.21 g, 80%) as 
white shiny solid.  
m.p. 94-97 °C; vmax/cm
-1
 (film), 3295 ( NH), 2924, 2355, 2160,1651, 1519, 1427, 1265, 1111, 964; 
671.MS (ESI) (MH
-
), C21H17F6N6O2S1 requires m/z 531.1032 found m/z 531.1028 
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δH (400 MHz, CDCl3) 7.80 (1H, dd, J 6, 2), 7.34-7.37 (2H, m),  7.11 (1H, d, J 7.6 ), 5.36 (2H broad 
s), 5.28 (2H, broad s) 3.91-3.75 (4H, m), 3.72-3.47 (4H, m); δF (376 MHz, CDCl3) 72.54 (1F, t, J 
23.3), 69.59 (1F, t, J 22.9), 23.99 (1F, dd, J 29.9, 7.1), 14.27 (1F, dd, J 30.8, 10.2), 8.33 (1F, dd, J 
22.9, 7.1), 0.27 (1F, dd, J 23.3, 7.7); δC (100 MHz, CDCl3) 143.2 (Ar Cq), 135.6  (Ar Cq), 123.2 (Ar 
CH), 120.4 (Ar CH) , 110.0 (Ar CH), 61.7 (CH2-O), 61.5 (CH2-O), 53.5 (CH2-N), 43.4 (CH2-N), (C-
F, C-S and C-N could not be detected). 
4.2.47.   N1-(4-((1-(2-((2-Aminoethyl)amino)-3,5,6-trifluoropyridin-4-yl)-1H-benzo[d]imidazol-2-
yl)thio)-3,5,6-trifluoropyridin-2-yl)ethane-1,2-diamine 196 
 
A solution of ethylenediamine 186 (1 mmol, 0.06 g) in THF (5 mL) was added dropwise to a stirred 
solution triethylamine (1 mmol, 0.14 mL) in THF (3 mL). A solution of scaffold 194 (0.5 mmol, 0.22 
g) in THF (8 mL) was added dropwise to the mixture and the reaction left to stir at room temperature 
overnight under a N2 atmosphere. Distilled water (10 mL) was added to reaction mixture and it was 
extracted with ethyl acetate (3×20 mL). The organic extract was washed with aqueous sodium 
chloride and dried over MgSO4, filtrated and evaporated to give yellow sugary solid 196 (0.19 g, 
72%).  
Decomposed at 119 °C; vmax/cm
-1
 (film), 3464 (NH), 3232 (N-H), 2893, 1651, 1427, 1257, 1072, 
972, 810, 663; MS (ESI) (MH
-
), C21H19F6N8S1 requires m/z 529.1352 found m/z 529.1350; δH (400 
MHz, CDCl3 ) 7.78 (1H, dd, J 2.4, 5.2), 7.31-7.32 (2H, m),  7.14 (1H, d, J 6.8), 5.45 (1H, s, N-H), 
5.08 (1H, s, N-H), 3.73-3.38 (4H, m),  3.01-2.87 (4H,m), 1.23 (4H, s, N-H); δF (376 MHz, CDCl3) 
75.38 (1F, t, J 23.3), 69.62 (1F, t, J  24.4), 23.60 (1F, dd, J 5.6, 28.5),  13.91 (1F, dd, J 8.6, 28.9), 
7.76 (1F, dd, J 4.5, 23.3), 0.94 (1F, dd J 10.1, 23.3).  
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4.2.48.   4-(3,5,6-Trifluoro-4-((1-(2,3,5-trifluoro-6-morpholinopyridin-4-yl)-1H-benzo[d]imidazol-
2-yl)thio)pyridin-2-yl)morpholine 198 
 
A solution of morpholine 197 (1 mmol, 0.086 mL) in THF (4 mL) was added dropwise to a stirred 
solution triethylamine (1 mmol, 0.14 mL) in THF (3 mL). A solution of scaffold 194 (0.5 mmol, 0.22 
g) in THF (6 mL) was added dropwise to the mixture and the reaction left to stir at room temperature 
overnight under N2. The solvent was evaporated and water (10 mL) was added to the residue. A 
white solid precipitated, and was filtered (0.3 g). Column chromatography purification using eluting 
solvent 80% ethyl acetate and 20% light petroleum gave white sugary 198 (0.2 g, 67%).  
m.p. 99-102 °C; vmax/cm
-1
 (film) 2854, 1620, 1442, 1257, 1116, 972, 740; MS (ESI) (MH
-
), 
C25H21F6N6O2S1 requires m/z 583.1345 found m/z 583.1345; δH (400 MHz, CDCl3 ) 7.77 (1H, dd, J 
2.4, 8), 7.37-7.33 (2H, m),  7.11 (1H, d, J 8 ), 3.83 (4H, t, J 4.4 ), 3.75 (4H, t, J 4.4 ), 3.54 (4H, t, J 
4), 3.39 (4H, t, J 4.4 ), δF (376 MHz, CDCl3) 75.18 (1F, t, J 26.3), 72.28 (1F, t, J 24.4), 36.32 (1F, d, 
J 30.4), 25.26 (1F, d, J 31.5), 15.53 (1F, dd, J 5.6, 25.9), 5.96 (1F, d J 24.4); δC (100 MHz, CDCl3) 
143.6 (Ar Cq), 135.5 (Ar Cq), ), 125.1 (Ar CH), 124.2 (Ar CH), 120.3 (Ar CH ), 109.9 (Ar CH), 
66.62 (d, J 4, CH2-O), 47.8 (d, J 5.7, CH2-N), 47.6 (d, J 5.7, CH2-N),  (C-F, C-S and C-N could not 
be detected); Analysis (%) for C25H21F6N6O2S1 (582) required: C, 51.55; H, 3.46; N, 14.43 Found: C, 
51.63; H, 3.30; N, 13.94. 
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4.2.49.   N-(2-(2-(2-((4-(1H-benzo[d]imidazol-1-yl)-3,5,6-trifluoropyridin-2-
yl)amino)ethoxy)ethoxy)ethyl)-4-(1H-benzo[d]imidazol-1-yl)-3,5-difluoro-6-
morpholinopyridin-2-amine 200 
 
A solution of morpholine 197 (1 mmol, 0.086 mL) in dioxane (4 mL) was added dropwise to a 
stirred solution of scaffold 163 (0.5 mmol, 0.32 g) in dioxane (6 mL). the reaction left to stir at room 
temperature overnight under N2. The solvent was evaporated and water (10 mL) was added to the 
residue. A white solid precipitated, and was filtered (0.35 g). Column chromatography purification 
using eluting solvent 95% ethyl acetate and 5% light petroleum gave 200 as white sugary solid (0.05 
g, 15%). Only partial data available due to lack of time, and the polarity of compound which made  
purification difficult. 
δH (400 MHz, CDCl3 ) 8.06 (1H, s),  8.03 (1H, s), 7.92-7.88 (2H, m), 7.42-7.30 (6H, m), 5.28-5.27 
(1H, m), 5.0-4.98 (1H, m), 3.83 (4H, t, J 3.6 ), 3.78-3.68 (12H, m ), 3.46 (2H, t, J 2.8 ), 2.92 (2H, t, J 
3.6); δF (376 MHz, CDCl3) 75.16 (1F, dt, J 18.8, 3.8), 14.21 (1F, dd, J 22.5, 7.5), 11.49 (1F, dd, J 
18.8, 8.2), 5.37 (1F, d, J 7.53), 1.13-1.01 (1F, m). 
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4.2.50.  2-(2-(2-((4-(1H-benzo[d]imidazol-1-yl)-3,5,6-trifluoropyridin-2-
yl)thio)ethoxy)ethoxy)ethane-1-thiol 202 
 
 
A solution of 3,6-dioxa-1,8-octanedithiol 201 (1mmol, 0.18 g) in THF (3 mL) was added dropwise to 
stirred solution of NaHCO3 (2 mmol, 0.17 g) in THF (3 mL). A solution of compound 109 (2 mmol, 
0.56 g) in THF (6 mL) was added dropwise to the mixture and the reaction mixture was refluxed at 
65 °C for 24 h under N2. The solvent was evaporated and distilled water (10 mL) added to 
residue.The mixture was extracted with DCM (3×20 mL). The organic extract was dried over 
MgSO4, filtered and evaporated to give a white solid (0.67 g). Column chromatography purification 
using 45% ethyl acetate and 55% light petroleum as eluting solvent gave compound 202 (0.18 g, 
41%) as white oil with some impurity which could not be purified further due to lack of time, 
therefore only partial data are available. 
MS (ESI) (MH
-
), C18H19F3N3O2S2 requires m/z 430.0871 found m/z 430.0869; δF (376 MHz, CDCl3) 
72.20 (1F, t, J 23.1), 33.24 (1F, d, J 28.9), 11.54 (1F, d, J 23.3). 
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4.3. Biological activity studies 
4.3.1. Preparation of Trisma base buffer 
Trisma base (0.30 g) was dissolved into distilled water (500 ml) to make 2.5 x 10
-3 
M trisma base 
buffer. The pH was adjusted to 7.55 by adding 0.1 M HCl. 
4.3.2.  Preparation of DNA stock solution 
SS-DNA (50 mg) was purchased from Sigma and was dissolved by stirring overnight in double 
deionized water (pH 7.0) and kept at 4 °C. A solution of (SS-DNA) in the trisma buffer gave a ratio 
of UV absorbance at 260 and 280 nm (A260/A280) of ca. ~1.8, showing the DNA was free from any 
protein. SS-DNA concentration was found from absorption spectroscopy using molar absorption 
coefficient of 6600 M
-1
cm
-1 
(260 nm).
 
4.3.3. Preparation of synthesis and references compounds solution 
Each synthesised compound or reference compound (ACTD and naproxen) was weighed and 
dissolved in DMSO to make 10
-2
 M stock solutions of each substance. Further dilutions were 
performed with DMSO to prepare different concentrations of each compound (10
-3–10-6 mol.dm-3). 
4.3.4. Method of UV absorption assay 
The UV absorption assay for each synthesis and references compound was carry out by keeping the 
fixed concentration of each compound while varying SS-DNA concentration. In this method, 
different amounts of SS-DNA solution were added to samples containing fixed concentrations of 
each compound. The mixtures were shaken well and were allowed to incubate for 30 min at room 
temperature to measure the absorption. Absorption spectra were recorded using cuvettes of 1 cm path 
length at room temperature (25 ± 1 °C). 
4.3.5. Method of fluorescence displacement assay 
In this method 0.3 mL of EB solution (10
-4 
M) in trisma was added to 0.3 mL of SS-DNA solution 
then each test compound solution (30, 60, 120, 180, 240, 300 μL of 10-6 M) ) was titrated into the 
DNA/EB mixture. Each mixture were diluted up to 3 mL with trisma buffer, making the solutions 
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with varied concentration of (10
-6
, 2 × 10
-6
, 4 × 10
-6
, 6 × 10
-6
, 8 × 10
-6
 and 10
-5
 M) each compound to 
SS-DNA. The mixtures were shaken and incubated at room temperature for 30 min. The 
fluorescence spectra of EB bound to SS-DNA were recorded at on emission wavelength of 605 nm 
with excitation of 480 nm. 
4.3.6. Hanging drop DNA crystallization method 
4.3.6.1. Preparation of DNA solution 
Cacodylate buffer (pH 6.5); 50 mM isopropanol 15% was used to prepare a stock buffer solution 
containing MgCl2 (10 mM) by adding MgCl2 (9 mg) to cacodylate buffer (10 ml). DNA solution (0.5 
mM) was prepared by adding (600 µl) of buffer stock solution to CGCGAATTCGCG DNA vial 
which contained (314 nmol). 
4.3.6.2. Preparation of the DNA-compound complex sample 
In hanging drop DNA crystallization method a sample vial and a piece of glass melting point tube to 
hold the drop were used. In order to make the drop, 20 µL of DNA solution was added to 2 µL of 
compound solution (0.01 M). The drop was held in the m.p. tube which was streaked to a sample vial 
which containing cotton wool wetted with buffer in the bottom. The sample vial was left at RT until 
the drops partially evaporated and crystals appeared. 
4.3.7.  Antimicrobial activity studies 
The synthesized compounds at 10
-2
 and 10 
-3
M concentration were tested against two bacterial strains 
Gram-positive strain (Escherichia coli) and Gram-negative strain (Staphylococcus aureus). The disk 
diffusion method was used for the determination of antibacterial activity. The bacteria (100 μL) were 
added to Muller-Hinton agar media (25 mL), mixed well and poured into 90 × 14 mm petri plate 
(diameter and height respectively) and the media was allowed to solidify. Sterilized disks (6 mm in 
diameter) were saturated with the compound solution and placed gently on the inoculated agar plates. 
Each plate contained a blank disk, which was saturated with DMSO, the compound-containing disk 
and a control disk containing the antibiotic penicillin. The petri plates were incubated at 37 °C for 48 
h. 
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6.  Appendix 
6.1. X-ray crystallography data 
6.1.1. Compound 109 X-ray crystal structure date 
 
Crystal data and structure refinement  
Identification code gw85 
Chemical formula C12H6F4N3O0.50 
Formula weight 276.20 
Temperature 150(2) K 
Radiation, wavelength MoK, 0.71073 Å 
Crystal system, space group monoclinic, Cc 
Unit cell parameters a = 27.76(4) Å  = 90° 
 b = 7.483(10) Å  = 99.29(2)° 
 c = 11.133(15) Å  = 90° 
Cell volume 2282(5) Å
3
 
Z 8 
Calculated density 1.608 g/cm
3
 
Absorption coefficient  0.148 mm1 
F(000) 1112 
Crystal colour and size colourless, 0.76  0.46  0.05 mm3 
Reflections for cell refinement 933 ( range 3.31 to 21.56°) 
Data collection method Bruker APEX 2 CCD diffractometer 
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 rotation with narrow frames 
range for data collection 2.82 to 28.49° 
Index ranges h 37 to 36, k 0 to 9, l 0 to 14 
Completeness to  = 26.00° 98.6 % 
Intensity decay 0% 
Reflections collected 2746 
Independent reflections 2746 (Rint = 0.1161) 
Reflections with F
2
>2 1450 
Absorption correction semi-empirical from equivalents 
Min. and max.transmission 0.896 and 0.993 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.1352, 0.0000 
Data / restraints / parameters 2746 / 2 / 359 
Final R indices [F
2
>2] R1 = 0.0780, wR2 = 0.1981 
R indices (all data) R1 = 0.1376, wR2 = 0.2206 
Goodness-of-fit on F
2
 0.937 
Extinction coefficient 0.0060(14) 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 0.456 and 0.386 e Å3 
6.1.2. Compound 110  X-ray crystal structure data 
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Crystal data and structure refinement  
Identification code gw86 
Chemical formula C19H10F3N5 
Formula weight 365.32 
Temperature 150(2) K 
Radiation, wavelength MoK, 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell parameters a = 12.0121(6) Å               = 90° 
b = 8.7895(5) Å                 = 100.5037(8)° 
c = 14.8138(8) Å               = 90° 
Cell volume 1537.84(14) Å
3
 
Z 4 
Calculated density 1.578 g/cm
3
 
Absorption coefficient  0.124 mm1 
F(000) 744 
Crystal colour and size colourless, 0.67  0.50  0.20 mm3 
Reflections for cell refinement 7716 ( range 2.71 to 30.56°) 
Data collection method Bruker APEX 2 CCD diffractometer 
 rotation with narrow frames 
range for data collection 2.71 to 30.59° 
Index ranges h 17 to 17, k 12 to 12, l 21 to 20 
Completeness to  = 30.59° 99.3 %  
Intensity decay 0% 
Reflections collected 17691 
Independent reflections 4707 (Rint = 0.0258) 
Reflections with F
2
>2 3987 
Absorption correction semi-empirical from equivalents 
Min. and max.transmission 0.921 and 0.976 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0741, 0.3637 
Data / restraints / parameters 4707 / 0 / 284 
Final R indices [F
2
>2] R1 = 0.0415, wR2 = 0.1189 
R indices (all data) R1 = 0.0483, wR2 = 0.1243 
Goodness-of-fit on F
2
 1.054 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.546 and 0.256 e Å3 
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6.1.3. Compound 111 (X isomer) X-ray crystal structure data 
 
Crystal data 
C11H4F4N4 F(000) = 536 
Mr = 268.18 Dx = 1.729 Mg m
-3
 
Monoclinic, P21/n Mo K radiation,  = 0.71073 Å 
a = 7.4413 (7) Å Cell parameters from 6886 reflections 
b = 13.0851 (12) Å  = 2.5–30.6° 
c = 10.9628 (10) Å  = 0.16 mm-1 
 = 105.1556 (13)° T = 150 K 
V = 1030.32 (16)  Å
3
 Block, colourless 
Z = 4 0.89 × 0.43 × 0.15 mm 
Data collection 
Bruker APEX 2 CCD area detector  
diffractometer 
2817 reflections with I > 2(I) 
Radiation source: fine-focus sealed tube Rint = 0.027 
 rotation with narrow frames scans max = 30.6°, min = 2.5° 
Absorption correction: multi-scan  
SADABS v2012/1, Sheldrick, G.M., (2012) 
h = -1010 
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Tmin = 0.870, Tmax = 0.976 k = -1818 
12124 measured reflections l = -1515 
3156 independent reflections  
Refinement 
Refinement on F
2
 Primary atom site location: structure-invariant direct 
methods 
Least-squares matrix: full Hydrogen site location: difference Fourier map 
R[F
2
 > 2(F2)] = 0.038 All H-atom parameters refined 
wR(F
2
) = 0.115 w = 1/[2(Fo
2
) + (0.0686P)
2
 + 0.2212P]   
where P = (Fo
2
 + 2Fc
2
)/3 
S = 1.04 (/)max < 0.001 
3156 reflections max = 0.41 e Å
-3
 
188 parameters min = -0.24 e Å
-3
 
0 restraints  
 
6.1.4. Compound 114 X-ray crystal structure data 
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Crystal data 
C29.02H16.02F3N3O0 Dx = 1.392 Mg m
-3
 
Mr = 463.77 Mo K radiation,  = 0.71073 Å 
Orthorhombic, P212121 Cell parameters from 4470 reflections 
a = 8.1301 (5) Å  = 2.2–22.0° 
b = 18.1470 (12) Å  = 0.10 mm-1 
c = 29.9929 (19) Å T = 150 K 
V = 4425.1 (5) Å
3
 Plate, colourless 
Z = 8 0.40 × 0.21 × 0.05 mm
3
 
F(000) = 1905  
Data collection 
Bruker APEX 2 CCD diffractometer 9768 independent reflections 
Radiation source: fine-focus sealed tube 6291 reflections with I > 2(I) 
Graphite monochromator Rint = 0.057 
 rotation with narrow frames scans max = 27.1°, min = 1.8° 
Absorption correction: multi-scan  
SADABS v2012/1, Sheldrick, G.M., (2012) 
h = -109 
Tmin = 0.961, Tmax = 0.995 k = -2323 
30333 measured reflections l = -3836 
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Refinement 
Refinement on F
2
 Secondary atom site location: difference Fourier map 
Least-squares matrix: full Hydrogen site location: inferred from neighbouring sites 
R[F
2
 > 2(F2)] = 0.045 H-atom parameters constrained 
wR(F
2
) = 0.089 w = 1/[2(Fo
2
) + (0.0303P)
2
]   
where P = (Fo
2
 + 2Fc
2
)/3 
S = 1.00 (/)max = 0.001 
9768 reflections max = 0.15 e Å
-3
 
760 parameters min = -0.15 e Å
-3
 
546 restraints Absolute structure:  Flack x determined using 2058 quotients 
[(I+)-(I-)]/[(I+)+(I-)]   (Parsons, Flack and Wagner, Acta Cryst. 
B69 (2013) 249-259). 
Primary atom site location: dual Absolute structure parameter: 0.5 (4) 
 
6.1.5. Compound 126 Xray crystal structure data 
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Crystal data and structure refinement  
Identification code gw83 
Chemical formula C24H13Br2F2N3S2 
Formula weight 605.31 
Temperature 150(2) K 
Radiation, wavelength MoK, 0.71073 Å 
Crystal system, space group triclinic, P1 
Unit cell parameters a = 8.2633(9) Å  = 73.7151(15)° 
 b = 10.5751(11) Å  = 78.7097(16)° 
 c = 13.8671(14) Å  = 70.2669(15)° 
Cell volume 1088.0(2) Å
3
 
Z 2 
Calculated density 1.848 g/cm
3
 
Absorption coefficient  3.954 mm1 
F(000) 596 
Crystal colour and size colourless, 0.37  0.29  0.06 mm3 
Reflections for cell refinement 4741 ( range 2.30 to 28.42°) 
Data collection method Bruker APEX 2 CCD diffractometer 
 rotation with narrow frames 
range for data collection 1.54 to 30.55° 
Index ranges h 11 to 11, k 15 to 14, l 19 to 19 
Completeness to  = 29.00° 99.5 %  
Intensity decay 0% 
Reflections collected 17054 
Independent reflections 6544 (Rint = 0.0366) 
Reflections with F
2
>2 4835 
Absorption correction semi-empirical from equivalents 
Min. and max.transmission 0.3224 and 0.797 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0520, 1.3591 
Data / restraints / parameters 6544 / 0 / 298 
Final R indices [F
2
>2] R1 = 0.0421, wR2 = 0.1024 
R indices (all data) R1 = 0.0660, wR2 = 0.1129 
Goodness-of-fit on F
2
 1.032 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 1.985 and 0.886 e Å3 
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6.1.6. Compound 134 X-ray crystal structure data 
 
Crystal data  
C18H18N4 Dx = 1.324 Mg m
-3
 
Mr = 290.36 Mo Kradiation, = 0.71073 Å 
Orthorhombic, Pbca Cell parameters from 3582 reflections 
a = 8.788 (3) Å  = 2.3–30.5° 
b = 9.340 (3) Å = 0.08 mm-1 
c = 17.743 (5) Å T = 150 K 
V = 1456.3 (8)  Å
3
 Lath, colourless 
Z = 4 1.13 × 0.23 × 0.15 mm 
F(000) = 616  
Data collection  
Bruker APEX 2 CCD diffractometer 1773 reflections  
Radiation source: fine-focus sealed tube Rint = 0.047 
 rotation with narrow frames scans max = 30.6°, min = 2.3° 
Absorption correction: multi-scan  
SADABS v2012/1, Sheldrick, G.M., (2012) 
h = -1212 
Tmin = 0.914, Tmax = 0.988  
15966 measured reflections 
2226 independent reflections  
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Refinement data  
Refinement on F
2
 Primary atom site location: structure-invariant direct 
methods 
Least-squares matrix: full Hydrogen site location: difference Fourier map 
R[F
2
 > 2(F2)] = 0.042 All H-atom parameters refined 
wR(F
2
) = 0.115 w = 1/[2(Fo
2
) + (0.0566P)
2
 + 0.3564P]   
where P = (Fo
2
 + 2Fc
2
)/3 
S = 1.05 (/)max < 0.001 
2226 reflections 

136 parameters 

0 restraints  
 
6.1.7. Compound 137 X-ray crystal structure data 
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Crystal data  
C16H4F8N6 F(000) = 856 
Mr = 432.25 Dx = 1.809 Mg m
-3
 
Monoclinic, P21/c Mo K radiation,  = 0.71073 Å 
a = 7.4893 (7) Å Cell parameters from 7665 reflections 
b = 20.898 (2) Å  = 2.2–30.5° 
c = 10.2489 (10) Å  = 0.18 mm-1 
 = 98.348 (2)° T = 150 K 
V = 1587.1 (3)  Å
3
 Rod, colourless 
Z = 4 0.80 × 0.23 × 0.21 mm 
Data collection  
Bruker APEX 2 CCD diffractometer 4039 reflections with I > 2(I) 
Radiation source: fine-focus sealed tube Rint = 0.025 
 rotation with narrow frames scans max = 30.6°, min = 2.0° 
Absorption correction: multi-scan  
SADABS v2009/1, Sheldrick, G.M., (2009) 
h = -1010 
Tmin = 0.869, Tmax = 0.963 k = -2929 
18321 measured reflections l = -1414 
4813 independent reflections  
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Refinement  
Refinement on F
2
 Primary atom site location: structure-invariant direct 
methods 
Least-squares matrix: full Secondary atom site location: all non-H atoms found by 
direct methods 
R[F
2
 > 2(F2)] = 0.037 Hydrogen site location: difference Fourier map 
wR(F
2
) = 0.104 All H-atom parameters refined 
S = 1.04 w = 1/[2(Fo
2
) + (0.051P)
2
 + 0.488P]     
where P = (Fo
2
 + 2Fc
2
)/3 
4813 reflections (/)max = 0.001 
287 parameters max = 0.37 e Å
-3
 
0 restraints min = -0.22 e Å
-3
 
 
6.1.8. Compound 151 Xray crystal structure data 
 
Crystal data 
C20H14F10N2O4 F(000) = 3240 
Mr = 536.33 Dx = 1.696 Mg m
-3
 
Monoclinic, P21/c Synchrotron radiation,  = 0.7749 Å 
a = 17.4161 (6) Å Cell parameters from 9918 reflections 
b = 14.3221 (5) Å  = 2.3–25.1° 
c = 25.7502 (9) Å  = 0.17 mm-1 
 = 101.207 (2)° T = 150 K 
V = 6300.5 (4) Å
3
 Plate, colourless 
Z = 12 0.05 × 0.03 × 0.01 mm
3
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Data collection 
Bruker D8 with PHOTON 100 detector  
diffractometer 
9083 independent reflections 
Radiation source: Advanced Light Station 11.3.1 6863 reflections with I > 2(I) 
Silicon 111 monochromator Rint = 0.056 
Detector resolution: 10.42 pixels mm
-1
 max = 25.6°, min = 2.1° 
 rotation with shutterless scans h = -1919 
Absorption correction: multi-scan  
SADABS v2012/1, Sheldrick, G.M., (2012) 
k = -1515 
Tmin = 0.992, Tmax = 0.998 l = -2828 
44141 measured reflections  
Refinement 
Refinement on F
2
 Primary atom site location: iterative 
Least-squares matrix: full Secondary atom site location: difference Fourier map 
R[F
2
 > 2(F2)] = 0.055 Hydrogen site location: mixed 
wR(F
2
) = 0.142 H atoms treated by a mixture of independent and 
constrained refinement 
S = 1.09 w = 1/[2(Fo
2
) + (0.0421P)
2
 + 15.2253P]   
where P = (Fo
2
 + 2Fc
2
)/3 
9083 reflections (/)max < 0.001 
991 parameters max = 0.83 e Å
-3
 
0 restraints min = -0.32 e Å
-3
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6.1.9. Compound 152 X-ray crystal structure data 
 
Crystal data 
C34H24F8N6O4 F(000) = 748 
Mr = 732.59 Dx = 1.517 Mg m
-3
 
Monoclinic, P21/n Synchrotron radiation,  = 0.7749 Å 
a = 12.7854 (5) Å Cell parameters from 9938 reflections 
b = 8.9381 (4) Å  = 2.5–33.6° 
c = 14.1393 (5) Å  = 0.12 mm-1 
 = 96.872 (2)° T = 150 K 
V = 1604.19 (11) Å
3
 Plate, colourless 
Z = 2 0.35 × 0.18 × 0.02 mm
3
 
Data collection 
Bruker D8 with PHOTON 100 detector  
diffractometer 
4910 independent reflections 
Radiation source: Advanced Light Station 11.3.1 3877 reflections with I > 2(I) 
Silicon 111 monochromator Rint = 0.030 
 rotation with shutterless scans max = 33.7°, min = 2.2° 
Absorption correction: multi-scan  
SADABS v2012/1, Sheldrick, G.M., (2012) 
h = -1818 
Tmin = 0.959, Tmax = 0.998 k = -1212 
20949 measured reflections l = -2020 
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Refinement 
Refinement on F
2
 Primary atom site location: interative 
Least-squares matrix: full Secondary atom site location: difference Fourier map 
R[F
2
 > 2(F2)] = 0.043 Hydrogen site location: mixed 
wR(F
2
) = 0.121 H atoms treated by a mixture of independent and 
constrained refinement 
S = 1.07 w = 1/[2(Fo
2
) + (0.058P)
2
 + 0.4702P]  
where P = (Fo
2
 + 2Fc
2
)/3 
4910 reflections (/)max < 0.001 
239 parameters max = 0.41 e Å
-3
 
0 restraints min = -0.20 e Å
-3
 
6.1.10. Compound 181 X-ray crystal structure data 
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Crystal data 
C34H30F6N8O2·2.5(H2O) Dx = 1.478 Mg m
-3
 
Mr = 741.70 Synchrotron radiation,  = 0.7749 Å 
Orthorhombic, P21212 Cell parameters from 5058 reflections 
a = 22.3299 (9) Å  = 2.7–29.5° 
b = 6.0739 (3) Å  = 0.15 mm-1 
c = 12.2892 (5) Å T = 100 K 
V = 1666.78 (13)  Å
3
 Lath, colourless 
Z = 2 0.10 × 0.03 × 0.02 mm
3 
F(000) = 770  
 
Data collection 
Bruker APEX 2 CCD area detector  
diffractometer 
3344 reflections with I > 2(I) 
Radiation source: ALS Station 11.3.1 Rint = 0.068 
 &  rotation with narrow frames scans max = 30.8°, min = 2.7° 
Absorption correction: multi-scan  
SADABS v2012/1, Sheldrick, G.M., (2012) 
h = -2929 
Tmin = 0.985, Tmax = 0.997 k = -88 
16401 measured reflections l = -1616 
4015 independent reflections  
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Refinement 
Refinement on F
2
 Hydrogen site location: inferred from neighbouring sites 
Least-squares matrix: full H-atom parameters constrained 
R[F
2
 > 2(F2)] = 0.053 w = 1/[2(Fo
2
) + (0.0652P)
2
 + 0.4696P]   
where P = (Fo
2
 + 2Fc
2
)/3 
wR(F
2
) = 0.140 (/)max < 0.001 
S = 1.05 max = 0.29 e Å
-3
 
4015 reflections min = -0.38 e Å
-3
 
278 parameters Extinction correction: SHELXL, 
Fc
*
=kFc[1+0.001xFc
23/sin(2)]-1/4 
49 restraints Extinction coefficient: 0.015 (3) 
Primary atom site location: intrinsic phasing Absolute structure:  Flack x determined using 1238 
quotients [(I+)-(I-)]/[(I+)+(I-)]   (Parsons, Flack and 
Wagner, Acta Cryst. B69 (2013) 249-259). 
Secondary atom site location: difference Fourier map Absolute structure parameter: 0.4 (5) 
 
6.1.11. Compound 183 X-ray crystal structure data 
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Crystal data 
C32H26F6N8O·C2H6O F(000) = 2896 
Mr = 698.67 Dx = 1.436 Mg m
-3
 
Monoclinic, C2/c Mo K radiation,  = 0.71073 Å 
a = 14.1373 (7) Å Cell parameters from 7141 reflections 
b = 17.2114 (8) Å  = 2.2–27.7° 
c = 27.3518 (13) Å  = 0.12 mm-1 
 = 103.7199 (8)° T = 150 K 
V = 6465.4 (5) Å
3
 Tablet, colourless 
Z = 8 0.25 × 0.18 × 0.07 mm
3 
Data collection 
Bruker APEX 2 CCD area detector  
diffractometer 
5498 reflections with I > 2(I) 
Radiation source: fine-focus sealed tube Rint = 0.047 
 rotation with narrow frames scans max = 28.3°, min = 1.9° 
Absorption correction: multi-scan  
SADABS v2012/1, Sheldrick, G.M., (2012) 
h = -1818 
Tmin = 0.971, Tmax = 0.992 k = -2222 
33520 measured reflections l = -3636 
8064 independent reflections  
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Refinement 
Refinement on F
2
 Primary atom site location: structure-invariant direct 
methods 
Least-squares matrix: full Hydrogen site location: mixed 
R[F
2
 > 2(F2)] = 0.042 H atoms treated by a mixture of independent and 
constrained refinement 
wR(F
2
) = 0.101 w = 1/[2(Fo
2
) + (0.0375P)
2
 + 2.548P]   
where P = (Fo
2
 + 2Fc
2
)/3 
S = 1.03 (/)max = 0.001 
8064 reflections max = 0.24 e Å
-3
 
477 parameters min = -0.21 e Å
-3
 
15 restraints  
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6.2. UV-Visible spectroscopy data 
The  spectra showed the absorbance of the of  synthesis compound s  in absence (a) and presence of 
5.2 µM (b), 18 µM (c), 28 µM (d), 39 µM (e), 48 µM (f) and 57 µM (g) of DNA. The arrow shows 
increasing of DNA concentration. Inside graph is plot of Ao/ (A-Ao) vs. 1/ [DNA] for determination 
K and ΔG values. 
6.2.1. UV-visible spectroscopy of compound 108 
 
 
Absorption spectra of 1 x 10
-5
 M of compound 108 (R
2
 = 0.9976 for six points) 
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6.2.2. UV-visible spectroscopy of compound 111 
 
 
Absorption spectra of 9 x 10 
-5 
M of compound 112. (R
2
 =0.9529 for six points) 
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6.2.3. UV-visible spectroscopy of compound 113  
 
Absorption spectra of 2 x 10 
-5 
M of compound 113. (R
2
 =0.9940 for six points) 
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6.2.4. UV-visible spectroscopy of compound 114 
 
 
Absorption spectra of 3.8 x 10 
-5 
M of compound 114. (R
2
 =0.9563 for six points) 
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6.2.5.  UV-visible spectroscopy of compound 137 
 
 
Absorption spectra of 1x 10
-5
 M of compound 137 (R
2
 = 0.9912 for six points) 
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6.2.6.  UV-visible spectroscopy of compound 138 
 
 
Absorption spectra of 1 x 10
-5
 M of compound 138 (R
2 
= 0.9826 for six points) 
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6.2.7. UV-visible spectroscopy of compound 143 
 
 
Absorption spectra of 1 x 10
-5
 M of compound 143. (R2 = 0.9744 for six points) 
 
 
 
 
 
 
 
 
 
205 
 
6.2.8. UV-visible spectroscopy of compound 148 
 
 
Absorption spectra of 3.8 x 10 
-5 
M of compound 148. (R
2 
=0.9785 for six points) 
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6.2.9. UV-visible spectroscopy of compound 151 
 
 
Absorption spectra of 6.5 x 10 
-5 
M of compound 151. (R
2
 =0.971 for six points) 
 
 
 
 
 
 
 
 
207 
 
6.2.10. UV-visible spectroscopy of compound 152 
 
 
Absorption spectra of 3.8 x 10 
-5 
M of compound 152 (R
2
 =0.9824 for six points) 
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6.2.11. UV-visible spectroscopy of compound 161 
 
 
Absorption spectra of 3.8 x 10 
-5 
M of compound 161. (R
2
 =0.9886 for six points) 
 
 
 
 
 
 
 
209 
 
6.2.12. UV-visible spectroscopy of compound 162 
 
 
Absorption spectra of 9 x 10 
-5 
M of compound 162 (R
2
 =0.9951 for six points) 
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6.2.13. UV-visible spectroscopy of compound 163 
 
Absorption spectra of 1 x 10
-5
 M of compound 163. (R
2
 = 0.9909 for six points) 
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6.2.14. UV-visible spectroscopy of compound 164 
 
 
Absorption spectra of 9 x 10 
-5 
M of compound 164. (R
2
 =0.9949 for six points) 
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6.2.15. UV-visible spectroscopy of compound 165 
 
 
Absorption spectra of 7 x 10 
-5 
M of compound 165. (R
2
 =0.9933 for six points) 
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6.2.16. UV-visible spectroscopy of compound 166 
 
 
Absorption spectra of 3.8 x 10 
-5 
M of compound 166. (R
2 
=0.9837 for six points) 
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6.2.17. UV-visible spectroscopy of compound 169 
 
 
Absorption spectra of 9 x 10 
-5 
M of compound 169 (R2 =0.9973 for six points) 
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6.2.18. UV-visible spectroscopy of compound 170 
 
 
Absorption spectra of 3.8 x 10 
-5 
M of compound 170 (R
2
 =0.9949 for six points) 
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6.2.19. UV-visible spectroscopy of compound 171 
 
 
Absorption spectra of 3.8 x 10 
-5 
M of compound 171. (R
2 
=0.9961 for six points) 
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6.2.20. UV-visible spectroscopy of compound 181 
 
 
Absorption spectra of 9 x 10 
-5 
M of compound 181 (R2 =0.9923 for six points) 
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6.2.21. UV-visible spectroscopy of compound 183 
 
 
Absorption spectra of 3.8 x 10 
-5 
M of compound 183. (R
2
 =0.9934 for six points) 
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6.2.22. UV-visible spectroscopy of compound 187 
 
Absorption spectra of 3.8 x 10 
-5 
M of compound 187 in (R
2
 =0.9837 for six points) 
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6.2.23. UV-visible spectroscopy of compound 189 
 
 
Absorption spectra of 3.8 x 10 
-5 
M of compound 189. (R
2
 =0.9769 for six points) 
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6.2.24. UV-visible spectroscopy of compound 191 
 
Absorption spectra of 3.8 x 10 
-5 
M of compound 191. (R
2 
=0.9866 for six points) 
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6.2.25. UV-visible spectroscopy of compound 195 
 
 
Absorption spectra of 3.8 x 10 
-5 
M of compound 195. (R
2
 =0.9689 for six points) 
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6.2.26. UV-visible spectroscopy of compound 196 
 
 
Absorption spectra of 3.8 x 10 
-5 
M of compound 196. (R2 =0.9848 for six points) 
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6.2.27. UV-visible spectroscopy of compound 198 
 
 
Absorption spectra of 9 x 10 
-5 
M of compound 198. (R
2 
=0.8887 for six points) 
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6.3. Fluorescence spectroscopy data for the ethidium boromide displacement assay 
Emission spectra of SS-DNA in trisma base buffer on titration of the sucssessfuly synthesised 
compounds .Kex = 480 nm; [EB] = 1x10
-6
 M; [DNA]=1.5 x10
-4
M. The arrow shows the increase of 
the complex concentration (a) 0.0, (b) 1x10
-6
, (c) 2 x 10
-6
, (d) 4 x10
-6
, (e) 6 x10
-6
, (f) 8 x10
-6
, (g) 1 
x10
-6
  M .inside graph in plot of I0 / I vs. complex concentration for determination of k and ∆G 
values. 
6.3.1. Fluorescence spectra of compound 108 
 
 
R² = 0.7217 for six points 
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6.3.2. Fluorescence spectra of compound 111 
 
R² = 0.965 for six points. 
6.3.3. Fluorescence spectra of compound 113 
 
R² = 0.9296 for six points. 
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6.3.4. Fluorescence spectra of compound 114 
 
 
R² = 0.9472 for six point 
6.3.5. Fluorescence spectra of compound 137 
 
 
 
 
 
 
 
 
 
R² = 0.7375 for six points 
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6.3.6. Fluorescence spectra of compound 138 
 
 
R² = 0.9786 for six points  
6.3.7. Fluorescence spectra of compound 143 
 
 
R² = 0.9921 for six points 
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6.3.8. Fluorescence spectra of compound 148 
 
R² = 0.9414 for six points 
6.3.9. Fluorescence spectra of compound 151 
 
R² = 0.9318 for six point 
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6.3.10. Fluorescence spectra of compound 152 
 
R² = 0.9622 for six points 
6.3.11. Fluorescence spectra of compound 161 
 
R² = 0.8476 for six points. 
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6.3.12. Fluorescence spectra of compound 162 
 
R² = 0.8765 for six points. 
6.3.13. Fluorescence spectra of compound 163 
 
R² = 0.8559 for six points 
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6.3.14. Fluorescence spectra of compound 164 
 
R² = 0.6235 for six point 
6.3.15. Fluorescence spectra of compound 165 
 
R² = 0.9601 for six points. 
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6.3.16. Fluorescence spectra of compound 166 
 
R² = 0.819 for six points. 
6.3.17. Fluorescence spectra of compound 169 
 
R² = 0.9221 for six points 
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6.3.18. Fluorescence spectra of compound 170 
 
R² = 0.7004 for six points. 
6.3.19. Fluorescence spectra of compound 181 
 
R² = 0.9827 for six point 
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6.3.20. Fluorescence spectra of compound 183 
 
R² = 0.9456 for six point 
6.3.21. Fluorescence spectra of compound 187 
 
R² = 0.9601 for six points 
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6.3.22. Fluorescence spectra of compound 189 
 
R² = 0.8443 for six point 
6.3.23. Fluorescence spectra of compound 191 
 
R² = 0.9071 for six point 
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6.3.24. Fluorescence spectra of compound 195 
 
R² = 0.8712 for six point 
 
6.3.25. Fluorescence spectra of compound 196 
 
R² = 0.8935 for six point 
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6.3.26. Fluorescence spectra of compound 198 
 
 
R² = 0.9744 for six points. 
